<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55070</article-id><article-id pub-id-type="doi">10.7554/eLife.55070</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Co-regulation and function of <italic>FOXM1</italic>/<italic>RHNO1</italic> bidirectional genes in cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-230720"><name><surname>Barger</surname><given-names>Carter J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170889"><name><surname>Chee</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170890"><name><surname>Albahrani</surname><given-names>Mustafa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230725"><name><surname>Munoz-Trujillo</surname><given-names>Catalina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230724"><name><surname>Boghean</surname><given-names>Lidia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-230726"><name><surname>Branick</surname><given-names>Connor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130268"><name><surname>Odunsi</surname><given-names>Kunle</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-153526"><name><surname>Drapkin</surname><given-names>Ronny</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-170769"><name><surname>Zou</surname><given-names>Lee</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-170892"><name><surname>Karpf</surname><given-names>Adam R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0866-0666</contrib-id><email>adam.karpf@unmc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Eppley Institute for Cancer Research and Fred &amp; Pamela Buffett Cancer Center, University of Nebraska Medical Center</institution><addr-line><named-content content-type="city">Omaha</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Departments of Gynecologic Oncology, Immunology, and Center for Immunotherapy, Roswell Park Comprehensive Cancer Center</institution><addr-line><named-content content-type="city">Buffalo</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Penn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine</institution><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Massachusetts General Hospital Cancer Center, Harvard Medical School</institution><addr-line><named-content content-type="city">Charlestown</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Reviewing Editor</role><aff><institution>University of Alberta</institution><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Murphy</surname><given-names>Maureen E</given-names></name><role>Senior Editor</role><aff><institution>The Wistar Institute</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>23</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e55070</elocation-id><history><date date-type="received" iso-8601-date="2020-01-11"><day>11</day><month>01</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-04-22"><day>22</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Barger et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Barger et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55070-v2.pdf"/><abstract><p>The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that <italic>FOXM1</italic> is co-amplified and co-expressed with <italic>RHNO1</italic>, a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress response. We demonstrate that <italic>FOXM1</italic> and <italic>RHNO1</italic> are head-to-head (i.e., bidirectional) genes (BDG) regulated by a bidirectional promoter (BDP) (named F/R-BDP). FOXM1 and RHNO1 each promote oncogenic phenotypes in HGSC cells, including clonogenic growth, DNA homologous recombination repair, and poly-ADP ribosylase inhibitor resistance. FOXM1 and RHNO1 are one of the first examples of oncogenic BDG, and therapeutic targeting of FOXM1/RHNO1 BDG is a potential therapeutic approach for ovarian and other cancers.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>FOXM1</kwd><kwd>RHNO1</kwd><kwd>ovarian cancer</kwd><kwd>PARP inhibitors</kwd><kwd>bidirectional genes</kwd><kwd>DNA repair</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30CA036727</award-id><principal-award-recipient><name><surname>Karpf</surname><given-names>Adam R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002300</institution-id><institution>Rivkin Center for Ovarian Cancer</institution></institution-wrap></funding-source><award-id>2018 Kirwin-Hinton Family Bridge Funding Award</award-id><principal-award-recipient><name><surname>Karpf</surname><given-names>Adam R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006518</institution-id><institution>University of Nebraska Medical Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Barger</surname><given-names>Carter J</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006518</institution-id><institution>University of Nebraska Medical Center</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Karpf</surname><given-names>Adam R</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32CA009476</award-id><principal-award-recipient><name><surname>Barger</surname><given-names>Carter J</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F99CA212470</award-id><principal-award-recipient><name><surname>Barger</surname><given-names>Carter J</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50CA228991</award-id><principal-award-recipient><name><surname>Drapkin</surname><given-names>Ronny</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>FOXM1 is co-expressed with its bidirectional gene partner RHNO1, and the two genes promote DNA repair, cell growth and survival, and chemotherapy resistance in ovarian cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The forkhead/winged helix domain transcription factor FOXM1 promotes cancer by transactivating genes with oncogenic potential (<xref ref-type="bibr" rid="bib44">Halasi and Gartel, 2013a</xref>; <xref ref-type="bibr" rid="bib54">Kalathil et al., 2020</xref>). Cell phenotypes promoted by FOXM1 include cell cycle transitions (<xref ref-type="bibr" rid="bib27">Costa, 2005</xref>; <xref ref-type="bibr" rid="bib65">Laoukili et al., 2005</xref>; <xref ref-type="bibr" rid="bib123">Wonsey and Follettie, 2005</xref>), DNA repair (<xref ref-type="bibr" rid="bib79">Maachani et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Park et al., 2012</xref>; <xref ref-type="bibr" rid="bib82">Monteiro et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Khongkow et al., 2014</xref>; <xref ref-type="bibr" rid="bib94">Roh et al., 2020</xref>), cell invasion and metastasis (<xref ref-type="bibr" rid="bib118">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib81">Mao et al., 2019</xref>; <xref ref-type="bibr" rid="bib87">Parashar et al., 2020</xref>), and chemoresistance (<xref ref-type="bibr" rid="bib94">Roh et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Fang et al., 2018</xref>; <xref ref-type="bibr" rid="bib106">Tassi et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Kwok et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Carr et al., 2010</xref>; <xref ref-type="bibr" rid="bib134">Zhao et al., 2014</xref>). Pan-cancer analyses have revealed that FOXM1 overexpression is widespread in human cancer and is linked to reduced patient survival and genomic instability (<xref ref-type="bibr" rid="bib51">Jiang et al., 2015</xref>; <xref ref-type="bibr" rid="bib69">Li et al., 2017a</xref>; <xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Gentles et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Carter et al., 2006</xref>). Accordingly, there is high interest in FOXM1 as a cancer therapeutic target (<xref ref-type="bibr" rid="bib103">Tabatabaei Dakhili et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Halasi and Gartel, 2013b</xref>; <xref ref-type="bibr" rid="bib40">Gormally et al., 2014</xref>; <xref ref-type="bibr" rid="bib135">Ziegler et al., 2019</xref>; <xref ref-type="bibr" rid="bib125">Xiang et al., 2017</xref>).</p><p>High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadly subtype of epithelial ovarian cancer (EOC) (<xref ref-type="bibr" rid="bib14">Bowtell et al., 2015</xref>). Molecular features of this tumor type include ubiquitous <italic>TP53</italic> mutations, defects in DNA homologous recombination repair (HR), <italic>BRCA</italic> gene mutations, and robust genomic instability characterized by widespread copy number alterations (CNAs) (<xref ref-type="bibr" rid="bib108">The Cancer Genome Atlas Research Network, 2011</xref>). Notably, FOXM1 pathway activation is a characteristic of &gt;85% of HGSC cases and is linked to genomic instability (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib108">The Cancer Genome Atlas Research Network, 2011</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib72">Li et al., 2020</xref>). FOXM1 overexpression in HGSC and other cancers is driven by several mechanisms, including copy number gains, loss of function of p53 and pRB, activation of SP1, E2F1, and cyclin E1, and YAP signaling (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib33">Fan et al., 2015</xref>; <xref ref-type="bibr" rid="bib91">Petrovic et al., 2010</xref>). In particular, <italic>FOXM1</italic> copy number gains in HGSC are localized to a region of chromosome 12p13.33 that contains 33 genes, and the <italic>FOXM1</italic> CNA is functional, meaning that <italic>FOXM1</italic> copy number directly correlates with <italic>FOXM1</italic> mRNA expression (<xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib99">Song et al., 2019</xref>). It is highly plausible that other genes in this amplicon contribute to HGSC, either independently or cooperatively with FOXM1.</p><p>The initial report of RHNO1 (first called C12orf32) showed that it was overexpressed in a breast cancer cell line, localized to the nucleus, and promoted cell survival (<xref ref-type="bibr" rid="bib60">Kim et al., 2010</xref>). RHNO1 (reported as RHINO) was later identified in a high-throughput screen for DNA damage response (DDR) regulators and was shown to physically interact with the RAD<underline>9</underline>, RAD<underline>1</underline>, HUS<underline>1</underline> DNA clamp (9-1-1). Through its interaction with 9-1-1 and TOPBP1, RHNO1 promotes the activation of ataxia telangiectasia and Rad3-related protein (ATR), a protein integral to the cellular DNA replication stress (RS) response (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>). The RHNO1 N-terminus contains a conserved APSES DNA binding domain, necessary for interaction with the 9-1-1 complex, while the C-terminus is required for interaction with 9-1-1 and TOPBP1 and localization to sites of DNA damage (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>). Recently, X-ray crystallography was used to study the 9-1-1/RHNO1 interaction, and the data revealed that RHNO1 specifically interacts with RAD1 (<xref ref-type="bibr" rid="bib47">Hara et al., 2020</xref>). The expression, regulation, and function of RHNO1 in normal tissues and cancer are largely unknown, but RHNO1 was recently identified as a hub gene associated with poor prognosis in colorectal cancer (<xref ref-type="bibr" rid="bib128">Yang et al., 2020</xref>). The prominence of the RS response in cancer cell survival and its recent emergence as a therapeutic target make investigation of the function of RHNO1 in cancer an important area of study (<xref ref-type="bibr" rid="bib113">Ubhi and Brown, 2019</xref>). Moreover, the ubiquity of elevated RS in HGSC makes this tumor type particularly relevant for RHNO1 investigation (<xref ref-type="bibr" rid="bib62">Konstantinopoulos et al., 2020</xref>).</p><p>We report that <italic>FOXM1</italic> and <italic>RHNO1</italic> are bidirectional genes (BDGs) that are co-amplified in HGSC. We show that <italic>FOXM1</italic> and <italic>RHNO1</italic> are tightly co-expressed in both normal and cancer cells and tissues, including individual cells, and that their co-expression is controlled by a bidirectional promoter (F/R-BDP). We show that FOXM1 and RHNO1 both contribute to several important HGSC cell phenotypes, including clonogenic growth and cell survival, DNA HR repair, and PARP inhibitor (PARPi) resistance. Based on these data, we hypothesize that the FOXM1/RHNO1 BDG pair promotes HGSC and other cancers, and is a potential target for cancer therapeutic intervention.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The 12p13.33 HGSC amplicon contains <italic>FOXM1</italic> and <italic>RHNO1</italic>, co-expressed BDGs</title><p> <italic>FOXM1</italic> is located at chromosome 12p13.33, a region showing frequent copy number gains in HGSC, and amplification at this locus is associated with reduced patient survival (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>). Moreover, a recent study demonstrated that 12p13.33 amplification is detected from cell-free DNA in the plasma of HGSC patients at diagnosis and is further enriched in patients experiencing disease relapse (<xref ref-type="bibr" rid="bib86">Paracchini et al., 2020</xref>). The minimal amplicon contains <italic>FOXM1</italic> and 32 additional genes (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Based on recent studies of other cancer amplifications (<xref ref-type="bibr" rid="bib53">Justilien et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Fields et al., 2016</xref>), we hypothesized that additional genes at 12p13.33 might harbor oncogenic functions that act in concert with FOXM1. To test this hypothesis and search for gene candidates, we focused on genes showing correlated expression with <italic>FOXM1</italic> in HGSC. Using The Cancer Genome Atlas (TCGA) data, we found that, among all amplicon genes, <italic>FOXM1</italic> expression shows the strongest correlation with <italic>RHNO1</italic> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Intriguingly, genomic analyses revealed that <italic>FOXM1</italic> and <italic>RHNO1</italic> are located next to each other and arranged ‘head-to-head’, that is, they are BDGs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Greater than 10% of human genes are bidirectional, and the paired genes may be regulated by a bidirectional promoter (BDP) and have related functions (<xref ref-type="bibr" rid="bib111">Trinklein et al., 2004</xref>; <xref ref-type="bibr" rid="bib115">Wakano et al., 2012</xref>; <xref ref-type="bibr" rid="bib127">Yang et al., 2007</xref>; <xref ref-type="bibr" rid="bib112">Tu et al., 2019</xref>). Furthermore, cancer-related genes were recently shown to be highly enriched for BDG (<xref ref-type="bibr" rid="bib24">Chen et al., 2020</xref>). Despite their strikingly high prevalence in the human genome and significant enrichment in cancer genes, the functional role of BDG has been infrequently studied (<xref ref-type="bibr" rid="bib24">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Li et al., 2019</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The 12p13.33 amplicon in high-grade serous carcinoma (HGSC).</title><p>(<bold>A</bold>) Recurrent copy number amplifications in The Cancer Genome Atlas HGSC data (n = 579), as determined by GISTIC. Black vertical line indicates the threshold for significance, corresponding to an false discovery rate (FDR) q-value &lt;0.25. The 12p13.33 genomic amplicon is indicated with an arrow. (<bold>B</bold>) The 33 genes in the 12p13.33 amplicon, listed top to bottom in genomic order from centromere to telomere. <italic>FOXM1</italic> and <italic>RHNO1</italic> are shown in red.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig1-v2.tif"/></fig><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>FOXM1</italic>/<italic>RHNO1</italic> expression correlation in high-grade serous carcinoma (HGSC) and genomic characteristics.</title><p>(<bold>A</bold>) Hierarchical clustering dendrogram of The Cancer Genome Atlas HGSC mRNA expression correlations of the 33 genes in the 12p13.33 amplicon. <italic>FOXM1</italic> and <italic>RHNO1</italic> are boxed. (<bold>B</bold>) Genomic configuration and characteristics of <italic>FOXM1</italic> and <italic>RHNO1</italic>. Transcript structure, CpG islands, epigenetic marks, and vertebrate genome conservation data are shown. Data were obtained from the UCSC Genome Browser and ENCODE.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>The <italic>FOXM1/RHNO1</italic> bidirectional promoter (F/R-BDP) region is hypomethylated in normal and cancer tissues.</title><p>(<bold>A</bold>) Distribution of DNA methylation at the F/R-BDP in The Cancer Genome Atlas normal and tumor tissues and Cancer Cell Line Encyclopedia cancer cell lines. Beta values represent the level of DNA methylation, averaged across seven CpG sites within the F/R-BDP CpG island. A value of 1 corresponds to fully methylated, while a value of 0 corresponds to fully unmethylated. (<bold>B</bold>) F/R-BDP regional DNA methylation as determined by sodium bisulfite clonal sequencing. Gene transcriptional start sites are indicated by the red broken arrows. Filled and open circles indicate methylated and unmethylated CpG sites, respectively, and each row represents one sequenced allele. Four separate epithelial ovarian cancer (EOC) samples with patient identifiers are shown. A mixture of normal ovary samples was analyzed as a control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>DNA sequence of the <italic>FOXM1/RHNO1</italic> bidirectional promoter (F/R-BDP).</title><p>Transcriptional start sites predicted by NCBI are shown with broken arrows. E2F and MYC sites, known to regulate BDPs and <italic>FOXM1</italic>, are indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig2-figsupp2-v2.tif"/></fig></fig-group><p>We next performed an in silico analysis of the putative <italic>FOXM1/RHNO1</italic> bidirectional promoter (F/R-BDP), that is, the genomic region spanning the putative <italic>FOXM1</italic>/<italic>RHNO1</italic> transcriptional start sites (TSS). The F/R-BDP contained a CpG island (CGI), a common feature of BDP (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="bibr" rid="bib115">Wakano et al., 2012</xref>; <xref ref-type="bibr" rid="bib104">Takai and Jones, 2004</xref>; <xref ref-type="bibr" rid="bib3">Antequera, 2003</xref>). Although differential DNA methylation of CGIs contained within BDP can regulate BDG expression (<xref ref-type="bibr" rid="bib98">Shu et al., 2006</xref>), we found that the F/R-BDP is fully hypomethylated in both normal and cancer tissues, including normal ovary (NO) and ovarian cancer, suggesting that differential DNA methylation is not a regulatory mechanism at this BDP (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In addition to a CGI, BDPs are often enriched with specific histone marks (<xref ref-type="bibr" rid="bib13">Bornelöv et al., 2015</xref>), and The Encyclopedia of DNA Elements (ENCODE) data revealed the presence of bimodal peaks of transcriptionally active histone modifications at the F/R-BDP, strongly suggestive of bidirectional transcriptional activity (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Additionally, the F/R-BDP was characterized by DNase I hypersensitivity, enriched TF binding, active chromatin segmentation, and vertebrate conservation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Among TF binding sites in the F/R-BDP were E2F and MYC sites, factors that are known to regulate both BDPs and FOXM1 (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib85">Pan et al., 2018</xref>; <xref ref-type="bibr" rid="bib12">Bolognese et al., 2006</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Thus, the F/R-BDP displays several known characteristics of BDPs.</p><p>To determine whether copy number status associates not only with <italic>FOXM1</italic> but also <italic>RHNO1</italic> expression in HGSC, we analyzed TCGA and Cancer Cell Line Encyclopedia (CCLE) data (<xref ref-type="bibr" rid="bib108">The Cancer Genome Atlas Research Network, 2011</xref>; <xref ref-type="bibr" rid="bib8">Barretina et al., 2012</xref>). These analyses revealed a progressive increase in both <italic>FOXM1</italic> and <italic>RHNO1</italic> expression with increasing copy number (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>). We validated that FOXM1 and RHNO1 mRNA and protein expression correlated with copy number, using a laboratory collection of cell lines, including immortalized Fallopian tube epithelium (FTE) cells (a precursor cell type for HGSC) and HGSC cells (<xref ref-type="fig" rid="fig3">Figure 3C, D</xref>). Although the associations were significant, they were not uniform, indicating that mechanisms besides copy number status regulate <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in HGSC. This is consistent with our prior studies of FOXM1 regulation (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression correlates with genomic copy number in high-grade serous carcinoma (HGSC).</title><p>(<bold>A</bold>) <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression (RNA-seq) vs. GISTIC copy number in The Cancer Genome Atlas HGSC data (N = 157). (<bold>B</bold>) <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression (microarray) vs. copy number (GISTIC) in Cancer Cell Line Encyclopedia HGSC cell lines (N = 23). p-values for ANOVA with post-test for linear trend are shown, and lines represent group medians. p-value designation: **p&lt;0.01, ****p&lt;0.0001. (<bold>C</bold>) <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression in FT282 immortalized Fallopian tube epithelium cells and HGSC cell lines (RT-qPCR). (<bold>D</bold>) FOXM1 and RHNO1 nuclear protein levels (western blot). Two nuclear protein loading controls are shown. <italic>FOXM1</italic>/<italic>RHNO1</italic> GISTIC copy number values for the cell lines are shown (−1: het loss; 0: diploid; 1: gain; 2: amp).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig3-v2.tif"/></fig></sec><sec id="s2-2"><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression correlates in bulk tissues, cell lines, and individual cells</title><p>We next analyzed whether <italic>FOXM1</italic> and <italic>RHNO1</italic> expression correlated in biological settings beyond HGSC. Consistent with TCGA HGSC data (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), reverse transcription quantitative PCR (RT-qPCR) analyses of an independent set of primary EOC tissues, and a panel of ovarian surface epithelium (OSE), FTE, and HGSC cell lines, indicated that <italic>FOXM1</italic> and <italic>RHNO1</italic> expression is highly correlated (<xref ref-type="fig" rid="fig4">Figure 4A, B</xref>). Next, to determine if this correlation occurs at the level of individual cells, we conducted single-cell RNA sequencing (scRNA-seq) of an immortalized human FTE cell line (FT282-C11, hereafter referred to as FT282) and a HGSC cell line (OVCAR8) (<xref ref-type="bibr" rid="bib6">Barger et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Domcke et al., 2013</xref>). Importantly, <italic>FOXM1</italic> and <italic>RHNO1</italic> showed significant co-expression in each case (<xref ref-type="fig" rid="fig4">Figure 4C, D</xref>). Both genes showed elevated expression in OVCAR8 vs. FT282 cells, consistent with overexpression in cancer (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). We next examined the degree of correlation seen between <italic>FOXM1</italic> and <italic>RHNO1</italic> as compared to other BDG genome-wide and, notably, observed that the <italic>FOXM1</italic>/<italic>RHNO1</italic> correlation ranked in the top 1% of all BDG in FT282 and in the top 9% in OVCAR8 cells (<xref ref-type="fig" rid="fig5">Figure 5</xref>). This observation supports a highly concordant regulatory process between <italic>FOXM1</italic> and <italic>RHNO1</italic> expression.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression correlates in high-grade serous carcinoma (HGSC) and in HGSC precursor cells.</title><p>(<bold>A</bold>) <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression in primary HGSC tumors, as determined by RT-qPCR. (<bold>B</bold>) <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression in Fallopian tube epithelium (N = 5), ovarian surface epithelium (N = 3), and HGSC (N = 10) cell lines, as determined by RT-qPCR. (<bold>C</bold>) <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression in FT282 cells, as determined by scRNA-seq. (<bold>D</bold>) <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression in OVCAR8 HGSC cells, as determined by scRNA-seq. (<bold>A</bold>–<bold>D</bold>) show the Spearman r value, p-value, and the number of samples analyzed. (<bold>E</bold>) <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in FT282 and OVCAR8 cells, plotting the median values from scRNA-seq data. Mann–Whitney p-values are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig4-v2.tif"/></fig><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Distribution of correlation coefficients for bidirectional gene pairs (n = 2172) from scRNA-seq data.</title><p>Data are shown for (<bold>A</bold>) FT282 and (<bold>B</bold>) OVCAR8 cell lines. The x-axis plots the degree of co-expression (Pearson's coefficient) between bidirectional gene pairs, and y-axis plots the frequency of bidirectional pairs. The rank percentile of the <italic>FOXM1</italic>/<italic>RHNO1</italic> correlation in each cell type is shown and is indicated by the dashed vertical line.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Principal component analyses (PCA) of FT282 (n = 1440) and OVCAR8 (n = 1454) single cells, using scRNA-seq data.</title><p>PCA analyses were performed using Python.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig5-figsupp1-v2.tif"/></fig></fig-group><p>To address whether <italic>FOXM1</italic> and <italic>RHNO1</italic> expression correlates in biological contexts unrelated to ovarian cancer or its progenitor cells, we analyzed in silico gene expression data sets, including normal and cancer tissues and cells, and mouse and human data. Importantly, all comparisons revealed a highly significant correlation between <italic>FOXM1</italic> and <italic>RHNO1</italic>, indicating that co-expression is a defining feature of this BDG unit (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>).</p></sec><sec id="s2-3"><title><italic>FOXM1</italic> and <italic>RHNO1</italic> are overexpressed in pan-cancer</title><p>While <italic>FOXM1</italic> is overexpressed in HGSC and pan-cancer (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib108">The Cancer Genome Atlas Research Network, 2011</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>), <italic>RHNO1</italic> expression in normal tissues vs. cancer is unknown. To address this question, we compared <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in Genotype-Tissue Expression (GTEx) normal tissues vs. TCGA pan-cancer tissues using the Toil method (<xref ref-type="bibr" rid="bib114">Vivian et al., 2017</xref>). Both <italic>FOXM1</italic> and <italic>RHNO1</italic> were overexpressed in each category of cancer samples (primary tumors, metastatic tumors, and recurrent tumors) as compared to normal tissues (<xref ref-type="fig" rid="fig6">Figure 6A, B</xref>). Moreover, <italic>FOXM1</italic> showed greater overexpression in tumor tissues compared to <italic>RHNO1,</italic> and, consistently, the <italic>FOXM1/RHNO1</italic> expression ratio was elevated in cancer (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). This was in part driven by relatively higher <italic>RHNO1</italic> expression in normal tissues (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). In addition, we hypothesized that increased <italic>FOXM1</italic>/<italic>RHNO1</italic> expression in tumors might reflect increased cell proliferation as <italic>FOXM1</italic> expression is closely associated with cell proliferation (<xref ref-type="bibr" rid="bib130">Ye et al., 1997</xref>). In agreement, after normalization to the canonical cell proliferation marker <italic>MKI67</italic> (<xref ref-type="bibr" rid="bib119">Whitfield et al., 2006</xref>), the <italic>FOXM1</italic>/<italic>RHNO1</italic> expression ratio was similar in normal and cancer tissues (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression and expression ratio in normal and cancer tissues.</title><p>(<bold>A</bold>) <italic>FOXM1</italic> and (<bold>B</bold>) <italic>RHNO1</italic> expression (RNA-seq) in normal tissues (from Genotype-Tissue Expression and The Cancer Genome Atlas [TCGA]) vs. different types of TCGA tumor tissues (i.e., primary, metastatic, and recurrent). The number of samples in each group is shown. All comparisons of normal vs. tumor samples were highly significant (p&lt;0.0001, t-tests). (<bold>C</bold>) <italic>FOXM1/RHNO1</italic> mRNA expression ratio in normal and cancer tissues, for the data shown in (<bold>A</bold>, <bold>B</bold>). The <italic>FOXM1/RHNO1</italic> ratio for the samples to the right of the dashed line was normalized to <italic>MKI67</italic> (a.k.a. Ki67), the canonical proliferation marker.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig6-v2.tif"/></fig></sec><sec id="s2-4"><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression in HGSC</title><p>Next, we examined the expression of <italic>FOXM1</italic> and <italic>RHNO1</italic> in HGSC. HGSC has traditionally been proposed to emanate from the OSE, but is now believed to predominantly, but not exclusively, arise from the FTE (<xref ref-type="bibr" rid="bib101">Soong et al., 2019</xref>). Comparison of TCGA HGSC vs. GTEx Fallopian tube RNA-seq data revealed that both <italic>FOXM1</italic> and <italic>RHNO1</italic> expression show relatively uniform and highly significant increases in HGSC vs. Fallopian tube (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). In agreement, <italic>FOXM1</italic> and <italic>RHNO1</italic> were both significantly elevated in HGSC cell lines as compared to primary or immortalized FTE/OSE cells (<xref ref-type="fig" rid="fig7">Figure 7B</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title><italic>FOXM1</italic> and <italic>RHNO1</italic> are overexpressed in high-grade serous carcinoma (HGSC).</title><p>(<bold>A</bold>) <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in Genotype-Tissue Expression normal Fallopian tube (FT; N = 5) vs. The Cancer Genome Atlas HGSC tissues (RNA-seq) (N = 427). (<bold>B</bold>) <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression in Fallopian tube epithelium/ovarian surface epithelium cells vs. HGSC cell lines (RT-qPCR). t-test p-values are shown. p-value designation: ****&lt;0.0001, ***&lt;0.001, **&lt;0.01, *&lt;0.05. The key shown at right indicates the cell types for each data point.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig7-v2.tif"/></fig><p>Following front-line therapy, most clinically advanced HGSC patients relapse with a chemoresistant recurrent disease, so developing improved treatments for these patients remains critical (<xref ref-type="bibr" rid="bib14">Bowtell et al., 2015</xref>). We compared <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression in primary and recurrent HGSC samples using two independent patient cohorts (<xref ref-type="bibr" rid="bib90">Patch et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Kreuzinger et al., 2017</xref>). In both cohorts, <italic>FOXM1</italic> and <italic>RHNO1</italic> expression significantly correlated in both primary and recurrent disease (<xref ref-type="fig" rid="fig8">Figure 8A, B</xref>). While, overall, <italic>FOXM1</italic> and <italic>RHNO1</italic> expression wa﻿s not significantly altered in primary vs. recurrent disease, 5/11 patients displayed coordinated upregulation of both <italic>FOXM1</italic> and <italic>RHNO1</italic> at recurrence (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). This observation suggests that <italic>FOXM1</italic> and <italic>RHNO1</italic> might contribute to disease recurrence in a large subset of HGSC patients.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression in primary and recurrent high-grade serous carcinoma (HGSC).</title><p>(<bold>A</bold>) <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression (RNA-seq data) in primary (left) and recurrent (right) HGSC samples from <xref ref-type="bibr" rid="bib63">Kreuzinger et al., 2017</xref>. (<bold>B</bold>) <italic>FOXM1</italic> vs. <italic>RHNO1</italic> expression (RNA-seq data) in primary (left) and recurrent (right) HGSC samples from <xref ref-type="bibr" rid="bib90">Patch et al., 2015</xref>. For (<bold>A</bold>, <bold>B</bold>) , the number of samples (n), Spearman r value, and p-value are shown. (<bold>C</bold>) <italic>FOXM1</italic> (top) and <italic>RHNO1</italic> (bottom) expression (RNA-seq) in patient-matched primary vs. recurrent HGSC samples from <xref ref-type="bibr" rid="bib90">Patch et al., 2015</xref>. Asterisks indicate patients showing coordinately increased expression of both <italic>FOXM1</italic> and <italic>RHNO1</italic> in recurrent tumors (5/11 = 45% of patients).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig8-v2.tif"/></fig></sec><sec id="s2-5"><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression is co-regulated by a BDP</title><p>We used functional assays to assess whether <italic>FOXM1</italic> and <italic>RHNO1</italic> expression is co-regulated by the F/R-BDP. Initially, we determined the TSS of <italic>FOXM1</italic> and <italic>RHNO1</italic> in FTE (FT282) and HGSC (OVCAR4, OVCAR8) cells using 5′ RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE). The data revealed TSSs consistent with NCBI Genome Browser data, revealing an intergenic span (i.e., between the 5′ ends of <italic>FOXM1</italic> and <italic>RHNO1</italic>) of approximately 150 bp (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1</xref>). These data also show that the TSS are consistent between normal vs. HGSC cells, and confirm that the TSS is &lt;1 kb, which is characteristic of BDPs. To define transcriptional activity at the F/R-BDP, we generated a luciferase reporter construct consisting of a 190 bp segment that includes the intergenic region as well as small portions of the 5′ ends of <italic>FOXM1</italic> and <italic>RHNO1</italic>. In this construct, the <italic>FOXM1</italic> promoter direction drives Renilla luciferase while the <italic>RHNO1</italic> promoter direction drives Firefly luciferase, from the opposite DNA strand (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). Studies in FTE and HGSC cells using this construct verified BDP activity and also revealed a direct correlation between <italic>FOXM1</italic> and <italic>RHNO1</italic> promoter activity (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). Moreover, <italic>FOXM1</italic> and <italic>RHNO1</italic> promoter activity significantly correlated with expression of the cognate endogenous mRNA (<xref ref-type="fig" rid="fig9">Figure 9C, D</xref>). This correlation was not perfect, suggesting that additional mechanisms, such as enhancer activity or post-transcriptional processes, regulate expression of the endogenous genes. We used a complementary approach to assess F/R-BDP activity in individual cells, wherein we generated a reporter construct where the <italic>FOXM1</italic> promoter direction drives green fluorescent protein (GFP) and the <italic>RHNO1</italic> promoter direction drives red fluorescent protein (RFP) expression, which can be measured by flow cytometry (<xref ref-type="fig" rid="fig9">Figure 9E</xref>). Experiments using this construct demonstrated a significant direct correlation between <italic>FOXM1</italic> and <italic>RHNO1</italic> promoter activity in individual cells (<xref ref-type="fig" rid="fig9">Figure 9F</xref>, <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2</xref>). This observation is consistent with the results of our scRNA-seq experiment that measured endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in individual cells (<xref ref-type="fig" rid="fig4">Figure 4C, D</xref>).</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>F/R-BDP promoter activity assays.</title><p>(<bold>A</bold>) Schematic of the <italic>F/R-BDP</italic> dual luciferase reporter construct. The <italic>FOXM1</italic> promoter direction drives Renilla luciferase, and the <italic>RHNO1</italic> promoter direction drives firefly luciferase. Secreted embryonic alkaline phosphatase (SEAP) was used as a normalization control for transfection efficiency. (<bold>B</bold>) Correlation of <italic>FOXM1</italic> and <italic>RHNO1</italic> promoter activity in Fallopian tube epithelium (FTE) (FT282) and high-grade serous carcinoma (HGSC) cell lines (OVCAR5, COV318, OVCAR4, Kuramochi, SNU119). (<bold>C, D</bold>) Correlation of <italic>FOXM1</italic> or <italic>RHNO1</italic> promoter activity vs. endogenous expression of the cognate gene in FTE (FT282) and HGSC (OVCAR5, COV318, Kuramochi, SNU119) cell lines, as measured by RT-qPCR. In (<bold>B–D</bold>), error bars represent standard deviations. (<bold>E</bold>) Schematic of the <italic>F/R-BDP</italic> dual fluorescence reporter construct. The <italic>FOXM1</italic> promoter direction drives red fluorescent protein (RFP) expression, and the <italic>RHNO1</italic> promoter direction drives green fluorescent protein (GFP) expression. (<bold>F</bold>) Fluorescence-activated cell sorting analysis of GFP and RFP fluorescence in 293T cells transfected with the F/R-BDP reporter shown in (<bold>E</bold>). Quadrant 2 (RFP + GFP + cell population) correlation statistics are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig9-v2.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title><italic>FOXM1</italic> and <italic>RHNO1</italic> transcriptional start sites.</title><p>5′ RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) mapping data of the 5′ ends of <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA. The arrows indicate the orientation of each gene 5′ to 3′. The bars indicate the sequenced 5′ ends of each transcript, with the names of the individual cell line samples (color coded) at left. NCBI RefSeq transcript assembly data is shown at bottom.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig9-figsupp1-v2.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 2.</label><caption><title>Fluorescence-activated cell sorting analyses of red fluorescent protein (RFP) and green fluorescent protein (GFP) expression in 293T cells.</title><p>(<bold>A, B</bold>) Empty vector transfections. (<bold>C, D</bold>) F/R-BPD dual reporter transfections. The reporter schematic is shown in <xref ref-type="fig" rid="fig9">Figure 9E</xref>. (<bold>E, F</bold>) Spearman correlation analyses of Quadrant 2 (i.e., RFP + GFP + cells) from (<bold>C</bold>, <bold>D</bold>) as indicated.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig9-figsupp2-v2.tif"/></fig></fig-group><p>Although promoter reporter assays are informative, they do not fully reflect mechanisms regulating endogenous genes. To address this, we used CRISPR-dCas9 and single-guide RNA (sgRNA) to deliver activator (VP64, i.e., CRISPRa) or repressor (KRAB, i.e., CRISPRi) proteins to the F/R-BDP region (<xref ref-type="bibr" rid="bib52">Joung et al., 2017</xref>; <xref ref-type="bibr" rid="bib107">Thakore et al., 2015</xref>). We used three sgRNA to directly target either the F/R-BDP or flanking regions (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). We first used CRISPRa in FT282 cells, which have low levels of endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> expression. sgRNA targeting outside the putative BDP, upstream of one gene and in the gene body of the other gene (i.e., sg070 or sg233), induced the expression of the distal (i.e., upstream) gene (<xref ref-type="fig" rid="fig10">Figure 10B</xref>). In contrast, sgRNA directly targeting the F/R-BDP (i.e., sg130) induced the expression of both <italic>FOXM1</italic> and <italic>RHNO1</italic>. Next, we used CRISPRi in OVCAR8 cells, which have high endogenous expression of <italic>FOXM1</italic> and <italic>RHNO1</italic>. CRISPRi targeting the F/R-BDP (sg130) efficiently repressed both <italic>FOXM1</italic> and <italic>RHNO1</italic>, while guides flanking the F/R-BDP had a lesser effect (<xref ref-type="fig" rid="fig10">Figure 10C</xref>). Also, sg233, located in <italic>RHNO1</italic> exon 1, had a greater repressive effect on both genes compared to sg070, which is located in <italic>FOXM1</italic> exon 1. One potential explanation for this result is that endogenous transcriptional activators of both genes have increased localization to <italic>RHNO1</italic> exon 1 compared to <italic>FOXM1</italic> exon 1. To validate these observations, we performed CRISPR knockout and CRISPRi experiments in 293T cells, which have high levels of endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> expression. These experiments further validated that the endogenous F/R-BDP co-regulates <italic>FOXM1</italic> and <italic>RHNO1</italic> (<xref ref-type="fig" rid="fig10">Figure 10D, E</xref>).</p><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> are co-regulated by their bidirectional promoter (F/R-BDP).</title><p>(<bold>A</bold>) Schematic of the experimental approach used in (<bold>B, C</bold>). The position of the CRISPR guide RNAs is indicated with black rectangles. (<bold>B</bold>) CRISPRa experiment in FT282 cells. Endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> expression was measured by RT-qPCR. (<bold>C</bold>) CRISPRi experiment in OVCAR8 cells. Endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression was measured by RT-qPCR. In (<bold>B</bold>, <bold>C</bold>), NT1 and NT2 indicate non-targeting control guide RNAs, and t-test p-values are shown for the comparison with NT1 control for either <italic>FOXM1</italic> or <italic>RHNO1</italic>. p-values: ****&lt;0.0001, ***&lt;0.001, **&lt;0.01, *&lt;0.05. (<bold>D</bold>) Genotyping data for 293T cells with knockout (KO) of the 200 bp F/R-BDP (BDP KO) or, as a control, the entire upstream regions (5′ of the translational start sites) of both <italic>FOXM1</italic> and <italic>RHNO1</italic> (ATG-ATG KO). N: no template control. (<bold>E</bold>) Endogenous <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in 293T cells with the indicated genetic configurations. BDP KO and ATG-ATG KO correspond to cells described in (<bold>D</bold>). KRAB data for 293T cells (i.e., CRISPRi), using the strategy shown in (<bold>A</bold>), are shown for comparison on the right.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig10-v2.tif"/></fig></sec><sec id="s2-6"><title>FOXM1 and RHNO1 promote HGSC cell clonogenic growth</title><p>Based on their genomic configuration, co-amplification, co-expression, and overexpression in HGSC, we hypothesized that FOXM1 and RHNO1 may each promote HGSC oncogenic phenotypes. Moreover, we noted that BDGs are enriched as cancer genes and in specific functions, including cell cycle and DNA repair, and may function cooperatively (<xref ref-type="bibr" rid="bib24">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib117">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Li et al., 2006</xref>; <xref ref-type="bibr" rid="bib102">Sun et al., 2021</xref>). We thus focused our investigations on known and potentially overlapping functions of FOXM1 and RHNO1, including clonogenic cell growth and survival, cell cycle, and DNA repair (<xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>; <xref ref-type="bibr" rid="bib136">Zona et al., 2014</xref>). We utilized two validated HGSC cell lines (OVCAR8 and CAOV3) for these studies (<xref ref-type="bibr" rid="bib32">Domcke et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Haley et al., 2016</xref>). These two lines express both FOXM1 and RHNO1 and harbor copy number gains at 12p13.33 (<xref ref-type="fig" rid="fig3">Figure 3C, D</xref>). We initially engineered the cell lines for doxycycline (dox)-inducible lentiviral expression of shRNA targeting either FOXM1 or RHNO1. We used this knockdown approach due to reported off-target effects of CRISRP-Cas9 gene targeting at amplified loci (<xref ref-type="bibr" rid="bib1">Aguirre et al., 2016</xref>). The engineered lines demonstrated efficient gene knockdown 72 hr after dox treatment (<xref ref-type="fig" rid="fig11">Figure 11A</xref>). Notably, either FOXM1 or RHNO1 knockdown reduced OVCAR8 and CAOV3 clonogenic growth (<xref ref-type="fig" rid="fig11">Figure 11B</xref>, <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1</xref>). To validate this observation (despite potential concerns with CRISPR-Cas9 targeting), we engineered OVCAR8 and CAOV3 cells for polyclonal CRISPR knockout of <italic>FOXM1</italic> or <italic>RHNO1</italic> (<xref ref-type="fig" rid="fig11">Figure 11C</xref>). The results verified that disruption of either gene reduces clonogenic growth of both HGSC cell lines (<xref ref-type="fig" rid="fig11">Figure 11D</xref>, <xref ref-type="fig" rid="fig11s2">Figure 11—figure supplements 1 and 2</xref>). Further experiments indicated that clonogenic growth disruption in OVCAR8 CRISPR knockout cells is caused in part by increased apoptosis (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1</xref>).</p><fig-group><fig id="fig11" position="float"><label>Figure 11.</label><caption><title>FOXM1 and RHNO1 each promote high-grade serous carcinoma cell clonogenic growth.</title><p>(<bold>A</bold>) OVCAR8 and CAOV3 cells engineered for doxycycline (dox)-inducible FOXM1 or RHNO1 shRNA knockdown. Cells were grown in the presence of dox for 72 hr, and protein was extracted for western blot analyses. (<bold>B</bold>) Cells were seeded into 6-well dishes, in triplicate. Dox was added at the time of seeding, and media containing dox was replenished every 48 hr. Clonogenic growth was measured at 12–14 days, and the number of colonies (&gt;50 cells) was counted. NS: nontargeting shRNA. (<bold>C</bold>) OVCAR8 and CAOV3 cells were engineered for FOXM1 or RHNO1 CRISPR knockout. Western blot analysis of polyclonal cell populations was performed 72 hr post-lentivirus infection. CTL: control guide RNA. (<bold>D</bold>) Clonogenic growth was measured as described in (<bold>B</bold>). t-test p-values vs. control: ****&lt;0.0001, ***&lt;0.001, **&lt;0.01, *&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig11-v2.tif"/></fig><fig id="fig11s1" position="float" specific-use="child-fig"><label>Figure 11—figure supplement 1.</label><caption><title>FOXM1 and RHNO1 each promote high-grade serous carcinoma cell clonogenic growth.</title><p>(<bold>A</bold>) Representative colony formation data for OVCAR8 and CAOV3 cells sustaining FOXM1 or RHNO1 knockdown. NS: nontargeting shRNA. (<bold>B</bold>) Representative colony formation data for OVCAR8 and CAOV3 cells sustaining FOXM1 or RHNO1 CRISPR knockout. CTL: control guide RNA. (<bold>C</bold>) Annexin V apoptosis assay results for OVCAR8 cells sustaining FOXM1 or RHNO1 CRISPR knockout. Etoposide-treated cells served as the positive control for apoptosis. t-test p-values: ****&lt;0.0001, ***&lt;0.001, **&lt;0.01, *&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig11-figsupp1-v2.tif"/></fig><fig id="fig11s2" position="float" specific-use="child-fig"><label>Figure 11—figure supplement 2.</label><caption><title>Representative TIDE analyses data for high-grade serous carcinoma cells sustaining FOXM1 or RHNO1 CRISPR gene knockout.</title><p>OVCAR8 and CAOV3 cells engineered for FOXM1 or RHNO1 CRISPR knockout were assessed for indel frequency among a mixed pool of cells. (<bold>A–D</bold>) Indel spectra for (<bold>A</bold>) OVCAR8 LCV2 FOXM1 462 cells; (<bold>B</bold>) CAOV3 LVC2 FOXM1 462 cells; (<bold>C</bold>) OVCAR8 LCV2 RHNO1 413 cells; (<bold>D</bold>) CAOV3 LCV2 RHNO1 413 cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig11-figsupp2-v2.tif"/></fig></fig-group><p>To determine the combined effect of FOXM1 and RHNO1 depletion, we engineered OVCAR8 HGSC cells for dual FOXM1 and RHNO1 shRNA knockdown (<xref ref-type="fig" rid="fig12">Figure 12A</xref>). Dual knockdown reduced OVCAR8 clonogenic growth to a greater degree than either single knockdown, although the effect was similar to that observed with RHNO1 knockdown alone (<xref ref-type="fig" rid="fig12">Figure 12B, C</xref>). To confirm these observations, we constructed CAOV3 HGSC cells with dual FOXM1 + RHNO1 knockdown. The data again showed greatest loss of clonogenic growth with dual FOXM1/RHNO1 knockdown (<xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1</xref>).</p><fig-group><fig id="fig12" position="float"><label>Figure 12.</label><caption><title>OVCAR8 cells with dual FOXM1 and RHNO1 shRNA knockdown have diminished clonogenic growth.</title><p>OVCAR8 high-grade serous carcinoma cells were engineered for doxycycline (dox)-inducible FOXM1 and/or RHNO1 shRNA knockdown. (<bold>A</bold>) OVCAR8 cells treated with dox for 72 hr followed by western blot analysis. (<bold>B</bold>) Representative clonogenic growth data. Cells were seeded into a 6-well dish, in triplicate, at a density of 500 cells. Dox was added at the time of seeding, and media containing dox was replenished every 48 hr. Clonogenic survival was measured at 12 days, and cells were fixed with methanol and stained with crystal violet. (<bold>C</bold>) Quantification of clonogenic growth data. Colonies containing more than 50 cells were counted, and clonogenic survival was quantified as an average of the replicates. NS: nontargeting shRNA. The ANOVA linear trend p-value is shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig12-v2.tif"/></fig><fig id="fig12s1" position="float" specific-use="child-fig"><label>Figure 12—figure supplement 1.</label><caption><title>CAOV3 cells with dual FOXM1 and RHNO1 shRNA knockdown have diminished clonogenic growth.</title><p>CAOV3 high-grade serous carcinoma cells were engineered for doxycycline (dox)-inducible FOXM1 and/or RHNO1 shRNA knockdown. CAOV3 cells treated with dox for 72 hr followed by (<bold>A</bold>) western blot confirmation of FOXM1 knockdown or (<bold>B</bold>) RT-qPCR confirmation of <italic>RHNO1</italic> knockdown. (<bold>C</bold>) Representative clonogenic growth data. Cells were seeded into a 6-well dish, in triplicate, at a density of 500 cells. Dox was added at the time of seeding, and media containing dox was replenished every 48 hr. Clonogenic survival was measured at 12 days, and cells were fixed with methanol and stained with crystal violet. (<bold>D</bold>) Quantification of clonogenic growth data. Colonies containing more than 50 cells were counted, and clonogenic survival was quantified as an average of the replicates. NS: nontargeting shRNA. The ANOVA linear trend p-value is shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig12-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-7"><title>RHNO1 promotes ATR-Chk1 signaling in HGSC cells</title><p>RHNO1 interacts with the 9-1-1 complex and TOPBP1 to promote ATR activation (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>), but this has not been assessed in cancer cells or after treatment with specific inducers of RS To address these questions, we first ectopically expressed HA-tagged RHNO1-WT (wild-type) and the RHNO1-SWV mutant in 293T cells and performed Co-IP/western blotting. RHNO1-SWV has mutations in the APSES DNA binding domain that disrupt its interaction with 9-1-1 but not TOPBP1 (<xref ref-type="fig" rid="fig13">Figure 13A</xref>; <xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>). As expected, RHNO1-WT interacted with RAD9 and RAD1 in 293T cells while RHNO1-SWV was deficient for these interactions (<xref ref-type="fig" rid="fig13">Figure 13B</xref>). Next, we assessed RHNO1 functions in OVCAR8 HGSC cells. RHNO1 was present in chromatin protein extracts at baseline, while treatment with hydroxyurea (HU), a specific inducer of RS, increased its chromatin localization (<xref ref-type="fig" rid="fig13">Figure 13C</xref>). To test RHNO1 interaction with the 9-1-1 complex, we depleted endogenous RHNO1 from OVCAR8 cells using dox-inducible shRNA knockdown, with concomitant dox-inducible expression of shRNA-resistant HA-tagged RHNO1-WT or RHNO1-SWV. The data showed that RHNO1-WT interacted with 9-1-1 and TOPBP1, but RHNO1-SWV interacted only with TOPBP1 (<xref ref-type="fig" rid="fig13">Figure 13D</xref>). Next, to assess the function of RHNO1 in ATR-Chk1 signaling in HGSC cells, we depleted RHNO1 from OVCAR8 cells using dox-inducible shRNA and measured P-Chk1-S345, the canonical readout of the cellular response to RS (<xref ref-type="bibr" rid="bib84">Niida et al., 2007</xref>). We observed an approximately twofold reduction of P-Chk1-S345 in RHNO1-depleted OVCAR8, a similar effect to that reported previously (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>; <xref ref-type="fig" rid="fig13">Figure 13E</xref>). To test RHNO1 function in DNA damage protection, we measured a canonical marker of DNA breaks (γ-H2AX) in different cell cycle phases in OVCAR8 cells. We observed a significant increase of γ-H2AX- in both S and G2 phase after RHNO1 knockdown (<xref ref-type="fig" rid="fig13">Figure 13F</xref>). Additionally, COMET analyses revealed increased DNA strand breaks in OVCAR8 cells after RHNO1 knockdown (<xref ref-type="fig" rid="fig13">Figure 13G</xref>). These data establish that RHNO1 functions in the RS response and DNA damage protection in HGSC cells.</p><fig id="fig13" position="float"><label>Figure 13.</label><caption><title>RHNO1 functions in the replication stress response in high-grade serous carcinoma cells.</title><p>(<bold>A</bold>) Schematic of RHNO1 wild-type and SWV mutant. The proteins are the same molecular weight but residues 55–61 are converted to alanine in the SWV mutant, disrupting its ability to interact with 9-1-1 proteins. (<bold>B</bold>) 293T cells were transfected with empty vector, vector expressing HA-RHNO1-WT or SWV mutant. Protein was harvested 24 hr post transfection for Co-IP and western blot analyses. The red asterisk indicates a non-specific band. (<bold>C</bold>) OVCAR8 cells were seeded for 24 hr, then treated with vehicle or 5 mM hydroxyurea (HU) for 1 hr, and cells were harvested for subcellular fraction into soluble nuclear and chromatin bound proteins and western blot analysis. Histone H3 was used as the chromatin control and Sp1 as the soluble nuclear control. (<bold>D</bold>) OVCAR8-inducible RHNO1 knockdown cells were engineered for inducible expression of HA-tagged RHNO1-WT or SWV mutant, grown in the presence of doxycycline (dox) for 72 hr, and then protein was harvested for Co-IP/western blot analyses. (<bold>E</bold>) OVCAR8 western blot measurement of P-Chk1 sustaining RHNO1 shRNA knockdown. (<bold>F</bold>) OVCAR8 cells were treated with the ATR inhibitor VE-822 or dox to induce RHNO1 shRNA knockdown, and gH2AX-positive cells in different cell cycle phases were quantified by fluorescence-activated cell sorting. (<bold>G</bold>) COMET analysis of DNA strand breakage in OVCAR8 cells following the treatments described in (<bold>F</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig13-v2.tif"/></fig></sec><sec id="s2-8"><title>RHNO1 binding to 9-1-1 is required for its role in the promotion of HGSC clonogenic growth</title><p>To determine whether RHNO1 interaction with 9-1-1 is required for promotion of clonogenic growth, we knocked down endogenous RHNO1 using dox-inducible shRNA in OVCAR8 cells and simultaneously ectopically expressed dox-inducible, shRNA-resistant, RHNO1-WT or RHNO1-SWV (<xref ref-type="fig" rid="fig14">Figure 14A, B</xref>). Importantly, RHNO1-SWV did not rescue the clonogenic growth defect while RHNO1-WT partially rescued the phenotype (<xref ref-type="fig" rid="fig14">Figure 14C, D</xref>). These data link RHNO1 function in clonogenic growth to its role in the RS response via binding to the 9-1-1 complex.</p><fig id="fig14" position="float"><label>Figure 14.</label><caption><title>Binding to the 9-1-1 complex is required for RHNO1 function in OVCAR8 cell clonogenic growth.</title><p>OVCAR8 cells were engineered for doxycycline (dox)-inducible RHNO1 knockdown and simultaneous dox-inducible expression of HA-RHNO1 WT or SWV mutant. (<bold>A, B</bold>) Cells were seeded in the presence of dox and grown for 72 hr to harvest RNA and protein extracts, followed by (<bold>A</bold>) RT-qPCR or (<bold>B</bold>) western blot to confirm knockdown efficiency. (<bold>B</bold>) also shows HA-RHNO1 protein ectopic expression efficiency. (<bold>C</bold>) Cells were seeded into 6-well dishes in triplicate, in the presence of dox and at a density of 500 cells. Media containing dox was replenished every 48 hr. Clonogenic survival was measured 12 days later. A representative data set is shown. (<bold>D</bold>) For the experiment described in (<bold>C</bold>), colonies containing more than 50 cells were counted and clonogenic survival was quantified as an average of the replicates. V: vector control; NS: nontargeting shRNA. t-test p-values are shown. p-value designation: ****&lt;0.0001, ***&lt;0.001, **&lt;0.01, *&lt;0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig14-v2.tif"/></fig></sec><sec id="s2-9"><title>FTE cells with RHNO1 knockout are viable and proliferate normally</title><p>The cell growth and viability studies described above were performed using HGSC cell lines, and the only prior publication linking RHNO1 to this phenotype utilized a breast cancer cell line (<xref ref-type="bibr" rid="bib60">Kim et al., 2010</xref>). To examine whether RHNO1 also contributes to the growth and survival of normal (nontransformed) cells, we used CRISPR-Cas9 to eliminate <italic>RHNO1</italic> in immortalized FTE cells (FT282), a model of HGSC precursor cells (<xref ref-type="bibr" rid="bib57">Karst et al., 2014</xref>; <xref ref-type="fig" rid="fig15">Figure 15A, B</xref>). Remarkably, FTE cells survived long-term expansion upon RHNO1 homozygous knockout and did not exhibit altered growth kinetics (<xref ref-type="fig" rid="fig15">Figure 15C</xref>). Clonogenic assays are not possible in this cell type as these cells do not form colonies (data not shown). This finding suggests that cancer cells may have an increased dependency on RHNO1 compared to nontransformed cells, possibly due to elevated RS in cancer cells (<xref ref-type="bibr" rid="bib19">Buisson et al., 2015</xref>). To test this, we compared the expression of two established markers of RS (P-CHK1-Ser345 and P-RPA2-Ser33) in FT282 cells and HGSC cell lines. The data reveal that HGSC cell lines, including OVCAR8, have robust elevation in RS biomarkers compared to FT282 cells (<xref ref-type="fig" rid="fig15">Figure 15D</xref>). Together, these data, along with the large elevation of RHNO1 expression seen in cancer vs. normal (<xref ref-type="fig" rid="fig6">Figures 6</xref> and <xref ref-type="fig" rid="fig7">7</xref>), suggest that cancer cells have a greater dependency on RHNO1 than do normal cells.</p><fig id="fig15" position="float"><label>Figure 15.</label><caption><title>Homozygous knockout of RHNO1 in FT282 cells does not impact cell proliferation, and high-grade serous carcinoma (HGSC) cells show elevated expression of replication stress (RS) biomarkers compared to Fallopian tube epithelium (FTE) cells.</title><p>RHNO1 knockout was achieved using CRISPR-Cas9 with guide RNAs that targeted near the start and stop codon of <italic>RHNO1</italic>. (<bold>A, B</bold>) <italic>RHNO1</italic> homozygous knockout was confirmed by (<bold>A</bold>) genomic DNA PCR and (<bold>B</bold>) <italic>RHNO1</italic> mRNA expression measured by end-point RT-PCR. NTC: no template control. (<bold>C</bold>) FT282 parental and RHNO1 clonal knockout cells were seeded in quadruplicate and grown in culture for a period of 1 week. Cell growth/viability was measured by the AlamarBlue assay every 24 hr. (<bold>D</bold>) Western blot analyses of two canonical phosphoprotein biomarkers of RS in FTE and HGSC cell lines. Cell line sample names are shown below.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig15-v2.tif"/></fig></sec><sec id="s2-10"><title>FOXM1 and RHNO1 promote DNA homologous recombination repair (HR)</title><p>Based on prior studies of FOXM1 and RHNO1 (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib79">Maachani et al., 2016</xref>; <xref ref-type="bibr" rid="bib88">Park et al., 2012</xref>; <xref ref-type="bibr" rid="bib82">Monteiro et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Khongkow et al., 2014</xref>), we investigated the function of these genes in promoting HR. For this task, we initially used U2OS cells engineered with a functional DNA repair reporter assay (DR-GFP), a widely used model for quantifying HR proficiency in single cells (<xref ref-type="bibr" rid="bib41">Gunn et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Gunn and Stark, 2012</xref>). We further engineered U2OS DR-GFP cells for dox-inducible FOXM1 and/or RHNO1 shRNA knockdown, and also engineered RAD51 knockdown as a positive control for HR impairment (<xref ref-type="fig" rid="fig16">Figure 16A, B</xref>; <xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>). The data revealed that RHNO1, but not FOXM1, knockdown significantly decreased HR capacity in U2OS cells. Interestingly, dual knockdown of FOXM1 and RHNO1 resulted in greater HR impairment, suggesting a cooperative interaction between FOXM1 and RHNO1 in promoting HR in this cell type (<xref ref-type="fig" rid="fig16">Figure 16C</xref>). Next, to address HR in the context of HGSC cells, we used OVCAR8 DR-GFP cells. OVCAR8 cells have monoallelic <italic>BRCA1</italic> promoter methylation but retain HR proficiency, similar to other HGSC cell lines with <italic>BRCA1</italic> methylation (<xref ref-type="bibr" rid="bib48">Huntoon et al., 2013</xref>; <xref ref-type="bibr" rid="bib55">Karakashev et al., 2020</xref>). We validated efficient FOXM1 and/or RHNO1 knockdown in OVCAR8 DR-GFP cells (<xref ref-type="fig" rid="fig16">Figure 16D, E</xref>). In contrast to U2OS in OVCAR8 cells both FOXM1 and RHNO1 knockdown impaired HR, but RHNO1 knockdown had a more substantial effect (<xref ref-type="fig" rid="fig16">Figure 16F</xref>). Similar to U2OS cells, dual FOXM1 + RHNO1 knockdown led to a greater reduction in HR capacity, but the effect was similar to that observed with RHNO1 knockdown alone (<xref ref-type="fig" rid="fig16">Figure 16C, F</xref>). Together, these data validate a significant role for RHNO1 in HR and show that FOXM1 also contributes to HR, potentially in cooperation with RHNO1, in a cell context-specific manner.</p><fig id="fig16" position="float"><label>Figure 16.</label><caption><title>FOXM1 and RHNO1 promote homologous recombination (HR).</title><p>DR-GFP cell lines were treated with doxycycline (dox) to induce shRNA expression, and mRNA knockdowns were measured by RT-qPCR. (<bold>A, B</bold>) <italic>FOXM1</italic>, <italic>RHNO1</italic>, and <italic>RAD51</italic> mRNA expression in U2OS-DR-GFP cells sustaining mRNA knockdown. (<bold>C</bold>) HR repair of I-SceI-induced DSBs in U2OS cells after the indicated mRNA knockdowns. Values are expressed relative to the percentage of green fluorescent protein (GFP)+ cells in I-SceI-transfected control cells. RAD51 knockdown was used as a robust positive control for HR impairment. (<bold>D, E</bold>) <italic>FOXM1</italic>, <italic>RHNO1</italic>, and <italic>RAD51</italic> mRNA expression in OVCAR8-DR-GFP cells. (<bold>F</bold>) HR repair of I-SceI-induced DSBs in OVCAR8 cells after the indicated mRNA knockdowns. Values are expressed relative to the percentage of GFP+ cells in I-SceI-transduced control cells. RAD51 knockdown was used as a robust positive control for HR impairment. All results are shown as mean ± SE from three independent replicates. (<bold>C</bold>) and (<bold>F</bold>) show p-values for the linear trend (excluding the RAD51 control).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig16-v2.tif"/></fig></sec><sec id="s2-11"><title>FOXM1 and RHNO1 promote PARPi resistance in HGSC cells</title><p>Approximately half of HGSC tumors show HR deficiency, which confers PARPi sensitivity through a synthetic lethal interaction (<xref ref-type="bibr" rid="bib108">The Cancer Genome Atlas Research Network, 2011</xref>; <xref ref-type="bibr" rid="bib35">Farmer et al., 2005</xref>; <xref ref-type="bibr" rid="bib77">Lord et al., 2015</xref>). HR-proficient HGSC are less sensitive to PARPi, which limits the clinical utility of these drugs (<xref ref-type="bibr" rid="bib55">Karakashev et al., 2020</xref>). Based on DR-GFP data (<xref ref-type="fig" rid="fig16">Figure 16</xref>), we hypothesized that FOXM1 and RHNO1 may promote PARPi resistance in HGSC cells. To test this, we utilized OVCAR8 cells engineered for dox-inducible knockdown of FOXM1 and/or RHNO1. OVCAR8 cells, which have monoallelic <italic>BRCA1</italic> methylation but still express BRCA1 protein, display an intermediate HR phenotype and are functional for HR in DR-GFP assays (<xref ref-type="fig" rid="fig16">Figure 16</xref>; <xref ref-type="bibr" rid="bib48">Huntoon et al., 2013</xref>). We utilized the prototype FDA-approved PARPi olaparib (<xref ref-type="bibr" rid="bib61">Kim et al., 2015</xref>). Cell proliferation and cell survival assays revealed that either FOXM1 or RHNO1 knockdown sensitized OVCAR8 cells to olaparib, while dual knockdown led to a significantly greater increase in olaparib sensitivity (<xref ref-type="fig" rid="fig17">Figure 17A, B</xref>). In agreement, dual knockdown cells showed the highest level of DNA damage, assessed by γ-H2AX levels, as well as the greatest degree of G2/M arrest (<xref ref-type="fig" rid="fig17">Figure 17C, D</xref>).</p><fig-group><fig id="fig17" position="float"><label>Figure 17.</label><caption><title>FOXM1 and RHNO1 knockdown-sensitize OVCAR8 cells to olaparib.</title><p>OVCAR8 cells engineered for doxycycline (dox)-inducible FOXM1 and/or RHNO1 shRNA knockdown were grown in dox for 72 hr prior to seeding cells for experiments. (<bold>A</bold>) Cells were seeded in 96-well plates in quadruplicate in the presence of dox at a density of 500 cells per well. 24 hr later, cells received media containing dox + vehicle control or olaparib, and this was repeated every 48 hr. Cell viability was measured at 8 days post-olaparib treatment using AlamarBlue assays. The ANOVA linear trend p-value is shown. (<bold>B</bold>) Cells were seeded into 6-well dishes in triplicate in the presence of dox at a density of 5000 cells per well. 24 hr later, cells received media containing dox and vehicle or olaparib, and this was repeated every 48 hr. After 8 days of growth, cells were fixed with methanol and stained with crystal violet for clonogenic assays. A representative result is shown. NS/CTL: nontargeting shRNA. (<bold>C</bold>) Western blot analysis of γ-H2AX in chromatin extracts from cells with dox-inducible control shRNA (NS), FOXM1 shRNA (FX), RHNO1 shRNA (RH), or both (FX/RH). After 48 hr in dox, cells were treated with vehicle control dimethyl sulfoxide (DMSO) or 1 µM olaparib for 24 hr, and protein extracts were harvested. Histone H3 served as a loading control. (<bold>D</bold>) Cells were treated as in (<bold>C</bold>), and cell cycle analyses were conducted 24 hr post-olaparib treatment.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig17-v2.tif"/></fig><fig id="fig17s1" position="float" specific-use="child-fig"><label>Figure 17—figure supplement 1.</label><caption><title>Quantification of γ-H2AX in OVCAR8 chromatin extracts following FOXM1 and/or RHNO1 knockdown and DMSO or olaparib treatment.</title><p>Western blots are shown in <xref ref-type="fig" rid="fig17">Figure 17C</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig17-figsupp1-v2.tif"/></fig></fig-group><p>As FOXM1 and RHNO1 are co-regulated by the F/R-BDP (<xref ref-type="fig" rid="fig10">Figure 10</xref>), we next determined whether F/R-BDP activity impacts olaparib sensitivity. For this task, we used a CRISPRi strategy in OVCAR8 cells (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). Notably, CRISPRi directed to the F/R-BDP reduced the expression of both <italic>FOXM1</italic> and <italic>RHNO1</italic> and significantly sensitized OVCAR8 cells to olaparib, as measured by cell viability assays and clonogenic assays (<xref ref-type="fig" rid="fig18">Figure 18A–C</xref>). In addition, F/R-BDP repression increased olaparib-mediated apoptosis and G2/M arrest (<xref ref-type="fig" rid="fig18">Figure 18D, E</xref>). These data validate FOXM1 and RHNO1 as contributors to the response of HGSC cells to olaparib and, importantly, link this function to F/R-BDP activity.</p><fig id="fig18" position="float"><label>Figure 18.</label><caption><title>CRISPRi repression of the F/R-BDP sensitizes OVCAR8 cells to olaparib.</title><p>(<bold>A</bold>) OVCAR8 cells expressing the KRAB transcriptional repressor and a guide RNA targeting the F/R-BDP, and the corresponding changes in mRNA expression as measured by RT-qPCR. NT: nontargeting guide RNA. (<bold>B</bold>) Cells were seeded in 96-well plates in quadruplicate at a density of 500 cells per well. 24 hr later, cells received media containing vehicle or olaparib, and this was repeated every 48 hr. Cell viability was measured at 8 days using AlamarBlue, and the IC50 for olaparib was determined. An F-test was used to compare IC50 values. (<bold>C</bold>) Cells were seeded into a 6-well dish, in triplicate, at a density of 5000 cells per well. 24 hr later, cells received media containing vehicle or olaparib, and this was repeated every 48 hr. After 8 days of growth, cells were fixed with methanol and stained with crystal violet to visualize colonies. (<bold>D</bold>) The indicated cells were treated with olaparib for 48 hr, and apoptosis was measured using Annexin V staining/fluorescence-activated cell sorting (FACS) analysis. (<bold>E</bold>) Cell cycle profiles were measured using propidium iodide staining/FACS analysis. ANOVA linear trend p-values are shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig18-v2.tif"/></fig></sec><sec id="s2-12"><title>FOXM1 and RHNO1 promote acquired PARPi resistance</title><p>Although HR-deficient HGSC tumors are initially sensitive to PARPi, they often acquire PARPi resistance (<xref ref-type="bibr" rid="bib77">Lord et al., 2015</xref>; <xref ref-type="bibr" rid="bib10">Bitler et al., 2017</xref>; <xref ref-type="bibr" rid="bib37">Fojo and Bates, 2013</xref>; <xref ref-type="bibr" rid="bib100">Sonnenblick et al., 2015</xref>). To assess the possible role of FOXM1 and RHNO1 in acquired PARPi resistance, we used the UWB1.289 (UWB1) cell model system. UWB1 cells are BRCA1 null and highly sensitive to PARPi (<xref ref-type="bibr" rid="bib30">DelloRusso et al., 2007</xref>; <xref ref-type="bibr" rid="bib20">Burgess et al., 2020</xref>), while SyR12 and SyR13 are two UWB1 cell clones selected in vitro for acquired olaparib resistance (<xref ref-type="bibr" rid="bib129">Yazinski et al., 2017</xref>). Notably, SyR clones are dependent on ATR for cell survival in the presence of PARPi (<xref ref-type="bibr" rid="bib129">Yazinski et al., 2017</xref>). We engineered SyR12 and SyR13 cells to express CRISPRi directed to the F/R-BDP, as described above for OVCAR8 cells (<xref ref-type="fig" rid="fig19">Figure 19A</xref>). In agreement with OVCAR8 cell data, F/R-BDP repression sensitized both SyR12 and SyR13 cells to olaparib-mediated loss of cell viability (<xref ref-type="fig" rid="fig19">Figure 19B, C</xref>). While F/R-BDP repression did not restore olaparib sensitivity to the level observed in parental UWB1 cells (<xref ref-type="fig" rid="fig19">Figure 19B, C</xref>), the magnitude of sensitization is quite similar to that seen following treatment with ATRi (<xref ref-type="bibr" rid="bib129">Yazinski et al., 2017</xref>).</p><fig id="fig19" position="float"><label>Figure 19.</label><caption><title>CRISPRi repression of the F/R-BDP in olaparib-resistant cells increases olaparib sensitivity.</title><p>Parental and olaparib-resistant UWB1 cells were engineered to express the KRAB transcriptional repressor and a control guide RNA or guide RNA targeting the F/R-BDP (sg130). (<bold>A</bold>) Cells were seeded and grown for 72 hr, and RNA was harvested for RT-qPCR to measure CRISPRi efficiency. (<bold>B, C</bold>) UWB1 parental KRAB and (<bold>B</bold>) SyR12 KRAB or (<bold>C</bold>) SyR13 KRAB cells were seeded in 96-well plates in quadruplicate at a density of 750 cells per well. 24 hr later, cells received media containing vehicle or olaparib, and this was repeated every 48 hr. Cell viability was measured at 8 days post-treatment using AlamarBlue assays, and the IC50 for olaparib was determined. NT1: nontargeting control guide RNA. FOXM1/RHNO1: sg130 targeting the F/R-BDP. In (<bold>B</bold>, <bold>C</bold>), ANOVA linear trend statistics for the IC50 values are shown. Linear trends were ordered – SyR12/13 NT, SyR12/13 FOXM1/RHNO1 sg130, parental NT.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig19-v2.tif"/></fig></sec><sec id="s2-13"><title>FOXM1 and RHNO1 promote carboplatin resistance</title><p>In addition to PARPi, HR-deficient tumors are sensitive to platinum drugs, a front-line chemotherapy for HGSC (<xref ref-type="bibr" rid="bib14">Bowtell et al., 2015</xref>). In addition, FOXM1 has previously been shown to promote platinum resistance in ovarian cancer (<xref ref-type="bibr" rid="bib132">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="bib17">Brückner et al., 2021</xref>), and we observed several chemoresistant recurrent HGSC patients that showed coordinate upregulation of <italic>FOXM1</italic> and <italic>RHNO1</italic> (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). We tested whether FOXM1 and RHNO1 influences the HGSC cellular response to carboplatin. Clonogenic assays of OVCAR8 cells revealed that dual FOXM1 + RHNO1 knockdown markedly enhanced the effects of carboplatin, while single-knockdown cells showed a substantial, but lesser, effect (<xref ref-type="fig" rid="fig20">Figure 20</xref>). These data further implicate FOXM1 and RHNO1 in the response of ovarian cancer cells to commonly utilized ovarian cancer chemotherapy.</p><fig id="fig20" position="float"><label>Figure 20.</label><caption><title>FOXM1 and RHNO1 knockdown enhances OVCAR8 cell sensitivity to carboplatin.</title><p>OVCAR8 cells were treated with doxycycline (dox) for 48 hr and seeded into triplicate wells of 6-well dishes in single-cell suspension. Cells were treated with carboplatin and dox the day after seeding and every 48 hr thereafter, and allowed to form colonies for 7–21 days. After incubation, cells were fixed in methanol and stained using 0.5% crystal violet; colonies containing &gt;~50 cells were counted. (<bold>A</bold>) Representative clonogenic growth data. (<bold>B</bold>) Quantified data for experimental groups. Each data set was normalized to the DMSO-only treatment data point. The ANOVA p-value for the group comparison is shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig20-v2.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We report that the well-known oncogene <italic>FOXM1</italic> is arranged in a head-to-head bidirectional configuration with <italic>RHNO1</italic>, a gene that promotes ATR-Chk1 signaling (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>). <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression correlate in both normal tissues and cancer, including HGSC, and is one of the most highly correlated BDG pairs genome-wide in FTE and HGSC cell models. These observations raise the possibility that some phenotypes characteristic of tumors with elevated FOXM1 expression might be mediated, in part, by RHNO1. Additionally, our data showing frequent genomic amplification of <italic>RHNO1</italic> in HGSC is consistent with recent observations that DDR genes are frequently amplified in human cancer (<xref ref-type="bibr" rid="bib124">Wu et al., 2020</xref>). More broadly, our findings support that co-expressed BDG pairs functionally contribute to oncogenesis. Recently, it was reported that CNAs are less frequent at BDG as compared to single genes (<xref ref-type="bibr" rid="bib109">Thompson et al., 2018</xref>). This suggests that the frequent copy number gains observed at the <italic>FOXM1</italic>/<italic>RHNO1</italic> BDG are under positive selection and may play an important role in oncogenesis.</p><p>We experimentally validated that the intergenic space separating the <italic>FOXM1</italic> and <italic>RHNO1</italic> TSS functions as a BDP and contributes to <italic>FOXM1</italic> and <italic>RHNO1</italic> co-expression. While the transcription factors that regulate F/R-BDP activity are unknown, BDPs are enriched in specific transcription factor motifs, including GABPA, MYC, E2F1, E2F4, NRF-1, CCAAT, and YY1 (<xref ref-type="bibr" rid="bib75">Lin et al., 2007</xref>). Of these, MYC and E2F1 are likely candidates for F/R-BDP regulation, as these factors are known to activate <italic>FOXM1</italic> expression (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib85">Pan et al., 2018</xref>; <xref ref-type="bibr" rid="bib11">Bollu et al., 2020</xref>), and the F/R-BDP contains motifs for these TFs. Whether specific transcription factors symmetrically or asymmetrically regulate F/R-BDP activity is a key question as the <italic>FOXM1/RHNO1</italic> expression ratio increased in cancer vs. normal. Notably, scRNA-seq of both immortalized FTE cells and HGSC cells revealed that <italic>FOXM1</italic> and <italic>RHNO1</italic> are co-expressed in individual cells. Moreover, <italic>FOXM1</italic> and <italic>RHNO1</italic> was one of the highest correlated BDG pairs genome-wide. This, along with conservation of the F/R-BDP in vertebrates, suggests that FOXM1 and RHNO1 function cooperatively in normal physiology and cancer.</p><p>HGSC tissues and cells overexpress both <italic>FOXM1</italic> and <italic>RHNO1</italic>, suggesting oncogenic functions for each gene. While FOXM1 protein is overexpressed in solid tumors (<xref ref-type="bibr" rid="bib44">Halasi and Gartel, 2013a</xref>; <xref ref-type="bibr" rid="bib70">Li et al., 2017b</xref>; <xref ref-type="bibr" rid="bib29">Dai et al., 2015</xref>), analogous studies of RHNO1 protein expression have not been reported. However, the present study demonstrates that individual targeting of either FOXM1 or RHNO1, using shRNA or CRISPR-Cas9, significantly reduces HGSC cell clonogenic growth, suggesting that each protein contributes to cancer phenotypes. In the case of RHNO1, our data show that it promotes HR, clonogenic growth, and chemotherapy resistance in HGSC cells. Furthermore, rescue experiments showed that the clonogenic growth phenotype promoted by RHNO1 is dependent on its binding to the 9-1-1 complex, in agreement with earlier characterizations of RHNO1 function (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Hara et al., 2020</xref>). In contrast to HGSC cells, CRISPR-mediated knockout of RHNO1 in immortalized FTE cells did not result in growth defects. These data are consistent with the idea that cancer cells, which have elevated RS, have an increased dependence on RHNO1 for survival compared to normal cells. In agreement, we show that HGSC cell lines have high elevation of canonical RS biomarker expression as compared to immortalized FTE cells.</p><p>While FOXM1 knockdown in HGSC cells reduced HR capacity, bulk RNA-seq data suggested that FOXM1 does not strongly regulate DNA repair genes in HGSC cell lines (data not shown). Nonetheless, FOXM1 transcriptional regulation of DNA repair is complex and includes both direct and indirect gene targets (<xref ref-type="bibr" rid="bib136">Zona et al., 2014</xref>). Thus, comprehensive gene expression analyses using several HGSC models will be required to help resolve the role of FOXM1 transcriptional activity in DNA repair. The DR-GFP assay may underestimate the impact of FOXM1 on HR as FOXM1 knockdown can lead to a partial G2/M arrest, which may indirectly increase HR capacity (<xref ref-type="bibr" rid="bib49">Hustedt and Durocher, 2016</xref>). Future experiments using cell cycle synchronizations will be important to address the precise role of FOXM1 and RHNO1 in HGSC cell cycle progression and its relation to HR capacity.</p><p>Consistent with their functions in HR, we show that FOXM1 and RHNO1 jointly promote PARPi resistance both in treatment-naive HGSC cells and in HGSC cells with acquired PARPi resistance. Interestingly, dual FOXM1 + RHNO1 knockdown led to increased olaparib sensitivity as measured using cell viability, G2/M accumulation, and clonogenic growth assays compared to single-gene knockdown. One possible explanation for these data is that RHNO1 may inhibit FOXM1-mediated S/G2 progression, a recently described novel cell cycle checkpoint that is enforced by ATR (<xref ref-type="bibr" rid="bib95">Saldivar et al., 2018</xref>). Thus, in the absence of RHNO1, due to reduced ATR/Chk1 activity, cells may progress more readily into G2/M, resulting in increased mitotic DNA damage (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>). Loss of RHNO1 leads to a less efficient RS response and increases DNA damage, while additional loss of FOXM1 might cause mitotic defects that increase the DNA-damaging effects of olaparib.</p><p>In addition to PARPi, FOXM1 and RHNO1 may impact the response to other chemotherapy. Both <italic>FOXM1</italic> and <italic>RHNO1</italic> were coordinately upregulated in approximately half of patients with chemoresistant recurrent HGSC, where the first-line therapy was carboplatin + paclitaxel. FOXM1 was reported to promote resistance to both of these drugs, and RHNO1, which promotes the DDR, might also augment carboplatin resistance (<xref ref-type="bibr" rid="bib106">Tassi et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Kwok et al., 2010</xref>; <xref ref-type="bibr" rid="bib21">Carr et al., 2010</xref>; <xref ref-type="bibr" rid="bib83">Nestal de Moraes et al., 2015</xref>; <xref ref-type="bibr" rid="bib116">Wang et al., 2013</xref>). In agreement, our data support a role for both proteins in decreasing HGSC cell sensitivity to carboplatin. Although there are currently no inhibitors of RHNO1, ATR, Chk1, and/or WEE1 inhibitors might help impair the oncogenic function of RHNO1. In contrast to the clinically advanced RS response inhibitors, to date, FOXM1 inhibitors (FOXM1i) have only been used in preclinical studies (<xref ref-type="bibr" rid="bib54">Kalathil et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Gormally et al., 2014</xref>; <xref ref-type="bibr" rid="bib135">Ziegler et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Brückner et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Gartel, 2008</xref>).</p><p>In some instances, we measured cell phenotypes downstream of dual FOXM1 + RHNO1 targeting and compared these to single knockdown. We note that the cellular response to dual FOXM1 + RHNO1 targeting is predicted to be complex due to the pleiotropic nature of FOXM1 function (<xref ref-type="bibr" rid="bib54">Kalathil et al., 2020</xref>). For example, FOXM1 contributes to several cell cycle transitions including G1/S, S/G2, G2/M, and mitotic progression (<xref ref-type="bibr" rid="bib44">Halasi and Gartel, 2013a</xref>; <xref ref-type="bibr" rid="bib27">Costa, 2005</xref>; <xref ref-type="bibr" rid="bib65">Laoukili et al., 2005</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Saldivar et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Arceci et al., 2019</xref>; <xref ref-type="bibr" rid="bib133">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="bib23">Chen et al., 2013</xref>; <xref ref-type="bibr" rid="bib105">Tan et al., 2010</xref>; <xref ref-type="bibr" rid="bib126">Xue et al., 2010</xref>). Thus, one model would predict that cells with reduced FOXM1 would have a reduced rate of inherited DNA damage caused by RHNO1 loss (<xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>) due to reduced cell cycle transit of cells with damaged DNA. This model seems to be in agreement with recent reports showing that FOXM1 sensitizes tumor cells to Chk1 and WEE1 inhibitors (<xref ref-type="bibr" rid="bib25">Chung et al., 2019</xref>; <xref ref-type="bibr" rid="bib15">Branigan et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Diab et al., 2020</xref>). In contrast, because FOXM1 is also required for proper mitotic progression and disruption of FOXM1 increases mitotic DNA damage (<xref ref-type="bibr" rid="bib65">Laoukili et al., 2005</xref>), it is plausible that targeting FOXM1 could, in some instances, augment the effects of RHNO1 depletion. The latter idea is consistent with the observation that decreased levels of FOXM1 cause mitotic decline, genomic instability, and senescence during human aging (<xref ref-type="bibr" rid="bib80">Macedo et al., 2018</xref>). This model is more consistent with our data as dual targeting of FOXM1 and RHNO1 mostly caused additive reductions in HR activity and clonogenic growth capacity, and was not antagonistic. Finally, reduced cell cycle progression and cell proliferation seen in FOXM1 knockdown cells might lead to additive effects with RHNO1 knockdown, which reduces cell survival, particularly in clonogenic growth assays (<xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Kim et al., 2010</xref>). In summary, the outcome of FOXM1/RHNO1 dual targeting, and how it compares to individual gene targeting, likely depends on the specific cellular context and cell phenotype examined.</p><p>A synopsis of our findings and its potential implications for HGSC biology and therapy are presented (<xref ref-type="fig" rid="fig21">Figure 21</xref>). <italic>FOXM1</italic> and <italic>RHNO1</italic> are BDG that are co-amplified in HGSC and other tumors due to focal amplification at 12p13.33 (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>; <xref ref-type="bibr" rid="bib86">Paracchini et al., 2020</xref>). <italic>FOXM1</italic> and <italic>RHNO1</italic> are co-expressed as a result of co-regulation by the F/R-BDP and are overexpressed in HGSC and numerous other cancers (<xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; this study). The oncogenic functions of FOXM1 in HGSC include cell cycle progression, genomic instability, tumor invasion, and metastatic spread (<xref ref-type="bibr" rid="bib87">Parashar et al., 2020</xref>; <xref ref-type="bibr" rid="bib7">Barger et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Barger et al., 2015</xref>). On the other hand, RHNO1 may promote oncogenesis by increasing the efficiency of the ATR-Chk1-dependent RS response, which protects cells from excessive DNA damage and promotes cell survival (<xref ref-type="bibr" rid="bib60">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="bib28">Cotta-Ramusino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Lindsey-Boltz et al., 2015</xref>).</p><fig id="fig21" position="float"><label>Figure 21.</label><caption><title>Model for FOXM1/RHNO1 bidirectional gene (BDG) function and cooperativity.</title><p><italic>FOXM1</italic> and <italic>RHNO1</italic> are BDGs regulated by a bidirectional promoter (BDP) and are co-amplified and co-expressed in high-grade serous carcinoma (HGSC), including single cells. Both genes are overexpressed in HGSC and other cancers. FOXM1, via the activation of specific gene targets, promotes oncogenic phenotypes, including cell cycle progression, proliferation, replication stress (RS), genomic instability, and metastatic progression; the latter phenotype may reflect activation of a distinct set of transcriptional targets later in tumor progression. In contrast, RHNO1 promotes ATR-Chk1 signaling via its binding to 9-1-1 and TOPBP1 and promotes the RS response. This protects HGSC cells from excessive RS and DNA damage and enhances cell survival. RHNO1 co-expression may help to mitigate excessive FOXM1-induced RS and thus facilitate other FOXM1 oncogenic functions. FOXM1 and RHNO1 co-expression may increase tumor resiliency by allowing tumor cells to gain a fitness advantage of increased growth and proliferation without accumulating excessive DNA damage. Consistently, FOXM1-expressing tumors are highly enriched for biomarkers of RS (<xref ref-type="bibr" rid="bib72">Li et al., 2020</xref>). Therapeutic targeting of the FOXM1/RHNO1 bidirectional gene unit may be accomplished using inhibitors of FOXM1 and/or ATR/Chk1/WEE1. RHNO1 inhibitors have not been reported (dashed line).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-55070-fig21-v2.tif"/></fig><p>What is the functional link between FOXM1 and RHNO1? We observed that ectopic expression of FOXM1 in FTE cells increases RS biomarker expression and alters replication fork dynamics (unpublished data). Thus, FOXM1 may induce RS, while RHNO1 responds to RS. Critical support for this model is provided by a recent study that demonstrated that FOXM1 expression induced RS and genomic instability in bronchial epithelial cells and U2OS cells (<xref ref-type="bibr" rid="bib72">Li et al., 2020</xref>). Additionally, the authors showed that FOXM1 expression correlates with RS biomarkers in The Cancer Protein Atlas data from several cancer types, including HGSC (<xref ref-type="bibr" rid="bib72">Li et al., 2020</xref>). We thus hypothesize that the mechanistic link between FOXM1 and RHNO1 centers around RS, in that RHNO1 may help to mitigate excessive RS driven by FOXM1 (<xref ref-type="fig" rid="fig21">Figure 21</xref>). FOXM1 and RHNO1 co-expression may provide a selective advantage to tumors by enabling a balance between increased proliferation and cell cycle progression, which promotes RS, and the RS response, which limits DNA damage and promotes cell survival. Co-activation of these two proteins may thus increase tumor resiliency, that is, allowing tumor cells to grow and survive in the face of challenges including hypoxia, DNA-damaging chemotherapy, immune cell infiltration, and other intrinsic and extrinsic insults.</p><p>Finally, regarding the timing of these events in ovarian cancer, it is known that FOXM1 is expressed in HGSC precursor lesions in the FTE, which may, along with other proteins such as cyclin E1, increase RS, thus providing a selective advantage for RHNO1 co-expression (<xref ref-type="bibr" rid="bib57">Karst et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Levanon et al., 2014</xref>). Later during tumor progression, genomic instability functions as an important driver of continued RS independent of particular oncoproteins (<xref ref-type="bibr" rid="bib89">Passerini et al., 2016</xref>; <xref ref-type="bibr" rid="bib120">Wilhelm et al., 2020</xref>). However, FOXM1 remains highly expressed because it promotes critical functions in late-stage progression unrelated to RS and genomic instability (<xref ref-type="bibr" rid="bib44">Halasi and Gartel, 2013a</xref>; <xref ref-type="bibr" rid="bib54">Kalathil et al., 2020</xref>). Additionally, in late-stage tumors, RHNO1 and other RS response proteins such as ATR, Chk1, and WEE1 become critically important to restrict excessive DNA damage, which would otherwise impair cell survival. Overall, this conceptual framework may prove useful to guide future studies of FOXM1 and RHNO1 and their interplay in normal physiology and cancer.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>TCGA, CCLE, GTEx, and RIKEN FANTOM5 data retrieval</title><p>TCGA, CCLE, and GTEx data sets were retrieved from cBioPortal and University of California Santa Cruz (UCSC) Xena Browser. The genomic profiles of <italic>FOXM1</italic> and <italic>RHNO1</italic> were analyzed in the TCGA HGSC data set (Ovarian Serous Cystadenocarcinoma-TCGA Provisional), including somatic CNAs from GISTIC (<xref ref-type="bibr" rid="bib9">Beroukhim et al., 2007</xref>) using Onco Query Language and mRNA expression using RNA-seq (RNA-seq V2 RSEM). <italic>FOXM1</italic> and <italic>RHNO1</italic> expression profiles from TOIL GTEx (cell lines removed) and TCGA HGSC RNA-seq data sets were obtained from UCSC Xena. <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression data from Cap Analysis of Gene Expression analysis of mouse tissues was obtained from the RIKEN FANTOM5 project (RNA-seq) data set obtained from <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk">http://www.ebi.ac.uk</ext-link>.</p></sec><sec id="s4-2"><title>UCSC Genome Browser data</title><p>The genomic region of <italic>FOXM1</italic> and <italic>RHNO1</italic> was retrieved from UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="http://genome.ucsc.edu">http://genome.ucsc.edu</ext-link>) (<xref ref-type="bibr" rid="bib58">Kent et al., 2002</xref>) using the human genome build hg19 and the genomic coordinates cHR12:2966150–2998815. Several tracks were selected and displayed, including <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA, CGI, DNAseI hypersensitivity, H3K4Me1, H3K4Me3, and H3K27Ac ChIP-seq tracks, transcription factor ChIP-seq, genome segmentations, and conserved genome tracks from 100 vertebrates and mammalian genomes. The Genome Browser screenshot tool was used to obtain images.</p></sec><sec id="s4-3"><title>Illumina Infinium HumanMethylation450K data</title><p>TCGA pan-cancer DNA methylation (HumanMethylation450K) data were downloaded from UCSC Xena (<ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu">http://xena.ucsc.edu</ext-link>) consisting of 9753 samples. This data set contains the DNA methylation 450K array beta values compiled by combining available data from all TCGA cohorts. The GDSC1000 collection (The Genomics of Drug Sensitivity in Cancer Project, Welcome Sanger Institute) was downloaded from NCBI GEO (GSE68379) (<xref ref-type="bibr" rid="bib50">Iorio et al., 2016</xref>). For all data sets, the DNA methylation profile was measured using the Illumina Infinium HumanMethylation450 platform and the Infinium HumanMethylation450 BeadChip Kit. The method consists of approximately 450,000 probes querying the methylation status of CpG sites within and outside CGI. The DNA methylation score of each CpG is represented as a beta value, which is a normalized value between 0 (fully unmethylated) and 1 (fully methylated).</p></sec><sec id="s4-4"><title>Sodium bisulfite DNA sequencing (bisulfite sequencing)</title><p>Bisulfite sequencing was used to determine the methylation status of the <italic>F/R-BDP</italic> region in NO and EOC human tissue samples (<xref ref-type="bibr" rid="bib26">Clark et al., 1994</xref>). Genomic DNA was isolated using the Puregene Tissue Kit (QIAGEN) and was chemically converted using the EZ DNA Methylation Kit (Zymo Research Corp.). The F/R-BDP region containing a CGI was amplified from the bisulfite-converted DNA using methylation PCR-specific primers, designed using MethPrimer (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>; <xref ref-type="bibr" rid="bib73">Li and Dahiya, 2002</xref>). Gradient PCR reactions were performed using a C1000 Touch Thermal Cycler (Bio-Rad) to optimize annealing temperatures. After gel purification using the QIAquick Gel Extraction Kit (QIAGEN), PCR products were cloned using the TOPO TA Cloning Kit (Invitrogen). Between 9 and 15 individual clones were sequenced for each sample, and Sanger sequencing was performed by the UNMC DNA Sequencing Core Facility. DNA sequence information was analyzed using the Lasergene SeqMan Pro program (DNASTAR).</p></sec><sec id="s4-5"><title>Cell lines</title><p>COV362 and COV318 cell lines (Sigma) were cultured in DMEM (Corning) supplemented with 10% fetal bovine serum (FBS, Invitrogen), 2 mM glutamine (Life Technologies), and 1% penicillin-streptomycin (pen-strep, Life Technologies). KURAMOCHI and OVSAHO (Japanese Collection of Research Bioresources Cell Bank) and SNU-119 (Korean Cell Line Bank) cell lines were cultured in RPMI-1640 (Hyclone) supplemented with 10% FBS and 1% pen-strep. OVCAR4 cells (National Cancer Institute Division of Cancer Treatment and Diagnosis Cell Line Repository) were cultured in RPMI-1640 supplemented with 10% FBS and 1% pen-strep. OVCAR8 cells (National Cancer Institute Division of Cancer Treatment and Diagnosis Cell Line Repository) were cultured in DMEM (Corning) supplemented with 10% FBS and 1% pen-strep. OVCAR3 cells (American Type Culture Collection) were cultured in DMEM with 10% FBS and 1% pen-strep. CAOV3 and OVCAR5 cell lines were a gift from Anirban Mitra (Indiana University) and were cultured in DMEM with 10% FBS and 1% pen-strep. UWB1.289, UWB1-SyR12, and UWB1-SyR13 cells were cultured in RPMI 1640/Mammary Epithelial Growth Media (1:1; Hyclone/PromoCell) supplemented with 3% FBS, MEGM growth factors, and 1% pen-step (<xref ref-type="bibr" rid="bib129">Yazinski et al., 2017</xref>). Primary hOSE cells (ScienCell) were cultured in Ovarian Epithelial Cell Medium (ScienCell, 7311). Human immortalized FTE cells (FT190, FT282-E1, and FT282) were cultured in DMEM-Ham’s F12 50/50 (Corning) supplemented with 2% USG (Pall Corporation) or 10% FBS and 1% pen-strep (<xref ref-type="bibr" rid="bib57">Karst et al., 2014</xref>; <xref ref-type="bibr" rid="bib56">Karst et al., 2011</xref>). IOSE-T cells (IOSE-21, hOSE immortalized with hTERT) (<xref ref-type="bibr" rid="bib68">Li et al., 2007</xref>) were a gift from Francis Balkwill (Cancer Research UK) and were cultured in Medium 199/MCDB105 (1:1, Sigma) supplemented with 15% FBS, 1% pen-strep, 10 ng/mL human epidermal growth factor (Life Technologies), 0.5 μg/mL hydrocortisone (Sigma), 5 μg/mL bovine insulin (Cell Applications), and 34 μg protein/mL bovine pituitary extract (Life Technologies). IOSE-SV cells (IOSE-121, hOSE immortalized with SV40 Large T antigen) were a gift from Nelly Auersperg (University of British Columbia) and were cultured in Medium 199/MCDB105 (1:1) supplemented with 10% FBS and 25 µg/mL gentamicin (Life Technologies). HEK293T cells (American Type Culture Collection) were cultured in DMEM with 10% FBS and 1% pen-strep. U2OS-DR-GFP (282C) cells were a gift from Jeremy Stark (City of Hope) and were grown in McCoy’s 5A (Corning), 10% FBS, and 1% pen-strep (<xref ref-type="bibr" rid="bib41">Gunn et al., 2011</xref>; <xref ref-type="bibr" rid="bib42">Gunn and Stark, 2012</xref>). OVCAR8-DR-GFP cells were a gift from Larry Karnitz and Scott Kaufmann (Mayo Clinic, Rochester) and were grown in the same conditions as OVCAR8 parental cells (<xref ref-type="bibr" rid="bib48">Huntoon et al., 2013</xref>). All cell lines were maintained at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Cell culture medium was changed every 3–5 days depending on cell density. For routine cell passage, cells were split at a ratio of 1:3 to 1:10 when they reached 85to–90% confluence. Doxycycline-inducible cells were treated every 48 hr with doxycycline unless otherwise noted.</p><p>Stocks of all cell lines were authenticated using short tandem repeat analysis at the DNA Services Facility, University of Illinois at Chicago. All cell line stocks were confirmed to be mycoplasma free using PCR analyses at the Epigenomics Core Facility, University of Nebraska Medical Center. Cells thawed for experimental use were discarded prior to 1 month post thaw.</p></sec><sec id="s4-6"><title>Reverse transcription quantitative PCR (RT-qPCR)</title><p>Total RNA was purified using TRIzol (Invitrogen) and RNA was DNase-treated using the DNA-free kit (Ambion) or Direct-zol RNA Purification Kit (Zymo Research) with in-column DNase treatment. RNA quality was determined by running samples on RNA denaturing gels (1.2% agarose gel in 1X MOPS buffer containing formaldehyde) and checking for RNA degradation. DNase-treated RNA was converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). 1 µL of 1:5 cDNA sample dilutions were used for qPCR reactions. Standard curves were prepared using gel-purified end-point RT-PCR products. All samples were run in triplicate using the CFX Connect Real-Time System (Bio-Rad), and all gene expression data were normalized to 18S rRNA. PCR was performed using an annealing temperature of 60°C and a total of 45 cycles for all primer pairs. Dissociation curves were performed to confirm specific product amplification. Gradient PCRs were performed using the C1000 Touch Thermal Cycler (Bio-Rad) to determine the annealing temperatures for each primer set. Primer sequences are listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Primer sequences were designed using NCBI Primer Blast (<xref ref-type="bibr" rid="bib131">Ye et al., 2012</xref>) or were selected from those previously reported in the literature.</p></sec><sec id="s4-7"><title>Western blotting</title><p>Whole-cell protein extracts were prepared using radio-immunoprecipitation assay (RIPA) buffer (1× PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) supplemented with protease and phosphatase inhibitors (Sigma). Briefly, cells were lysed for 10 min in RIPA buffer and then sonicated, and the resulting extracts were centrifuged at 4°C for 10 min at 14,000 <italic>g</italic> to remove cell debris. Nuclear protein extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific) supplemented with protease and phosphatase inhibitors. Protein concentrations were determined using the BCA protein assay (Thermo Scientific). Equal amounts of protein (~30–50 µg) were fractionated on 4–12% gradient SDS-polyacrylamide gel electrophoresis gels (Invitrogen) and transferred to PVDF membrane (Roche). Membranes were stained with Ponceau S to confirm efficient transfer and equal loading, and were then blocked with 5% nonfat dry milk in Tris-buffered saline Tween-20 (TBST) for 1 hr at room temperature. The membranes were then incubated with primary antibodies in 5% nonfat dry milk or 5% bovine serum albumin (BSA) in TBST at 4°C overnight followed by incubation with secondary antibodies in 5% nonfat dry milk in TBST for 1 hr at room temperature. Antibody information is provided in the Key resources table. Enhanced chemiluminescence (Thermo Scientific) was used for protein detection. Quantification of protein expression was performed using ImageJ software (Image Processing and Analysis in Java, National Institute of Health) (<xref ref-type="bibr" rid="bib96">Schneider et al., 2012</xref>).</p></sec><sec id="s4-8"><title>Tissues</title><p>Human NO tissues and EOC tissues were obtained from patients undergoing surgical resection at Roswell Park Comprehensive Cancer Center (RPCCC) using Institutional Review Board-approved protocols as described previously (<xref ref-type="bibr" rid="bib2">Akers et al., 2014</xref>). Pathology specimens were reviewed at RPCCC, and tumors were classified according to World Health Organization criteria (<xref ref-type="bibr" rid="bib97">Serov et al., 1973</xref>). Genomic DNA and total RNA extractions of tissues were performed as described previously (<xref ref-type="bibr" rid="bib122">Woloszynska-Read et al., 2008</xref>).</p></sec><sec id="s4-9"><title>Single-cell RNA sequencing</title><p>FT282 and OVCAR8 cells were seeded on day 0 at ~50% and ~30% confluency, respectively, and harvested on day 2 at ~80% confluence. Cells were trypsinized and cell suspensions were pipetted several times and passed through a 40 μm cell strainer to ensure a single-cell suspension. Cell viability (Trypan blue exclusion) was confirmed to be &gt;90% using the TC20 Automated Cell Counter (Bio-Rad). Cell pellets were washed twice in PBS containing 0.04% BSA, resuspended in PBS, and 0.04% BSA to ~500,000 cells/mL, and transported to the UNMC DNA Sequencing Core Facility for single-cell capture, library preparation, and scRNA-seq. As per manufacturer's instructions, ~2750 cells were loaded per channel to achieve a target of ~1500 captured cells. Single cells were loaded on a CHRomium Single Cell Instrument (10X Genomics) to generate single-cell gel bead in emulsions (GEMs) for the partitioning of samples and reagents into droplets. GEMs contain oligos, lysed cell components, and Master Mix. GEMs were processed as follows: cells were lysed, RNA extracted, and reverse transcribed to generate full-length, barcoded cDNA from the poly A-tailed mRNA transcripts. Barcoded cDNA molecules from each cell were PCR-amplified in bulk followed by enzymatic fragmentation. The Qubit was then used to measure and optimize the insert size of the double-stranded cDNA prior to library construction. Single-cell cDNA and RNA-Seq libraries were prepared using the Chromium Single Cell 3′ Library and Gel Bead Kit v2 (10x Genomics), and the products were quantified on the 2100 Bioanalyzer DNA High Sensitivity Chip (Agilent). Each fragment contains the 10x Barcode Unique Molecular Identifier (UMI) and cDNA insert sequence used for data analysis. During library construction, Read 2 is added by Adapter ligation. Both single-cell libraries were sequenced using the Illumina NextSeq 550 system using the following parameters: pair-end sequencing with single indexing, 26 cycles for Read 1 and 98 cycles for Read 2. FT282 cells produced a total of 85.6 million reads and OVCAR8 produced 82 million reads, and both had an overall Q30 for the run of 87.6%. Sequencing data were transferred to the Bioinformatics and Systems Biology Core Facility at UNMC for analysis. The Cell Ranger Single Cell Software (10X Genomics) was used to process raw bcl files to perform sample demultiplexing, barcode processing, and single-cell 3′ gene counting (<ext-link ext-link-type="uri" xlink:href="https://software.10xgenomics.com/single-cell/overview/welcome">https://software.10xgenomics.com/single-cell/overview/welcome</ext-link>). Each data set was aligned to a combined human (hg19) reference, and only cells that were identified as aligned to human in the ‘filtered’ output of the Cell Ranger count module were used for analysis.</p><p>The statistical method scImpute was used to accurately and robustly impute the transcript dropouts (zero values) that exist in scRNA-seq data from sequencing small amounts of RNA. The scImpute R package was downloaded from <ext-link ext-link-type="uri" xlink:href="https://github.com/Vivianstats/scImpute">https://github.com/Vivianstats/scImpute</ext-link>; <xref ref-type="bibr" rid="bib74">Li and Li, 2018</xref> and was run in R with default settings. FT282 and OVCAR8 scRNA-seq raw gene expression matrix files (.mtx) were converted into dense expression matrices using `cellRanger mat2csv` command. The scImpute input data consisted of a scRNA-seq matrices with rows representing genes and columns representing cells, and output data consisted of an imputed count matrix with the same dimension. FT282 and OVCAR8 scRNA-seq data were deposited into the GEO database (GSE150864).</p><p>BDG pairs were obtained by searching the UCSC database for protein-coding gene pairs in which the TSS diverge on opposite DNA strands and are located within 1000 base pairs. For each cell line, we computed the Pearson’s correlation coefficient between all BDG pairs. We performed principal component analysis (PCA) and computed correlation coefficients on the data sets using Python.</p></sec><sec id="s4-10"><title>scRNA-seq data set retrieval</title><p>scRNA-seq data sets from mouse normal colon epithelium (GSE92332) (<xref ref-type="bibr" rid="bib43">Haber et al., 2017</xref>) and human melanoma (GSE72056) (<xref ref-type="bibr" rid="bib110">Tirosh et al., 2016</xref>) were downloaded from NCBI GEO. scRNA-seq data for human HGSC tissues were obtained from a published data set (<xref ref-type="bibr" rid="bib121">Winterhoff et al., 2017</xref>). scRNA-seq data were normalized using sclmpute (<xref ref-type="bibr" rid="bib74">Li and Li, 2018</xref>).</p></sec><sec id="s4-11"><title><italic>FOXM1</italic> and <italic>RHNO1</italic> expression in primary and recurrent HGSC</title><p>We obtained <italic>FOXM1</italic> and <italic>RHNO1</italic> RNA-seq data from patient-matched primary and recurrent HGSC from the European Genome-phenome Archive (EGA) <ext-link ext-link-type="uri" xlink:href="https://ega-archive.org/">https://ega-archive.org/</ext-link>, using EGAD00001000877 and EGAD00010001403 (<xref ref-type="bibr" rid="bib90">Patch et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Kreuzinger et al., 2017</xref>).</p></sec><sec id="s4-12"><title>Promoter activity luciferase reporter assays</title><p>Luciferase reporter assays were performed using the pGL4 Luc Rluc Empty (Firefly and Renilla luciferase) and pCMV6-SEAP (SEAP, transfection control) plasmid constructs. Firefly and Renilla luciferase activities were measured 24 hr after transfection using the Dual-Luciferase Reporter Assay System (Promega) and a GloMax 20/20 luminometer (Promega). Luciferase activity was expressed in arbitrary units as displayed on the luminometer after a 10 s integration time. SEAP activity was measured 24 hr after transfection using the Phospha-Light kit (Thermo Scientific) and a POLARstar OPTIMA microplate reader (BMG Labtech). Transfections were performed in triplicate in each individual experiment.</p></sec><sec id="s4-13"><title>Promoter activity GFP/RFP reporter assays (FACS)</title><p>Single-cell F/R-BDP bidirectional promoter activity assays were performed using the pTurbo-RFP-GFP plasmid containing a cloned F/R-BDP promoter region. The pTurbo-RFP-GFP empty plasmid was used as the negative control. pTurbo plasmids containing the PGK promoter and either GFP or RFP alone were used as fluorescence-activated cell sorting (FACS) compensation controls. Briefly, 900,000 HEK293T cells were seeded into 6-well dishes and cells were transfected 24 hr later using Lipofectamine 2000 (Life Technologies) and 2 µg of plasmid DNA in Opti-MEM. Cells were harvested 24 hr after transfection, washed with PBS, and 10,000 events per sample were analyzed by FACS to determine GFP and RFP expression.</p></sec><sec id="s4-14"><title>RLM-RACE mapping</title><p>The TSS of <italic>FOXM1</italic> and <italic>RHNO1</italic> were determined using the FirstChoice RLM-RACE Kit (Ambion) according to the manufacturer's instructions. RNA was isolated using TRIzol reagent (Invitrogen) followed by purification with Direct-zol RNA MiniPrep with in-column genomic DNA digestion. RLM-RACE allows for the specific amplification of 5' capped RNA, which is found only in full-length mRNA. The specific outer and inner (nested) primers in combination with adaptor-specific primers were used for amplifying the 5' ends of <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). As negative controls, non-tobacco alkaline phosphatase (TAP)-treated aliquots from each RNA source were used; in all cases, this did not yield specific product amplification (data not shown). In contrast, <italic>FOXM1</italic>- and <italic>RHNO1</italic>-specific PCR products of various sizes were yielded from the TAP-containing reactions. PCR products were separated on 2% agarose gels, excised, and purified using the QIAquick gel extraction kit (QIAGEN). Gel-purified PCR products were cloned using the TOPO TA Cloning Kit (Invitrogen), and individual clones were Sanger sequenced by the UNMC DNA Sequencing Core Facility. DNA sequence information was analyzed using the Lasergene SeqMan Pro program (DNASTAR).</p></sec><sec id="s4-15"><title>Production of lentiviral particles and lentiviral transductions</title><p>Replication-deficient lentivirus was produced by transient transfection of 6.0 μg psPAX2 (Addgene #12260), 2.0 μg pMD2.G (Addgene #12259), and 8.0 μg transfer plasmid into HEK293T cells in a 10 cm dish with Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer’s instructions. Viral supernatants were collected 48 hr post-infection and passed through a 0.2 μm filter. Functional titration was performed by transduction of cells with serially diluted virus in the presence of polybrene (4 μg/mL, Sigma) for 6 hr, followed by puromycin, G418, blasticidin, or hygromycin (Life Technologies) selection for 48 hr post-infection. For dual knockdown and rescue experiments requiring two different lentiviral constructs, cell lines underwent sequential transduction and selection.</p></sec><sec id="s4-16"><title>CRISPR-Cas9 gene knockouts</title><p>CRISPR-Cas9-mediated knockout was performed as previously described (<xref ref-type="bibr" rid="bib93">Ran et al., 2013</xref>). Briefly, Lipofectamine 2000 (Life Technologies) was used to transfect HEK293T cells with PX458 (Addgene #48138), which expresses Cas9 and a guide RNA. <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> contains a list of all sgRNA used. Guide RNAs were designed using the Genetic Perturbation Platform Web Portal (<ext-link ext-link-type="uri" xlink:href="https://portals.broadinstitute.org/gpp/public/">https://portals.broadinstitute.org/gpp/public/</ext-link>), and the highest scoring guide RNAs were empirically tested for their cutting efficiency. Isolation of clonal cell lines was achieved with FACS followed by plating of GFP-positive cells into 96-well dishes for clonal growth. DNA was isolated from clones using QuickExtract (Epicentre) for genotyping and replica plated for clonal expansion. Genotyping was performed by PCR with an annealing temperature of 60°C and 30 cycles for all primer pairs listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. Primers were designed with NCBI Primer-BLAST, then empirically tested by gradient end-point PCR to optimize specificity and sensitivity.</p><p><italic>FOXM1</italic> and <italic>RHNO1</italic> lentiCRISPR gene editing efficiency was assessed by PCR using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific) followed by Sanger sequencing. TIDE analysis was performed to decompose the Sanger sequencing data and quantify the insertions and deletions (indels) in the DNA of the targeted cell pools (<xref ref-type="bibr" rid="bib16">Brinkman et al., 2014</xref>). TIDE analysis was performed using the default settings, and parental genomic DNA was used as the control.</p></sec><sec id="s4-17"><title>RNA interference and plasmid constructs</title><p><xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> lists the miR-30-based short hairpin RNAs used (shRNAs, Dharmacon). The Key resources table lists all plasmids used. shRNAs were expressed from the TRIPZ dox-inducible lentiviral plasmid (Dharmacon), which co-expresses RFP and puromycin. The miR-30 shRNA cassettes containing RFP-shRNA were subcloned from TRIPZ into pCW57 (pCW57-MCS1-P2A-MCS2-Hygro, Addgene# 80922; pCW57-MCS1-P2A-MCS2-Blast, Addgene# 80921; and pCW57-MCS1-P2A-MCS2-Neo, Addgene# 89180) using the restrictions enzymes AgeI and MluI to generate an RNAi system with additional selection markers beyond puromycin (hygromycin, neomycin, and blasticidin). All plasmids were sequence verified. Plasmids were transfected with Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions.</p></sec><sec id="s4-18"><title>Drug treatments</title><p>Detailed information on the drugs used in this study (i.e., olaparib, berzosertib, hydroxyurea, etoposide, carboplatin, and doxycycline) is given in the Key resources table. Specific drug concentrations and time points used in experiments are described in the figures and legends.</p></sec><sec id="s4-19"><title>Clonogenic growth (i.e., colony formation) assays</title><p>Cells were trypsinized, counted, and seeded at a density of 500–1500 cells per well in triplicate wells of 6-well dishes in single-cell suspension and allowed to form colonies for 7–21 days. Following incubation, cells were fixed in methanol and stained using 0.5% crystal violet in PBS, rinsed with water, and air-dried overnight. Colonies containing &gt;~50 cells were counted using inverted light microscope manually or from captured images using countPHICS (count and Plot HIstograms of Colony Size) software, a macro written for ImageJ (<xref ref-type="bibr" rid="bib18">Brzozowska et al., 2019</xref>).</p></sec><sec id="s4-20"><title>Apoptosis assays</title><p>Cellular apoptosis was measured using the Muse Annexin V and Dead Cell kit (Millipore) according to the manufacturer's instructions. Briefly, the spent cell culture media containing floating cells was collected and saved, and adherent cells were harvested with trypsin-EDTA. Media containing 10% FBS was added to the trypsinized cells and then combined with the spent media and total cell numbers were counted. The cell suspension was centrifuged at 300 × <italic>g</italic> for 5 min, and the cell pellet was resuspended to a final concentration of 1 × 10<sup>5</sup> cells/mL using media containing 1% FBS. Untreated cells were used as the negative control. Annexin V staining was achieved by first warming the Muse Annexin V and Dead Cell Reagent to room temperature before adding 100 μL to each tube of cell suspensions. The suspensions were gently and thoroughly mixed by pipetting up and down 10 times with a 1000 μL pipette. Samples were incubated for 20 min at room temperature in the dark. Immediately after incubation, the percentage of apoptotic cells was analyzed by flow cytometry using Muse Cell Analyzer (Millipore) system.</p></sec><sec id="s4-21"><title>Co-immunoprecipitation assays</title><p>Cells expressing empty vector and HA-tagged ORFs were lysed with M-PER (Pierce) containing Halt Protease and Phosphatase Cocktail (Pierce) and Nuclease S1. Lysates were mixed end-over-end at 4°C for 30 min, then centrifuged at 4°C for 10 min at 14,000 <italic>g</italic> to remove cell debris. Protein concentration were determined using the BCA protein assay (Thermo Scientific). Immunoprecipitations were performed using anti-HA magnetic beads and 500 µg total protein per sample. Samples were incubated overnight at 4°C with end-over-end mixing. The next day the magnetic beads were washed, and proteins were eluted using sample loading buffer. The entire sample was then loaded onto western blots. 5–10% total protein was used for input comparisons.</p></sec><sec id="s4-22"><title>FACS analyses of cell cycle and γ-H2AX expression</title><p>Cells were fixed in 70% ethanol overnight for cell cycle and/or γ-H2AX expression analysis of single cells. Fixed cells were washed with PBS and incubated overnight in PBS containing 1% BSA, 10% goat serum, and pS139-H2AX antibody (Millipore), then washed and incubated in goat anti-mouse Alexa Fluor 647 antibody for 30 min at room temperature. Cells were then incubated in 50 μg/mL propidium iodide and 100 μg/mL RNase A for 30 min, and 10,000 cells per sample were analyzed using a BD FACSarray (BD Biosciences) using 532 and 635 nm excitations and collecting fluorescent emissions with filters at 585/42 nm and 661/16 nm (yellow and red parameters, respectively). In other experiments, the γ-H2AX staining procedure was omitted and cells were only processed for cell cycle analyses using propidium iodide staining.</p></sec><sec id="s4-23"><title>Comet assays</title><p>The Comet Assay Kit (Trevigen) was used according to the manufacturer's instructions. Briefly, cells were suspended in low-melt agarose, layered onto treated slides to promote attachment (500 cells per slide), lysed, and subjected to electrophoresis (1 V/cm) under alkaline conditions to reveal single- and double-stranded DNA breaks using the Comet Assay Electrophoresis System II (Trevigen). Samples were then fixed, dried, and stained with SYBR Gold. Images were acquired with a ×10× objective lens using the EVOS FL Cell Imaging System (Thermo Fisher). Comet tail size was quantified using Comet Analysis Software (Trevigen).</p></sec><sec id="s4-24"><title>Homologous recombination repair (HR) assay (DR-GFP assay)</title><p>U2OS and OVCAR8 cells were previously generated for stable integration of DR-GFP, an HR substrate that generates a functional GFP upon successful HR after I-SceI cutting (<xref ref-type="bibr" rid="bib42">Gunn and Stark, 2012</xref>; <xref ref-type="bibr" rid="bib48">Huntoon et al., 2013</xref>; <xref ref-type="bibr" rid="bib92">Pierce et al., 1999</xref>). U2OS and OVCAR8 cells were grown in the presence of doxycycline for 48 hr to induce shRNA expression and gene knockdown. U2OS cells were transfected with pCBASceI (Addgene; #26477) in the presence of 1 µg/mL doxycycline. Media containing doxycycline was changed 3 hr post-transfection, and cells were kept in culture for an additional 48 hr. OVCAR8 cells were transduced for 8 hr with AdNGUS24i, an adenovirus expressing I-SceI (a gift from Drs. Frank Graham and Phillip Ng, Baylor College of Medicine). Cells were harvested and fixed with 10% formaldehyde, then washed and analyzed by FACS to determine the fraction of GFP-positive cells.</p></sec><sec id="s4-25"><title>AlamarBlue cell viability assays</title><p>Cells were seeded at a density of 500–1000 cells per well into quadruplicate wells of sterile 96-well plates and treated as described in the figures and legends. AlamarBlue (Bio-Rad) was used to assess cell proliferation and cell viability. Background fluorescence values were obtained from wells containing only media and were subtracted from all data points. Data from drug-treated cells were normalized to vehicle-treated controls.</p></sec><sec id="s4-26"><title>Statistical analyses</title><p>The Student’s t-test was used to compare differences between means of two groups. The Mann–Whitney test was used to compare differences between medians of two groups. The F-test was used to compare statistical models that were fitted to a data set by nonlinear regression. One-way analysis of variance (ANOVA) with a post-test for linear trend was used to compare two or more groups. For all analyses, significance was inferred at p&lt;0.05 and the computed p values were two-sided. GraphPad Prism (GraphPad Software, Inc) was used to perform statistical tests.</p></sec><sec id="s4-27"><title>Data deposit</title><p>Newly generated scRNA-seq data was deposited into the GEO database under accession number GSE150864.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Keith Johnson for original project insight and Gargi Ghosal for critical reading of the manuscript. We thank Anirban Mitra for CAOV3 and OVCAR5 cells, Larry Karnitz and Scott Kaufmann for OVCAR8 DR-GFP cells, Jeremy Stark and Tadayoshi Bessho for U2OS DR-GFP cells, Francis Balkwill for IOSE-T cells, Nelly Auersperg for IOSE-SV cells, Frank Graham and Philip Ng for SceI adenovirus, Stephen Elledge for the RHNO1-SWV mutant, and Aziz Sancar for RHNO1 antibody. We thank the UNMC Epigenomics, Genomics, Bioinformatics, and Flow Cytometry Core Facilities for expert assistance. This work was funded by the Rivkin Center for Ovarian Cancer, the Fred and Pamela Buffett Cancer Center, NCI P30 CA036727, NIH T32CA009476, NCI F99CA212470, NCI P50CA228991, the University of Nebraska Core Facility Grant Program, a UNMC Program of Excellence Assistantship, and the Betty J and Charles D McKinsey Ovarian Cancer Research Fund.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Resources</p></fn><fn fn-type="con" id="con8"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title><italic>FOXM1</italic> vs. <italic>RHNO1</italic> mRNA expression correlations.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-55070-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Oligonucleotide sequences.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55070-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of bidirectional gene pairs to support <xref ref-type="fig" rid="fig5">Figure 5</xref> (Excel file).</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-55070-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-55070-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated are found within the manuscript and supporting files. sc-RNA-seq data is deposited in GEO under accession number GSE150864.</p><p>The following dataset was generated:</p><p><element-citation id="dataset11" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Barger</surname><given-names>CJ</given-names></name><name><surname>Chee</surname><given-names>L</given-names></name><name><surname>Albahrani</surname><given-names>M</given-names></name><name><surname>Munoz-Trujillo</surname><given-names>C</given-names></name><name><surname>Boghean</surname><given-names>L</given-names></name><name><surname>Branick</surname><given-names>C</given-names></name><name><surname>Odunsi</surname><given-names>K</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Karpf</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Single cell RNA sequencing of human high-grade serous ovarian cancer (HGSC) cells and human immortalized fallopian tube epitheilal (FTE) cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE150864">GSE150864</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Abugessaisa</surname><given-names>I</given-names></name><name><surname>Ramilowski</surname><given-names>JA</given-names></name><name><surname>Lizio</surname><given-names>M</given-names></name><name><surname>Severin</surname><given-names>J</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Harshbarger</surname><given-names>J</given-names></name><name><surname>Kondo</surname><given-names>A</given-names></name><name><surname>Noguchi</surname><given-names>S</given-names></name><name><surname>Yip</surname><given-names>CW</given-names></name><name><surname>Ooi</surname><given-names>JL</given-names></name><name><surname>Tagami</surname><given-names>M</given-names></name><name><surname>Hori</surname><given-names>T</given-names></name><name><surname>Agrawal</surname><given-names>S</given-names></name><name><surname>Hon</surname><given-names>CC</given-names></name><name><surname>Cardon</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Bono</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Hoon</surname><given-names>M</given-names></name><name><surname>Hayashizaki</surname><given-names>Y</given-names></name><name><surname>Carninci</surname><given-names>P</given-names></name><name><surname>Kawaji</surname><given-names>H</given-names></name><name><surname>Kasukawa</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>RNAseq</data-title><source>RIKEN FANTOM5</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://fantom.gsc.riken.jp/5/datafiles/latest/">FANTOM5</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Barretina</surname><given-names>J</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Venkatesan</surname><given-names>K</given-names></name><name><surname>Margolin</surname><given-names>AA</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>CJ</given-names></name><name><surname>Lehár</surname><given-names>J</given-names></name><name><surname>Kryukov</surname><given-names>GV</given-names></name><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Reddy</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>L</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Monahan</surname><given-names>JE</given-names></name><name><surname>Morais</surname><given-names>P</given-names></name><name><surname>Meltzer</surname><given-names>J</given-names></name><name><surname>Korejwa</surname><given-names>A</given-names></name><name><surname>Jané-Valbuena</surname><given-names>J</given-names></name><name><surname>Mapa</surname><given-names>FA</given-names></name><name><surname>Thibault</surname><given-names>J</given-names></name><name><surname>Bric-Furlong</surname><given-names>E</given-names></name><name><surname>Raman</surname><given-names>P</given-names></name><name><surname>Shipway</surname><given-names>A</given-names></name><name><surname>Engels</surname><given-names>IH</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>GK</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Aspesi</surname><given-names>P</given-names></name><name><surname>de Silva</surname><given-names>M</given-names></name><name><surname>Jagtap</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>MD</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hatton</surname><given-names>C</given-names></name><name><surname>Palescandolo</surname><given-names>E</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Mahan</surname><given-names>S</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Onofrio</surname><given-names>RC</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>MacConaill</surname><given-names>L</given-names></name><name><surname>Winckler</surname><given-names>W</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Gabriel</surname><given-names>SP</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Ardlie</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Myer</surname><given-names>VE</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name><name><surname>Porter</surname><given-names>J</given-names></name><name><surname>Warmuth</surname><given-names>M</given-names></name><name><surname>Finan</surname><given-names>P</given-names></name><name><surname>Harris</surname><given-names>JL</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Morrissey</surname><given-names>MP</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><data-title>Cancer Cell Line Encyclopedia</data-title><source>CCLE</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://data.broadinstitute.org/ccle/CCLE_DepMap_18Q2_RNAseq_RPKM_20180502.gct">CCLE_DepMap_18Q2_RNAseq_RPKM_20180502.gct</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2017">2017</year><data-title>GTEx</data-title><source>GTEx</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://toil-xena-hub.s3.us-east-1.amazonaws.com/download/gtex_RSEM_Hugo_norm_count.gz">gtex_RSEM_Hugo_norm_count.gz</pub-id></element-citation></p><p><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>TCGA Consortium</collab></person-group><year iso-8601-date="2018">2018</year><data-title>TCGA Pan Cancer</data-title><source>TCGA Pan Cancer</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://tcga-pancan-atlas-hub.s3.us-east-1.amazonaws.com/download/EB%2B%2BAdjustPANCAN_IlluminaHiSeq_RNASeqV2.geneExp.xena.gz">EB%2B%2BAdjustPANCAN_IlluminaHiSeq_RNASeqV2.geneExp.xena.gz</pub-id></element-citation></p><p><element-citation id="dataset5" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>TCGA Consortium</collab></person-group><year iso-8601-date="2011">2011</year><data-title>TCGA Ovarian Cancer</data-title><source>TCGA HGSC</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://tcga-xena-hub.s3.us-east-1.amazonaws.com/download/TCGA.OV.sampleMap%2FHiSeqV2.gz">TCGA.OV.sampleMap%2FHiSeqV2.gz</pub-id></element-citation></p><p><element-citation id="dataset6" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Haber</surname><given-names>AL</given-names></name><name><surname>Biton</surname><given-names>M</given-names></name><name><surname>Rogel</surname><given-names>N</given-names></name><name><surname>Herbst</surname><given-names>RH</given-names></name><name><surname>Shekhar</surname><given-names>K</given-names></name><name><surname>Smillie</surname><given-names>C</given-names></name><name><surname>Burgin</surname><given-names>G</given-names></name><name><surname>Delorey</surname><given-names>TM</given-names></name><name><surname>Howitt</surname><given-names>MR</given-names></name><name><surname>Katz</surname><given-names>Y</given-names></name><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Beyaz</surname><given-names>S</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Raychowdhury</surname><given-names>R</given-names></name><name><surname>Garrett</surname><given-names>WS</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Ning Shi</surname><given-names>H</given-names></name><name><surname>Yilmaz</surname><given-names>O</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>scRNA-seq intestine</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92332">GSE92332</pub-id></element-citation></p><p><element-citation id="dataset7" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Tirosh</surname><given-names>I</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Prakadan</surname><given-names>SM</given-names></name><name><surname>Wadsworth</surname><given-names>MH</given-names></name><name><surname>Treacy</surname><given-names>D</given-names></name><name><surname>Trombetta</surname><given-names>JJ</given-names></name><name><surname>Rotem</surname><given-names>A</given-names></name><name><surname>Rodman</surname><given-names>C</given-names></name><name><surname>Lian</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>G</given-names></name><name><surname>Fallahi-Sichani</surname><given-names>M</given-names></name><name><surname>Dutton-Regester</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>O</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Genshaft</surname><given-names>AS</given-names></name><name><surname>Hughes</surname><given-names>TK</given-names></name><name><surname>Ziegler</surname><given-names>CGK</given-names></name><name><surname>Kazer</surname><given-names>SW</given-names></name><name><surname>Gaillard</surname><given-names>A</given-names></name><name><surname>Kolb</surname><given-names>KE</given-names></name><name><surname>Villani</surname><given-names>A</given-names></name><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Andreev</surname><given-names>AY</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Bertagnolli</surname><given-names>M</given-names></name><name><surname>Sorger</surname><given-names>PK</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Frederick</surname><given-names>DT</given-names></name><name><surname>Jané-Valbuena</surname><given-names>J</given-names></name><name><surname>Yoon</surname><given-names>CH</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>scRNA-seq melanoma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72056">GSE72056</pub-id></element-citation></p><p><element-citation id="dataset9" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Christie</surname><given-names>EL</given-names></name><name><surname>Etemadmoghadam</surname><given-names>D</given-names></name><name><surname>Garsed</surname><given-names>DW</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Fereday</surname><given-names>S</given-names></name><name><surname>Nones</surname><given-names>K</given-names></name><name><surname>Cowin</surname><given-names>P</given-names></name><name><surname>Alsop</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>PJ</given-names></name><name><surname>Kassahn</surname><given-names>KS</given-names></name><name><surname>Newell</surname><given-names>F</given-names></name><name><surname>Quinn</surname><given-names>MCJ</given-names></name><name><surname>Kazakoff</surname><given-names>S</given-names></name><name><surname>Quek</surname><given-names>K</given-names></name><name><surname>Wilhelm-Benartzi</surname><given-names>C</given-names></name><name><surname>Curry</surname><given-names>E`</given-names></name><name><surname>Leong</surname><given-names>HS</given-names></name><collab>Australian Ovarian Cancer Study Group; Anne Hamilton</collab><name><surname>Mileshkin</surname><given-names>L</given-names></name><name><surname>Au-Yeung</surname><given-names>G</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Chiew</surname><given-names>YE</given-names></name><name><surname>Harnett</surname><given-names>P</given-names></name><name><surname>Friedlander</surname><given-names>M</given-names></name><name><surname>Quinn</surname><given-names>M</given-names></name><name><surname>Pyman</surname><given-names>J</given-names></name><name><surname>Cordner</surname><given-names>S</given-names></name><name><surname>O'Brien</surname><given-names>P</given-names></name><name><surname>Leditschke</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>G</given-names></name><name><surname>Strachan</surname><given-names>K</given-names></name><name><surname>Waring</surname><given-names>P</given-names></name><name><surname>Azar</surname><given-names>W</given-names></name><name><surname>Mitchell</surname><given-names>C</given-names></name><name><surname>Traficante</surname><given-names>N</given-names></name><name><surname>Hendley</surname><given-names>J</given-names></name><name><surname>Thorne</surname><given-names>H</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>DK</given-names></name><name><surname>Arnau</surname><given-names>GM</given-names></name><name><surname>Tothill</surname><given-names>RW</given-names></name><name><surname>Holloway</surname><given-names>TP</given-names></name><name><surname>Semple</surname><given-names>T</given-names></name><name><surname>Harliwong</surname><given-names>I</given-names></name><name><surname>Nourse</surname><given-names>C</given-names></name><name><surname>Nourbakhsh</surname><given-names>E</given-names></name><name><surname>Manning</surname><given-names>S</given-names></name><name><surname>Idrisoglu</surname><given-names>S</given-names></name><name><surname>Bruxner</surname><given-names>TJC</given-names></name><name><surname>Christ</surname><given-names>AN</given-names></name><name><surname>Poudel</surname><given-names>B</given-names></name><name><surname>Holmes</surname><given-names>O</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name><name><surname>Leonard</surname><given-names>C</given-names></name><name><surname>Lonie</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>N</given-names></name><name><surname>Wood</surname><given-names>S</given-names></name><name><surname>Taylor</surname><given-names>DF</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Fink</surname><given-names>JL</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Stronach</surname><given-names>E</given-names></name><name><surname>Gabra</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Jewell</surname><given-names>A</given-names></name><name><surname>Nagaraj</surname><given-names>SH</given-names></name><name><surname>Markham</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>PJ</given-names></name><name><surname>Ellul</surname><given-names>J</given-names></name><name><surname>McNally</surname><given-names>O</given-names></name><name><surname>Doyle</surname><given-names>MA</given-names></name><name><surname>Vedururu</surname><given-names>R</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Lengyel</surname><given-names>E</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>deFazio</surname><given-names>A</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Bowtell</surname><given-names>DDL</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>HGSC RNA-seq</data-title><source>European Genome-Phenome Archive</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ega-archive.org/datasets/EGAD00001000877">EGAD00001000877</pub-id></element-citation></p><p><element-citation id="dataset10" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Kreuzinger</surname><given-names>C</given-names></name><name><surname>Geroldinger</surname><given-names>A</given-names></name><name><surname>Smeets</surname><given-names>D</given-names></name><name><surname>Braicu</surname><given-names>EI</given-names></name><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Koller</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>A</given-names></name><name><surname>Darb-Esfahani</surname><given-names>S</given-names></name><name><surname>Joehrens</surname><given-names>K</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Vanderstichele</surname><given-names>A</given-names></name><name><surname>Boeckx</surname><given-names>B</given-names></name><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Gabra</surname><given-names>H</given-names></name><name><surname>Wisman</surname><given-names>GBA</given-names></name><name><surname>Trillsch</surname><given-names>F</given-names></name><name><surname>Heinze</surname><given-names>G</given-names></name><name><surname>Horvat</surname><given-names>R</given-names></name><name><surname>Polterauer</surname><given-names>S</given-names></name><name><surname>Berns</surname><given-names>E</given-names></name><collab>Theillet C</collab><name><surname>Castillo-Tong</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>HGSC RNA-seq</data-title><source>European Genome-Phenome Archive</source><pub-id assigning-authority="other" pub-id-type="accession" xlink:href="https://ega-archive.org/datasets/EGAD00010001403">EGAD00010001403</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguirre</surname> <given-names>AJ</given-names></name><name><surname>Meyers</surname> <given-names>RM</given-names></name><name><surname>Weir</surname> <given-names>BA</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Zhang</surname> <given-names>CZ</given-names></name><name><surname>Ben-David</surname> <given-names>U</given-names></name><name><surname>Cook</surname> <given-names>A</given-names></name><name><surname>Ha</surname> <given-names>G</given-names></name><name><surname>Harrington</surname> <given-names>WF</given-names></name><name><surname>Doshi</surname> <given-names>MB</given-names></name><name><surname>Kost-Alimova</surname> <given-names>M</given-names></name><name><surname>Gill</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Ali</surname> <given-names>LD</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Pantel</surname> <given-names>S</given-names></name><name><surname>Lee</surname> <given-names>Y</given-names></name><name><surname>Goodale</surname> <given-names>A</given-names></name><name><surname>Cherniack</surname> <given-names>AD</given-names></name><name><surname>Oh</surname> <given-names>C</given-names></name><name><surname>Kryukov</surname> <given-names>G</given-names></name><name><surname>Cowley</surname> <given-names>GS</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Stegmaier</surname> <given-names>K</given-names></name><name><surname>Roberts</surname> <given-names>CW</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Tsherniak</surname> <given-names>A</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>914</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0154</pub-id><pub-id pub-id-type="pmid">27260156</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akers</surname> <given-names>SN</given-names></name><name><surname>Moysich</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Collamat Lai</surname> <given-names>G</given-names></name><name><surname>Miller</surname> <given-names>A</given-names></name><name><surname>Lele</surname> <given-names>S</given-names></name><name><surname>Odunsi</surname> <given-names>K</given-names></name><name><surname>Karpf</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients</article-title><source>Gynecologic Oncology</source><volume>132</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.12.024</pub-id><pub-id pub-id-type="pmid">24374023</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antequera</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Structure, function and evolution of CpG island promoters</article-title><source>Cellular and Molecular Life Sciences</source><volume>60</volume><fpage>1647</fpage><lpage>1658</lpage><pub-id pub-id-type="doi">10.1007/s00018-003-3088-6</pub-id><pub-id pub-id-type="pmid">14504655</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arceci</surname> <given-names>A</given-names></name><name><surname>Bonacci</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Stewart</surname> <given-names>K</given-names></name><name><surname>Damrauer</surname> <given-names>JS</given-names></name><name><surname>Hoadley</surname> <given-names>KA</given-names></name><name><surname>Emanuele</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer</article-title><source>Cell Reports</source><volume>26</volume><fpage>3076</fpage><lpage>3086</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.054</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barger</surname> <given-names>CJ</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Hillman</surname> <given-names>J</given-names></name><name><surname>Stablewski</surname> <given-names>AB</given-names></name><name><surname>Higgins</surname> <given-names>MJ</given-names></name><name><surname>Vanderhyden</surname> <given-names>BC</given-names></name><name><surname>Odunsi</surname> <given-names>K</given-names></name><name><surname>Karpf</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression</article-title><source>Oncotarget</source><volume>6</volume><fpage>27613</fpage><lpage>27627</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4546</pub-id><pub-id pub-id-type="pmid">26243836</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barger</surname> <given-names>CJ</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Sharma</surname> <given-names>A</given-names></name><name><surname>Chee</surname> <given-names>L</given-names></name><name><surname>James</surname> <given-names>SR</given-names></name><name><surname>Kufel</surname> <given-names>CN</given-names></name><name><surname>Miller</surname> <given-names>A</given-names></name><name><surname>Meza</surname> <given-names>J</given-names></name><name><surname>Drapkin</surname> <given-names>R</given-names></name><name><surname>Odunsi</surname> <given-names>K</given-names></name><name><surname>Klinkebiel</surname> <given-names>D</given-names></name><name><surname>Karpf</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expression of the POTE gene family in human ovarian cancer</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>17136</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-35567-1</pub-id><pub-id pub-id-type="pmid">30459449</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barger</surname> <given-names>C</given-names></name><name><surname>Branick</surname> <given-names>C</given-names></name><name><surname>Chee</surname> <given-names>L</given-names></name><name><surname>Karpf</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pan-Cancer analyses reveal genomic features of FOXM1 overexpression in Cancer</article-title><source>Cancers</source><volume>11</volume><elocation-id>251</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11020251</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Caponigro</surname> <given-names>G</given-names></name><name><surname>Stransky</surname> <given-names>N</given-names></name><name><surname>Venkatesan</surname> <given-names>K</given-names></name><name><surname>Margolin</surname> <given-names>AA</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Wilson</surname> <given-names>CJ</given-names></name><name><surname>Lehár</surname> <given-names>J</given-names></name><name><surname>Kryukov</surname> <given-names>GV</given-names></name><name><surname>Sonkin</surname> <given-names>D</given-names></name><name><surname>Reddy</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Murray</surname> <given-names>L</given-names></name><name><surname>Berger</surname> <given-names>MF</given-names></name><name><surname>Monahan</surname> <given-names>JE</given-names></name><name><surname>Morais</surname> <given-names>P</given-names></name><name><surname>Meltzer</surname> <given-names>J</given-names></name><name><surname>Korejwa</surname> <given-names>A</given-names></name><name><surname>Jané-Valbuena</surname> <given-names>J</given-names></name><name><surname>Mapa</surname> <given-names>FA</given-names></name><name><surname>Thibault</surname> <given-names>J</given-names></name><name><surname>Bric-Furlong</surname> <given-names>E</given-names></name><name><surname>Raman</surname> <given-names>P</given-names></name><name><surname>Shipway</surname> <given-names>A</given-names></name><name><surname>Engels</surname> <given-names>IH</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Yu</surname> <given-names>GK</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Aspesi</surname> <given-names>P</given-names></name><name><surname>de Silva</surname> <given-names>M</given-names></name><name><surname>Jagtap</surname> <given-names>K</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Palescandolo</surname> <given-names>E</given-names></name><name><surname>Gupta</surname> <given-names>S</given-names></name><name><surname>Mahan</surname> <given-names>S</given-names></name><name><surname>Sougnez</surname> <given-names>C</given-names></name><name><surname>Onofrio</surname> <given-names>RC</given-names></name><name><surname>Liefeld</surname> <given-names>T</given-names></name><name><surname>MacConaill</surname> <given-names>L</given-names></name><name><surname>Winckler</surname> <given-names>W</given-names></name><name><surname>Reich</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name><name><surname>Gabriel</surname> <given-names>SB</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Ardlie</surname> <given-names>K</given-names></name><name><surname>Chan</surname> <given-names>V</given-names></name><name><surname>Myer</surname> <given-names>VE</given-names></name><name><surname>Weber</surname> <given-names>BL</given-names></name><name><surname>Porter</surname> <given-names>J</given-names></name><name><surname>Warmuth</surname> <given-names>M</given-names></name><name><surname>Finan</surname> <given-names>P</given-names></name><name><surname>Harris</surname> <given-names>JL</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Morrissey</surname> <given-names>MP</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Schlegel</surname> <given-names>R</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title><source>Nature</source><volume>483</volume><fpage>603</fpage><lpage>607</lpage><pub-id pub-id-type="doi">10.1038/nature11003</pub-id><pub-id pub-id-type="pmid">22460905</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Nghiemphu</surname> <given-names>L</given-names></name><name><surname>Barretina</surname> <given-names>J</given-names></name><name><surname>Hsueh</surname> <given-names>T</given-names></name><name><surname>Linhart</surname> <given-names>D</given-names></name><name><surname>Vivanco</surname> <given-names>I</given-names></name><name><surname>Lee</surname> <given-names>JC</given-names></name><name><surname>Huang</surname> <given-names>JH</given-names></name><name><surname>Alexander</surname> <given-names>S</given-names></name><name><surname>Du</surname> <given-names>J</given-names></name><name><surname>Kau</surname> <given-names>T</given-names></name><name><surname>Thomas</surname> <given-names>RK</given-names></name><name><surname>Shah</surname> <given-names>K</given-names></name><name><surname>Soto</surname> <given-names>H</given-names></name><name><surname>Perner</surname> <given-names>S</given-names></name><name><surname>Prensner</surname> <given-names>J</given-names></name><name><surname>Debiasi</surname> <given-names>RM</given-names></name><name><surname>Demichelis</surname> <given-names>F</given-names></name><name><surname>Hatton</surname> <given-names>C</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Nelson</surname> <given-names>SF</given-names></name><name><surname>Liau</surname> <given-names>L</given-names></name><name><surname>Mischel</surname> <given-names>PS</given-names></name><name><surname>Cloughesy</surname> <given-names>TF</given-names></name><name><surname>Meyerson</surname> <given-names>M</given-names></name><name><surname>Golub</surname> <given-names>TA</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mellinghoff</surname> <given-names>IK</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma</article-title><source>PNAS</source><volume>104</volume><fpage>20007</fpage><lpage>20012</lpage><pub-id pub-id-type="doi">10.1073/pnas.0710052104</pub-id><pub-id pub-id-type="pmid">18077431</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bitler</surname> <given-names>BG</given-names></name><name><surname>Watson</surname> <given-names>ZL</given-names></name><name><surname>Wheeler</surname> <given-names>LJ</given-names></name><name><surname>Behbakht</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>PARP inhibitors: Clinical utility and possibilities of overcoming resistance</article-title><source>Gynecologic Oncology</source><volume>147</volume><fpage>695</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2017.10.003</pub-id><pub-id pub-id-type="pmid">29037806</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollu</surname> <given-names>LR</given-names></name><name><surname>Shepherd</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>D</given-names></name><name><surname>Ma</surname> <given-names>Y</given-names></name><name><surname>Tahaney</surname> <given-names>W</given-names></name><name><surname>Speers</surname> <given-names>C</given-names></name><name><surname>Mazumdar</surname> <given-names>A</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Brown</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1</article-title><source>NPJ Breast Cancer</source><volume>6</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1038/s41523-019-0143-5</pub-id><pub-id pub-id-type="pmid">31909186</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolognese</surname> <given-names>F</given-names></name><name><surname>Forni</surname> <given-names>C</given-names></name><name><surname>Caretti</surname> <given-names>G</given-names></name><name><surname>Frontini</surname> <given-names>M</given-names></name><name><surname>Minuzzo</surname> <given-names>M</given-names></name><name><surname>Mantovani</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The Pole3 bidirectional unit is regulated by MYC and E2Fs</article-title><source>Gene</source><volume>366</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2005.07.046</pub-id><pub-id pub-id-type="pmid">16403426</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bornelöv</surname> <given-names>S</given-names></name><name><surname>Komorowski</surname> <given-names>J</given-names></name><name><surname>Wadelius</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Different distribution of histone modifications in genes with unidirectional and bidirectional transcription and a role of CTCF and cohesin in directing transcription</article-title><source>BMC Genomics</source><volume>16</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.1186/s12864-015-1485-5</pub-id><pub-id pub-id-type="pmid">25881024</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowtell</surname> <given-names>DD</given-names></name><name><surname>Böhm</surname> <given-names>S</given-names></name><name><surname>Ahmed</surname> <given-names>AA</given-names></name><name><surname>Aspuria</surname> <given-names>PJ</given-names></name><name><surname>Bast</surname> <given-names>RC</given-names></name><name><surname>Beral</surname> <given-names>V</given-names></name><name><surname>Berek</surname> <given-names>JS</given-names></name><name><surname>Birrer</surname> <given-names>MJ</given-names></name><name><surname>Blagden</surname> <given-names>S</given-names></name><name><surname>Bookman</surname> <given-names>MA</given-names></name><name><surname>Brenton</surname> <given-names>JD</given-names></name><name><surname>Chiappinelli</surname> <given-names>KB</given-names></name><name><surname>Martins</surname> <given-names>FC</given-names></name><name><surname>Coukos</surname> <given-names>G</given-names></name><name><surname>Drapkin</surname> <given-names>R</given-names></name><name><surname>Edmondson</surname> <given-names>R</given-names></name><name><surname>Fotopoulou</surname> <given-names>C</given-names></name><name><surname>Gabra</surname> <given-names>H</given-names></name><name><surname>Galon</surname> <given-names>J</given-names></name><name><surname>Gourley</surname> <given-names>C</given-names></name><name><surname>Heong</surname> <given-names>V</given-names></name><name><surname>Huntsman</surname> <given-names>DG</given-names></name><name><surname>Iwanicki</surname> <given-names>M</given-names></name><name><surname>Karlan</surname> <given-names>BY</given-names></name><name><surname>Kaye</surname> <given-names>A</given-names></name><name><surname>Lengyel</surname> <given-names>E</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Lu</surname> <given-names>KH</given-names></name><name><surname>McNeish</surname> <given-names>IA</given-names></name><name><surname>Menon</surname> <given-names>U</given-names></name><name><surname>Narod</surname> <given-names>SA</given-names></name><name><surname>Nelson</surname> <given-names>BH</given-names></name><name><surname>Nephew</surname> <given-names>KP</given-names></name><name><surname>Pharoah</surname> <given-names>P</given-names></name><name><surname>Powell</surname> <given-names>DJ</given-names></name><name><surname>Ramos</surname> <given-names>P</given-names></name><name><surname>Romero</surname> <given-names>IL</given-names></name><name><surname>Scott</surname> <given-names>CL</given-names></name><name><surname>Sood</surname> <given-names>AK</given-names></name><name><surname>Stronach</surname> <given-names>EA</given-names></name><name><surname>Balkwill</surname> <given-names>FR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer</article-title><source>Nature Reviews. Cancer</source><volume>15</volume><fpage>668</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1038/nrc4019</pub-id><pub-id pub-id-type="pmid">26493647</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branigan</surname> <given-names>TB</given-names></name><name><surname>Kozono</surname> <given-names>D</given-names></name><name><surname>Schade</surname> <given-names>AE</given-names></name><name><surname>Deraska</surname> <given-names>P</given-names></name><name><surname>Rivas</surname> <given-names>HG</given-names></name><name><surname>Sambel</surname> <given-names>L</given-names></name><name><surname>Reavis</surname> <given-names>HD</given-names></name><name><surname>Shapiro</surname> <given-names>GI</given-names></name><name><surname>D'Andrea</surname> <given-names>AD</given-names></name><name><surname>DeCaprio</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity</article-title><source>Cell Reports</source><volume>34</volume><elocation-id>108808</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.108808</pub-id><pub-id pub-id-type="pmid">33657372</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkman</surname> <given-names>EK</given-names></name><name><surname>Chen</surname> <given-names>T</given-names></name><name><surname>Amendola</surname> <given-names>M</given-names></name><name><surname>van Steensel</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Easy quantitative assessment of genome editing by sequence trace decomposition</article-title><source>Nucleic Acids Research</source><volume>42</volume><elocation-id>e168</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gku936</pub-id><pub-id pub-id-type="pmid">25300484</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brückner</surname> <given-names>L</given-names></name><name><surname>Reinshagen</surname> <given-names>A</given-names></name><name><surname>Hoang</surname> <given-names>NA</given-names></name><name><surname>Höhn</surname> <given-names>AK</given-names></name><name><surname>Lordick</surname> <given-names>F</given-names></name><name><surname>Bechmann</surname> <given-names>I</given-names></name><name><surname>Aktas</surname> <given-names>B</given-names></name><name><surname>Nel</surname> <given-names>I</given-names></name><name><surname>Kallendrusch</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>FOXM1 inhibition in ovarian Cancer tissue cultures affects individual treatment susceptibility ex vivo</article-title><source>Cancers</source><volume>13</volume><elocation-id>956</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13050956</pub-id><pub-id pub-id-type="pmid">33668819</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzozowska</surname> <given-names>B</given-names></name><name><surname>Gałecki</surname> <given-names>M</given-names></name><name><surname>Tartas</surname> <given-names>A</given-names></name><name><surname>Ginter</surname> <given-names>J</given-names></name><name><surname>Kaźmierczak</surname> <given-names>U</given-names></name><name><surname>Lundholm</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Freeware tool for analysing numbers and sizes of cell colonies</article-title><source>Radiation and Environmental Biophysics</source><volume>58</volume><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/s00411-018-00772-z</pub-id><pub-id pub-id-type="pmid">30673853</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname> <given-names>R</given-names></name><name><surname>Boisvert</surname> <given-names>JL</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase</article-title><source>Molecular Cell</source><volume>59</volume><fpage>1011</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.07.029</pub-id><pub-id pub-id-type="pmid">26365377</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname> <given-names>BT</given-names></name><name><surname>Anderson</surname> <given-names>AM</given-names></name><name><surname>McCorkle</surname> <given-names>JR</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Ueland</surname> <given-names>FR</given-names></name><name><surname>Kolesar</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Olaparib combined with an ATR or Chk1 inhibitor as a treatment strategy for acquired Olaparib-Resistant BRCA1 mutant ovarian cells</article-title><source>Diagnostics</source><volume>10</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics10020121</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carr</surname> <given-names>JR</given-names></name><name><surname>Park</surname> <given-names>HJ</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Kiefer</surname> <given-names>MM</given-names></name><name><surname>Raychaudhuri</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FoxM1 mediates resistance to herceptin and paclitaxel</article-title><source>Cancer Research</source><volume>70</volume><fpage>5054</fpage><lpage>5063</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0545</pub-id><pub-id pub-id-type="pmid">20530690</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>SL</given-names></name><name><surname>Eklund</surname> <given-names>AC</given-names></name><name><surname>Kohane</surname> <given-names>IS</given-names></name><name><surname>Harris</surname> <given-names>LN</given-names></name><name><surname>Szallasi</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers</article-title><source>Nature Genetics</source><volume>38</volume><fpage>1043</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1038/ng1861</pub-id><pub-id pub-id-type="pmid">16921376</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Müller</surname> <given-names>GA</given-names></name><name><surname>Quaas</surname> <given-names>M</given-names></name><name><surname>Fischer</surname> <given-names>M</given-names></name><name><surname>Han</surname> <given-names>N</given-names></name><name><surname>Stutchbury</surname> <given-names>B</given-names></name><name><surname>Sharrocks</surname> <given-names>AD</given-names></name><name><surname>Engeland</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1128/MCB.00881-12</pub-id><pub-id pub-id-type="pmid">23109430</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>YY</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-Cancer Analysis of Head-to-Head Gene Pairs in Terms of Transcriptional Activity, Co-expression and Regulation</article-title><source>Frontiers in Genetics</source><volume>11</volume><elocation-id>560997</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2020.560997</pub-id><pub-id pub-id-type="pmid">33488665</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>S</given-names></name><name><surname>Vail</surname> <given-names>P</given-names></name><name><surname>Witkiewicz</surname> <given-names>AK</given-names></name><name><surname>Knudsen</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>2290</fpage><lpage>2304</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1620</pub-id><pub-id pub-id-type="pmid">30538111</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname> <given-names>SJ</given-names></name><name><surname>Harrison</surname> <given-names>J</given-names></name><name><surname>Paul</surname> <given-names>CL</given-names></name><name><surname>Frommer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>High sensitivity mapping of methylated cytosines</article-title><source>Nucleic Acids Research</source><volume>22</volume><fpage>2990</fpage><lpage>2997</lpage><pub-id pub-id-type="doi">10.1093/nar/22.15.2990</pub-id><pub-id pub-id-type="pmid">8065911</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>FoxM1 dances with mitosis</article-title><source>Nature Cell Biology</source><volume>7</volume><fpage>108</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/ncb0205-108</pub-id><pub-id pub-id-type="pmid">15689977</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotta-Ramusino</surname> <given-names>C</given-names></name><name><surname>McDonald</surname> <given-names>ER</given-names></name><name><surname>Hurov</surname> <given-names>K</given-names></name><name><surname>Sowa</surname> <given-names>ME</given-names></name><name><surname>Harper</surname> <given-names>JW</given-names></name><name><surname>Elledge</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling</article-title><source>Science</source><volume>332</volume><fpage>1313</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1126/science.1203430</pub-id><pub-id pub-id-type="pmid">21659603</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>J</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Ruan</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review</article-title><source>Disease Markers</source><volume>2015</volume><elocation-id>352478</elocation-id><pub-id pub-id-type="doi">10.1155/2015/352478</pub-id><pub-id pub-id-type="pmid">26451068</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DelloRusso</surname> <given-names>C</given-names></name><name><surname>Welcsh</surname> <given-names>PL</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Garcia</surname> <given-names>RL</given-names></name><name><surname>King</surname> <given-names>MC</given-names></name><name><surname>Swisher</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation</article-title><source>Molecular Cancer Research: MCR</source><volume>5</volume><fpage>35</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-06-0234</pub-id><pub-id pub-id-type="pmid">17259345</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diab</surname> <given-names>A</given-names></name><name><surname>Gem</surname> <given-names>H</given-names></name><name><surname>Swanger</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>HY</given-names></name><name><surname>Smith</surname> <given-names>K</given-names></name><name><surname>Zou</surname> <given-names>G</given-names></name><name><surname>Raju</surname> <given-names>S</given-names></name><name><surname>Kao</surname> <given-names>M</given-names></name><name><surname>Fitzgibbon</surname> <given-names>M</given-names></name><name><surname>Loeb</surname> <given-names>KR</given-names></name><name><surname>Rodriguez</surname> <given-names>CP</given-names></name><name><surname>Méndez</surname> <given-names>E</given-names></name><name><surname>Galloway</surname> <given-names>DA</given-names></name><name><surname>Sidorova</surname> <given-names>JM</given-names></name><name><surname>Clurman</surname> <given-names>BE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition</article-title><source>PNAS</source><volume>117</volume><fpage>28287</fpage><lpage>28296</lpage><pub-id pub-id-type="doi">10.1073/pnas.2013921117</pub-id><pub-id pub-id-type="pmid">33093209</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domcke</surname> <given-names>S</given-names></name><name><surname>Sinha</surname> <given-names>R</given-names></name><name><surname>Levine</surname> <given-names>DA</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Evaluating cell lines as tumour models by comparison of genomic profiles</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2126</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3126</pub-id><pub-id pub-id-type="pmid">23839242</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>Q</given-names></name><name><surname>Cai</surname> <given-names>Q</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer</article-title><source>Oncotarget</source><volume>6</volume><fpage>27688</fpage><lpage>27699</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4280</pub-id><pub-id pub-id-type="pmid">26299613</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname> <given-names>P</given-names></name><name><surname>Madden</surname> <given-names>JA</given-names></name><name><surname>Neums</surname> <given-names>L</given-names></name><name><surname>Moulder</surname> <given-names>RK</given-names></name><name><surname>Forrest</surname> <given-names>ML</given-names></name><name><surname>Chien</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition</article-title><source>Molecular Cancer Research: MCR</source><volume>16</volume><fpage>961</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0607</pub-id><pub-id pub-id-type="pmid">29545475</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname> <given-names>H</given-names></name><name><surname>McCabe</surname> <given-names>N</given-names></name><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Tutt</surname> <given-names>AN</given-names></name><name><surname>Johnson</surname> <given-names>DA</given-names></name><name><surname>Richardson</surname> <given-names>TB</given-names></name><name><surname>Santarosa</surname> <given-names>M</given-names></name><name><surname>Dillon</surname> <given-names>KJ</given-names></name><name><surname>Hickson</surname> <given-names>I</given-names></name><name><surname>Knights</surname> <given-names>C</given-names></name><name><surname>Martin</surname> <given-names>NM</given-names></name><name><surname>Jackson</surname> <given-names>SP</given-names></name><name><surname>Smith</surname> <given-names>GC</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title><source>Nature</source><volume>434</volume><fpage>917</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1038/nature03445</pub-id><pub-id pub-id-type="pmid">15829967</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname> <given-names>AP</given-names></name><name><surname>Justilien</surname> <given-names>V</given-names></name><name><surname>Murray</surname> <given-names>NR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The chromosome 3q26 OncCassette: A multigenic driver of human cancer</article-title><source>Advances in Biological Regulation</source><volume>60</volume><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.jbior.2015.10.009</pub-id><pub-id pub-id-type="pmid">26754874</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fojo</surname> <given-names>T</given-names></name><name><surname>Bates</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanisms of resistance to PARP inhibitors--three and counting</article-title><source>Cancer Discovery</source><volume>3</volume><fpage>20</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0514</pub-id><pub-id pub-id-type="pmid">23319766</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gartel</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>FoxM1 inhibitors as potential anticancer drugs</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>12</volume><fpage>663</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1517/14728222.12.6.663</pub-id><pub-id pub-id-type="pmid">18479213</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentles</surname> <given-names>AJ</given-names></name><name><surname>Newman</surname> <given-names>AM</given-names></name><name><surname>Liu</surname> <given-names>CL</given-names></name><name><surname>Bratman</surname> <given-names>SV</given-names></name><name><surname>Feng</surname> <given-names>W</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Nair</surname> <given-names>VS</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Khuong</surname> <given-names>A</given-names></name><name><surname>Hoang</surname> <given-names>CD</given-names></name><name><surname>Diehn</surname> <given-names>M</given-names></name><name><surname>West</surname> <given-names>RB</given-names></name><name><surname>Plevritis</surname> <given-names>SK</given-names></name><name><surname>Alizadeh</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title><source>Nature Medicine</source><volume>21</volume><fpage>938</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/nm.3909</pub-id><pub-id pub-id-type="pmid">26193342</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gormally</surname> <given-names>MV</given-names></name><name><surname>Dexheimer</surname> <given-names>TS</given-names></name><name><surname>Marsico</surname> <given-names>G</given-names></name><name><surname>Sanders</surname> <given-names>DA</given-names></name><name><surname>Lowe</surname> <given-names>C</given-names></name><name><surname>Matak-Vinković</surname> <given-names>D</given-names></name><name><surname>Michael</surname> <given-names>S</given-names></name><name><surname>Jadhav</surname> <given-names>A</given-names></name><name><surname>Rai</surname> <given-names>G</given-names></name><name><surname>Maloney</surname> <given-names>DJ</given-names></name><name><surname>Simeonov</surname> <given-names>A</given-names></name><name><surname>Balasubramanian</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5165</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6165</pub-id><pub-id pub-id-type="pmid">25387393</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname> <given-names>A</given-names></name><name><surname>Bennardo</surname> <given-names>N</given-names></name><name><surname>Cheng</surname> <given-names>A</given-names></name><name><surname>Stark</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Correct end use during end joining of multiple chromosomal double strand breaks is influenced by repair protein RAD50, DNA-dependent protein kinase DNA-PKcs, and transcription context</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>42470</fpage><lpage>42482</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.309252</pub-id><pub-id pub-id-type="pmid">22027841</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunn</surname> <given-names>A</given-names></name><name><surname>Stark</surname> <given-names>JM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks</article-title><source>Methods in Molecular Biology</source><volume>920</volume><fpage>379</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1007/978-1-61779-998-3_27</pub-id><pub-id pub-id-type="pmid">22941618</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haber</surname> <given-names>AL</given-names></name><name><surname>Biton</surname> <given-names>M</given-names></name><name><surname>Rogel</surname> <given-names>N</given-names></name><name><surname>Herbst</surname> <given-names>RH</given-names></name><name><surname>Shekhar</surname> <given-names>K</given-names></name><name><surname>Smillie</surname> <given-names>C</given-names></name><name><surname>Burgin</surname> <given-names>G</given-names></name><name><surname>Delorey</surname> <given-names>TM</given-names></name><name><surname>Howitt</surname> <given-names>MR</given-names></name><name><surname>Katz</surname> <given-names>Y</given-names></name><name><surname>Tirosh</surname> <given-names>I</given-names></name><name><surname>Beyaz</surname> <given-names>S</given-names></name><name><surname>Dionne</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Raychowdhury</surname> <given-names>R</given-names></name><name><surname>Garrett</surname> <given-names>WS</given-names></name><name><surname>Rozenblatt-Rosen</surname> <given-names>O</given-names></name><name><surname>Shi</surname> <given-names>HN</given-names></name><name><surname>Yilmaz</surname> <given-names>O</given-names></name><name><surname>Xavier</surname> <given-names>RJ</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A single-cell survey of the small intestinal epithelium</article-title><source>Nature</source><volume>551</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature24489</pub-id><pub-id pub-id-type="pmid">29144463</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halasi</surname> <given-names>M</given-names></name><name><surname>Gartel</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>FOX(M1) news--it is cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>12</volume><fpage>245</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0712</pub-id><pub-id pub-id-type="pmid">23443798</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halasi</surname> <given-names>M</given-names></name><name><surname>Gartel</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Targeting FOXM1 in cancer</article-title><source>Biochemical Pharmacology</source><volume>85</volume><fpage>644</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2012.10.013</pub-id><pub-id pub-id-type="pmid">23103567</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haley</surname> <given-names>J</given-names></name><name><surname>Tomar</surname> <given-names>S</given-names></name><name><surname>Pulliam</surname> <given-names>N</given-names></name><name><surname>Xiong</surname> <given-names>S</given-names></name><name><surname>Perkins</surname> <given-names>SM</given-names></name><name><surname>Karpf</surname> <given-names>AR</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name><name><surname>Nephew</surname> <given-names>KP</given-names></name><name><surname>Mitra</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease</article-title><source>Oncotarget</source><volume>7</volume><fpage>32810</fpage><lpage>32820</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9053</pub-id><pub-id pub-id-type="pmid">27147568</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname> <given-names>K</given-names></name><name><surname>Iida</surname> <given-names>N</given-names></name><name><surname>Tamafune</surname> <given-names>R</given-names></name><name><surname>Ohashi</surname> <given-names>E</given-names></name><name><surname>Sakurai</surname> <given-names>H</given-names></name><name><surname>Ishikawa</surname> <given-names>Y</given-names></name><name><surname>Hishiki</surname> <given-names>A</given-names></name><name><surname>Hashimoto</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of the RAD9-RAD1-HUS1 checkpoint clamp bound to RHINO sheds light on the other side of the DNA clamp</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>899</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)49902-9</pub-id><pub-id pub-id-type="pmid">31776186</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huntoon</surname> <given-names>CJ</given-names></name><name><surname>Flatten</surname> <given-names>KS</given-names></name><name><surname>Wahner Hendrickson</surname> <given-names>AE</given-names></name><name><surname>Huehls</surname> <given-names>AM</given-names></name><name><surname>Sutor</surname> <given-names>SL</given-names></name><name><surname>Kaufmann</surname> <given-names>SH</given-names></name><name><surname>Karnitz</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status</article-title><source>Cancer Research</source><volume>73</volume><fpage>3683</fpage><lpage>3691</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-0110</pub-id><pub-id pub-id-type="pmid">23548269</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hustedt</surname> <given-names>N</given-names></name><name><surname>Durocher</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The control of DNA repair by the cell cycle</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/ncb3452</pub-id><pub-id pub-id-type="pmid">28008184</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iorio</surname> <given-names>F</given-names></name><name><surname>Knijnenburg</surname> <given-names>TA</given-names></name><name><surname>Vis</surname> <given-names>DJ</given-names></name><name><surname>Bignell</surname> <given-names>GR</given-names></name><name><surname>Menden</surname> <given-names>MP</given-names></name><name><surname>Schubert</surname> <given-names>M</given-names></name><name><surname>Aben</surname> <given-names>N</given-names></name><name><surname>Gonçalves</surname> <given-names>E</given-names></name><name><surname>Barthorpe</surname> <given-names>S</given-names></name><name><surname>Lightfoot</surname> <given-names>H</given-names></name><name><surname>Cokelaer</surname> <given-names>T</given-names></name><name><surname>Greninger</surname> <given-names>P</given-names></name><name><surname>van Dyk</surname> <given-names>E</given-names></name><name><surname>Chang</surname> <given-names>H</given-names></name><name><surname>de Silva</surname> <given-names>H</given-names></name><name><surname>Heyn</surname> <given-names>H</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Egan</surname> <given-names>RK</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Mironenko</surname> <given-names>T</given-names></name><name><surname>Mitropoulos</surname> <given-names>X</given-names></name><name><surname>Richardson</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Moran</surname> <given-names>S</given-names></name><name><surname>Sayols</surname> <given-names>S</given-names></name><name><surname>Soleimani</surname> <given-names>M</given-names></name><name><surname>Tamborero</surname> <given-names>D</given-names></name><name><surname>Lopez-Bigas</surname> <given-names>N</given-names></name><name><surname>Ross-Macdonald</surname> <given-names>P</given-names></name><name><surname>Esteller</surname> <given-names>M</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Stratton</surname> <given-names>MR</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Wessels</surname> <given-names>LFA</given-names></name><name><surname>Saez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>McDermott</surname> <given-names>U</given-names></name><name><surname>Garnett</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A Landscape of Pharmacogenomic Interactions in Cancer</article-title><source>Cell</source><volume>166</volume><fpage>740</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.06.017</pub-id><pub-id pub-id-type="pmid">27397505</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>P</given-names></name><name><surname>Freedman</surname> <given-names>ML</given-names></name><name><surname>Liu</surname> <given-names>JS</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Inference of transcriptional regulation in cancers</article-title><source>PNAS</source><volume>112</volume><fpage>7731</fpage><lpage>7736</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424272112</pub-id><pub-id pub-id-type="pmid">26056275</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joung</surname> <given-names>J</given-names></name><name><surname>Konermann</surname> <given-names>S</given-names></name><name><surname>Gootenberg</surname> <given-names>JS</given-names></name><name><surname>Abudayyeh</surname> <given-names>OO</given-names></name><name><surname>Platt</surname> <given-names>RJ</given-names></name><name><surname>Brigham</surname> <given-names>MD</given-names></name><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening</article-title><source>Nature Protocols</source><volume>12</volume><fpage>828</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1038/nprot.2017.016</pub-id><pub-id pub-id-type="pmid">28333914</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Justilien</surname> <given-names>V</given-names></name><name><surname>Walsh</surname> <given-names>MP</given-names></name><name><surname>Ali</surname> <given-names>SA</given-names></name><name><surname>Thompson</surname> <given-names>EA</given-names></name><name><surname>Murray</surname> <given-names>NR</given-names></name><name><surname>Fields</surname> <given-names>AP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma</article-title><source>Cancer Cell</source><volume>25</volume><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.01.008</pub-id><pub-id pub-id-type="pmid">24525231</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalathil</surname> <given-names>D</given-names></name><name><surname>John</surname> <given-names>S</given-names></name><name><surname>Nair</surname> <given-names>AS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis</article-title><source>Frontiers in Oncology</source><volume>10</volume><elocation-id>626836</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2020.626836</pub-id><pub-id pub-id-type="pmid">33680951</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakashev</surname> <given-names>S</given-names></name><name><surname>Fukumoto</surname> <given-names>T</given-names></name><name><surname>Zhao</surname> <given-names>B</given-names></name><name><surname>Lin</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Fatkhutdinov</surname> <given-names>N</given-names></name><name><surname>Park</surname> <given-names>PH</given-names></name><name><surname>Semenova</surname> <given-names>G</given-names></name><name><surname>Jean</surname> <given-names>S</given-names></name><name><surname>Cadungog</surname> <given-names>MG</given-names></name><name><surname>Borowsky</surname> <given-names>ME</given-names></name><name><surname>Kossenkov</surname> <given-names>AV</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>EZH2 inhibition sensitizes CARM1-High, homologous recombination proficient ovarian cancers to PARP inhibition</article-title><source>Cancer Cell</source><volume>37</volume><fpage>157</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.12.015</pub-id><pub-id pub-id-type="pmid">32004442</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karst</surname> <given-names>AM</given-names></name><name><surname>Levanon</surname> <given-names>K</given-names></name><name><surname>Drapkin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Modeling high-grade serous ovarian carcinogenesis from the fallopian tube</article-title><source>PNAS</source><volume>108</volume><fpage>7547</fpage><lpage>7552</lpage><pub-id pub-id-type="doi">10.1073/pnas.1017300108</pub-id><pub-id pub-id-type="pmid">21502498</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karst</surname> <given-names>AM</given-names></name><name><surname>Jones</surname> <given-names>PM</given-names></name><name><surname>Vena</surname> <given-names>N</given-names></name><name><surname>Ligon</surname> <given-names>AH</given-names></name><name><surname>Liu</surname> <given-names>JF</given-names></name><name><surname>Hirsch</surname> <given-names>MS</given-names></name><name><surname>Etemadmoghadam</surname> <given-names>D</given-names></name><name><surname>Bowtell</surname> <given-names>DD</given-names></name><name><surname>Drapkin</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers</article-title><source>Cancer Research</source><volume>74</volume><fpage>1141</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2247</pub-id><pub-id pub-id-type="pmid">24366882</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname> <given-names>WJ</given-names></name><name><surname>Sugnet</surname> <given-names>CW</given-names></name><name><surname>Furey</surname> <given-names>TS</given-names></name><name><surname>Roskin</surname> <given-names>KM</given-names></name><name><surname>Pringle</surname> <given-names>TH</given-names></name><name><surname>Zahler</surname> <given-names>AM</given-names></name><name><surname>Haussler</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The human genome browser at UCSC</article-title><source>Genome Research</source><volume>12</volume><fpage>996</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1101/gr.229102</pub-id><pub-id pub-id-type="pmid">12045153</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khongkow</surname> <given-names>P</given-names></name><name><surname>Karunarathna</surname> <given-names>U</given-names></name><name><surname>Khongkow</surname> <given-names>M</given-names></name><name><surname>Gong</surname> <given-names>C</given-names></name><name><surname>Gomes</surname> <given-names>AR</given-names></name><name><surname>Yagüe</surname> <given-names>E</given-names></name><name><surname>Monteiro</surname> <given-names>LJ</given-names></name><name><surname>Kongsema</surname> <given-names>M</given-names></name><name><surname>Zona</surname> <given-names>S</given-names></name><name><surname>Man</surname> <given-names>EP</given-names></name><name><surname>Tsang</surname> <given-names>JW</given-names></name><name><surname>Coombes</surname> <given-names>RC</given-names></name><name><surname>Wu</surname> <given-names>KJ</given-names></name><name><surname>Khoo</surname> <given-names>US</given-names></name><name><surname>Medema</surname> <given-names>RH</given-names></name><name><surname>Freire</surname> <given-names>R</given-names></name><name><surname>Lam</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance</article-title><source>Oncogene</source><volume>33</volume><fpage>4144</fpage><lpage>4155</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.457</pub-id><pub-id pub-id-type="pmid">24141789</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>JW</given-names></name><name><surname>Fukukawa</surname> <given-names>C</given-names></name><name><surname>Ueda</surname> <given-names>K</given-names></name><name><surname>Nishidate</surname> <given-names>T</given-names></name><name><surname>Katagiri</surname> <given-names>T</given-names></name><name><surname>Nakamura</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Involvement of C12orf32 overexpression in breast carcinogenesis</article-title><source>International Journal of Oncology</source><volume>37</volume><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.3892/ijo_00000737</pub-id><pub-id pub-id-type="pmid">20811708</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>G</given-names></name><name><surname>Ison</surname> <given-names>G</given-names></name><name><surname>McKee</surname> <given-names>AE</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Tang</surname> <given-names>S</given-names></name><name><surname>Gwise</surname> <given-names>T</given-names></name><name><surname>Sridhara</surname> <given-names>R</given-names></name><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>Tzou</surname> <given-names>A</given-names></name><name><surname>Philip</surname> <given-names>R</given-names></name><name><surname>Chiu</surname> <given-names>HJ</given-names></name><name><surname>Ricks</surname> <given-names>TK</given-names></name><name><surname>Palmby</surname> <given-names>T</given-names></name><name><surname>Russell</surname> <given-names>AM</given-names></name><name><surname>Ladouceur</surname> <given-names>G</given-names></name><name><surname>Pfuma</surname> <given-names>E</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Zhao</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Venugopal</surname> <given-names>R</given-names></name><name><surname>Ibrahim</surname> <given-names>A</given-names></name><name><surname>Pazdur</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-Mutated advanced ovarian Cancer treated with three or more lines of chemotherapy</article-title><source>Clinical Cancer Research</source><volume>21</volume><fpage>4257</fpage><lpage>4261</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0887</pub-id><pub-id pub-id-type="pmid">26187614</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Konstantinopoulos</surname> <given-names>PA</given-names></name><name><surname>Lheureux</surname> <given-names>S</given-names></name><name><surname>Moore</surname> <given-names>KN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PARP inhibitors for ovarian Cancer: current indications, future combinations, and novel assets in development to target DNA damage repair</article-title><conf-name>American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting</conf-name><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1200/EDBK_288015</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreuzinger</surname> <given-names>C</given-names></name><name><surname>Geroldinger</surname> <given-names>A</given-names></name><name><surname>Smeets</surname> <given-names>D</given-names></name><name><surname>Braicu</surname> <given-names>EI</given-names></name><name><surname>Sehouli</surname> <given-names>J</given-names></name><name><surname>Koller</surname> <given-names>J</given-names></name><name><surname>Wolf</surname> <given-names>A</given-names></name><name><surname>Darb-Esfahani</surname> <given-names>S</given-names></name><name><surname>Joehrens</surname> <given-names>K</given-names></name><name><surname>Vergote</surname> <given-names>I</given-names></name><name><surname>Vanderstichele</surname> <given-names>A</given-names></name><name><surname>Boeckx</surname> <given-names>B</given-names></name><name><surname>Lambrechts</surname> <given-names>D</given-names></name><name><surname>Gabra</surname> <given-names>H</given-names></name><name><surname>Wisman</surname> <given-names>GBA</given-names></name><name><surname>Trillsch</surname> <given-names>F</given-names></name><name><surname>Heinze</surname> <given-names>G</given-names></name><name><surname>Horvat</surname> <given-names>R</given-names></name><name><surname>Polterauer</surname> <given-names>S</given-names></name><name><surname>Berns</surname> <given-names>E</given-names></name><name><surname>Theillet</surname> <given-names>C</given-names></name><name><surname>Cacsire Castillo-Tong</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A complex network of tumor microenvironment in human High-Grade serous ovarian Cancer</article-title><source>Clinical Cancer Research</source><volume>23</volume><fpage>7621</fpage><lpage>7632</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1159</pub-id><pub-id pub-id-type="pmid">28972047</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname> <given-names>JM-M</given-names></name><name><surname>Peck</surname> <given-names>B</given-names></name><name><surname>Monteiro</surname> <given-names>LJ</given-names></name><name><surname>Schwenen</surname> <given-names>HDC</given-names></name><name><surname>Millour</surname> <given-names>J</given-names></name><name><surname>Coombes</surname> <given-names>RC</given-names></name><name><surname>Myatt</surname> <given-names>SS</given-names></name><name><surname>Lam</surname> <given-names>EW-F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FOXM1 confers acquired cisplatin resistance in breast Cancer cells</article-title><source>Molecular Cancer Research</source><volume>8</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-09-0432</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laoukili</surname> <given-names>J</given-names></name><name><surname>Kooistra</surname> <given-names>MR</given-names></name><name><surname>Brás</surname> <given-names>A</given-names></name><name><surname>Kauw</surname> <given-names>J</given-names></name><name><surname>Kerkhoven</surname> <given-names>RM</given-names></name><name><surname>Morrison</surname> <given-names>A</given-names></name><name><surname>Clevers</surname> <given-names>H</given-names></name><name><surname>Medema</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>FoxM1 is required for execution of the mitotic programme and chromosome stability</article-title><source>Nature Cell Biology</source><volume>7</volume><fpage>126</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1038/ncb1217</pub-id><pub-id pub-id-type="pmid">15654331</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levanon</surname> <given-names>K</given-names></name><name><surname>Sapoznik</surname> <given-names>S</given-names></name><name><surname>Bahar-Shany</surname> <given-names>K</given-names></name><name><surname>Brand</surname> <given-names>H</given-names></name><name><surname>Shapira-Frommer</surname> <given-names>R</given-names></name><name><surname>Korach</surname> <given-names>J</given-names></name><name><surname>Hirsch</surname> <given-names>MS</given-names></name><name><surname>Roh</surname> <given-names>MH</given-names></name><name><surname>Miron</surname> <given-names>A</given-names></name><name><surname>Liu</surname> <given-names>JF</given-names></name><name><surname>Vena</surname> <given-names>N</given-names></name><name><surname>Ligon</surname> <given-names>AH</given-names></name><name><surname>Fotheringham</surname> <given-names>S</given-names></name><name><surname>Bailey</surname> <given-names>D</given-names></name><name><surname>Flavin</surname> <given-names>RJ</given-names></name><name><surname>Birrer</surname> <given-names>MJ</given-names></name><name><surname>Drapkin</surname> <given-names>RI</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis</article-title><source>Oncogene</source><volume>33</volume><fpage>4424</fpage><lpage>4432</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.394</pub-id><pub-id pub-id-type="pmid">24077281</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>YY</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Guo</surname> <given-names>ZM</given-names></name><name><surname>Guo</surname> <given-names>TQ</given-names></name><name><surname>Tu</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>YX</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Systematic analysis of head-to-head gene organization: evolutionary conservation and potential biological relevance</article-title><source>PLOS Computational Biology</source><volume>2</volume><elocation-id>e74</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0020074</pub-id><pub-id pub-id-type="pmid">16839196</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>NF</given-names></name><name><surname>Broad</surname> <given-names>S</given-names></name><name><surname>Lu</surname> <given-names>YJ</given-names></name><name><surname>Yang</surname> <given-names>JS</given-names></name><name><surname>Watson</surname> <given-names>R</given-names></name><name><surname>Hagemann</surname> <given-names>T</given-names></name><name><surname>Wilbanks</surname> <given-names>G</given-names></name><name><surname>Jacobs</surname> <given-names>I</given-names></name><name><surname>Balkwill</surname> <given-names>F</given-names></name><name><surname>Dafou</surname> <given-names>D</given-names></name><name><surname>Gayther</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression</article-title><source>Cell Proliferation</source><volume>40</volume><fpage>780</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2184.2007.00462.x</pub-id><pub-id pub-id-type="pmid">17877616</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Transcriptional landscape of human cancers</article-title><source>Oncotarget</source><volume>8</volume><fpage>34534</fpage><lpage>34551</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15837</pub-id><pub-id pub-id-type="pmid">28427185</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Yu</surname> <given-names>Q</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis</article-title><source>Oncotarget</source><volume>8</volume><fpage>32298</fpage><lpage>32308</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.15764</pub-id><pub-id pub-id-type="pmid">28427178</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Du</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>C</given-names></name><name><surname>Bai</surname> <given-names>Y</given-names></name><name><surname>Feng</surname> <given-names>Z</given-names></name><name><surname>Su</surname> <given-names>C</given-names></name><name><surname>Wu</surname> <given-names>R</given-names></name><name><surname>Song</surname> <given-names>S</given-names></name><name><surname>Yan</surname> <given-names>P</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Jain</surname> <given-names>A</given-names></name><name><surname>Huang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PLAGL2 and POFUT1 are regulated by an evolutionarily conserved bidirectional promoter and are collaboratively involved in colorectal cancer by maintaining stemness</article-title><source>EBioMedicine</source><volume>45</volume><fpage>124</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2019.06.051</pub-id><pub-id pub-id-type="pmid">31279780</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Yu</surname> <given-names>DS</given-names></name><name><surname>Doetsch</surname> <given-names>PW</given-names></name><name><surname>Werner</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Replication stress and FOXM1 drive radiation induced genomic instability and cell transformation</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0235998</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0235998</pub-id><pub-id pub-id-type="pmid">33253193</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>LC</given-names></name><name><surname>Dahiya</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>MethPrimer: designing primers for methylation PCRs</article-title><source>Bioinformatics</source><volume>18</volume><fpage>1427</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/18.11.1427</pub-id><pub-id pub-id-type="pmid">12424112</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>WV</given-names></name><name><surname>Li</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An accurate and robust imputation method scImpute for single-cell RNA-seq data</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>997</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-03405-7</pub-id><pub-id pub-id-type="pmid">29520097</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>JM</given-names></name><name><surname>Collins</surname> <given-names>PJ</given-names></name><name><surname>Trinklein</surname> <given-names>ND</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Xi</surname> <given-names>H</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name><name><surname>Weng</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Transcription factor binding and modified histones in human bidirectional promoters</article-title><source>Genome Research</source><volume>17</volume><fpage>818</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1101/gr.5623407</pub-id><pub-id pub-id-type="pmid">17568000</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsey-Boltz</surname> <given-names>LA</given-names></name><name><surname>Kemp</surname> <given-names>MG</given-names></name><name><surname>Capp</surname> <given-names>C</given-names></name><name><surname>Sancar</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RHINO forms a stoichiometric complex with the 9-1-1 checkpoint clamp and mediates ATR-Chk1 signaling</article-title><source>Cell Cycle</source><volume>14</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.4161/15384101.2014.967076</pub-id><pub-id pub-id-type="pmid">25602520</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname> <given-names>CJ</given-names></name><name><surname>Tutt</surname> <given-names>AN</given-names></name><name><surname>Ashworth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors</article-title><source>Annual Review of Medicine</source><volume>66</volume><fpage>455</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1146/annurev-med-050913-022545</pub-id><pub-id pub-id-type="pmid">25341009</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>W</given-names></name><name><surname>Gao</surname> <given-names>F</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Liu</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>FoxM1 Promotes Cell Proliferation, Invasion, and Stem Cell Properties in Nasopharyngeal Carcinoma</article-title><source>Frontiers in Oncology</source><volume>8</volume><elocation-id>483</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2018.00483</pub-id><pub-id pub-id-type="pmid">30416986</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maachani</surname> <given-names>UB</given-names></name><name><surname>Shankavaram</surname> <given-names>U</given-names></name><name><surname>Kramp</surname> <given-names>T</given-names></name><name><surname>Tofilon</surname> <given-names>PJ</given-names></name><name><surname>Camphausen</surname> <given-names>K</given-names></name><name><surname>Tandle</surname> <given-names>AT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells</article-title><source>Oncotarget</source><volume>7</volume><fpage>77365</fpage><lpage>77377</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12670</pub-id><pub-id pub-id-type="pmid">27764801</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macedo</surname> <given-names>JC</given-names></name><name><surname>Vaz</surname> <given-names>S</given-names></name><name><surname>Bakker</surname> <given-names>B</given-names></name><name><surname>Ribeiro</surname> <given-names>R</given-names></name><name><surname>Bakker</surname> <given-names>PL</given-names></name><name><surname>Escandell</surname> <given-names>JM</given-names></name><name><surname>Ferreira</surname> <given-names>MG</given-names></name><name><surname>Medema</surname> <given-names>R</given-names></name><name><surname>Foijer</surname> <given-names>F</given-names></name><name><surname>Logarinho</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>FoxM1 repression during human aging leads to mitotic decline and aneuploidy-driven full senescence</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2834</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05258-6</pub-id><pub-id pub-id-type="pmid">30026603</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname> <given-names>L</given-names></name><name><surname>Le</surname> <given-names>S</given-names></name><name><surname>Jin</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CSN5 promotes the invasion and metastasis of pancreatic cancer by stabilization of FOXM1</article-title><source>Experimental Cell Research</source><volume>374</volume><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2018.10.012</pub-id><pub-id pub-id-type="pmid">30352219</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname> <given-names>LJ</given-names></name><name><surname>Khongkow</surname> <given-names>P</given-names></name><name><surname>Kongsema</surname> <given-names>M</given-names></name><name><surname>Morris</surname> <given-names>JR</given-names></name><name><surname>Man</surname> <given-names>C</given-names></name><name><surname>Weekes</surname> <given-names>D</given-names></name><name><surname>Koo</surname> <given-names>CY</given-names></name><name><surname>Gomes</surname> <given-names>AR</given-names></name><name><surname>Pinto</surname> <given-names>PH</given-names></name><name><surname>Varghese</surname> <given-names>V</given-names></name><name><surname>Kenny</surname> <given-names>LM</given-names></name><name><surname>Charles Coombes</surname> <given-names>R</given-names></name><name><surname>Freire</surname> <given-names>R</given-names></name><name><surname>Medema</surname> <given-names>RH</given-names></name><name><surname>Lam</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment</article-title><source>Oncogene</source><volume>32</volume><fpage>4634</fpage><lpage>4645</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.491</pub-id><pub-id pub-id-type="pmid">23108394</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestal de Moraes</surname> <given-names>G</given-names></name><name><surname>Delbue</surname> <given-names>D</given-names></name><name><surname>Silva</surname> <given-names>KL</given-names></name><name><surname>Robaina</surname> <given-names>MC</given-names></name><name><surname>Khongkow</surname> <given-names>P</given-names></name><name><surname>Gomes</surname> <given-names>AR</given-names></name><name><surname>Zona</surname> <given-names>S</given-names></name><name><surname>Crocamo</surname> <given-names>S</given-names></name><name><surname>Mencalha</surname> <given-names>AL</given-names></name><name><surname>Magalhães</surname> <given-names>LM</given-names></name><name><surname>Lam</surname> <given-names>EW</given-names></name><name><surname>Maia</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance</article-title><source>Cellular Signalling</source><volume>27</volume><fpage>2496</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.09.013</pub-id><pub-id pub-id-type="pmid">26404623</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niida</surname> <given-names>H</given-names></name><name><surname>Katsuno</surname> <given-names>Y</given-names></name><name><surname>Banerjee</surname> <given-names>B</given-names></name><name><surname>Hande</surname> <given-names>MP</given-names></name><name><surname>Nakanishi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Specific role of Chk1 phosphorylations in cell survival and checkpoint activation</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>2572</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1128/MCB.01611-06</pub-id><pub-id pub-id-type="pmid">17242188</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Wei</surname> <given-names>W</given-names></name><name><surname>Shao</surname> <given-names>S</given-names></name><name><surname>Rui</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer</article-title><source>World Journal of Surgical Oncology</source><volume>16</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.1186/s12957-018-1352-3</pub-id><pub-id pub-id-type="pmid">29554906</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paracchini</surname> <given-names>L</given-names></name><name><surname>Beltrame</surname> <given-names>L</given-names></name><name><surname>Grassi</surname> <given-names>T</given-names></name><name><surname>Inglesi</surname> <given-names>A</given-names></name><name><surname>Fruscio</surname> <given-names>R</given-names></name><name><surname>Landoni</surname> <given-names>F</given-names></name><name><surname>Ippolito</surname> <given-names>D</given-names></name><name><surname>Delle Marchette</surname> <given-names>M</given-names></name><name><surname>Paderno</surname> <given-names>M</given-names></name><name><surname>Adorni</surname> <given-names>M</given-names></name><name><surname>Jaconi</surname> <given-names>M</given-names></name><name><surname>Romualdi</surname> <given-names>C</given-names></name><name><surname>D'Incalci</surname> <given-names>M</given-names></name><name><surname>Siravegna</surname> <given-names>G</given-names></name><name><surname>Marchini</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genome-wide Copy-number alterations in circulating tumor DNA as a novel biomarker for patients with High-grade serous ovarian Cancer</article-title><source>Clinical Cancer Research</source><volume>1</volume><elocation-id>3345</elocation-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-3345</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parashar</surname> <given-names>D</given-names></name><name><surname>Nair</surname> <given-names>B</given-names></name><name><surname>Geethadevi</surname> <given-names>A</given-names></name><name><surname>George</surname> <given-names>J</given-names></name><name><surname>Nair</surname> <given-names>A</given-names></name><name><surname>Tsaih</surname> <given-names>SW</given-names></name><name><surname>Kadamberi</surname> <given-names>IP</given-names></name><name><surname>Gopinadhan Nair</surname> <given-names>GK</given-names></name><name><surname>Lu</surname> <given-names>Y</given-names></name><name><surname>Ramchandran</surname> <given-names>R</given-names></name><name><surname>Uyar</surname> <given-names>DS</given-names></name><name><surname>Rader</surname> <given-names>JS</given-names></name><name><surname>Ram</surname> <given-names>PT</given-names></name><name><surname>Mills</surname> <given-names>GB</given-names></name><name><surname>Pradeep</surname> <given-names>S</given-names></name><name><surname>Chaluvally-Raghavan</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Peritoneal spread of ovarian Cancer harbors therapeutic vulnerabilities regulated by FOXM1 and EGFR/ERBB2 signaling</article-title><source>Cancer Research</source><volume>80</volume><fpage>5554</fpage><lpage>5568</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-3717</pub-id><pub-id pub-id-type="pmid">33087324</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>YY</given-names></name><name><surname>Jung</surname> <given-names>SY</given-names></name><name><surname>Jennings</surname> <given-names>NB</given-names></name><name><surname>Rodriguez-Aguayo</surname> <given-names>C</given-names></name><name><surname>Peng</surname> <given-names>G</given-names></name><name><surname>Lee</surname> <given-names>SR</given-names></name><name><surname>Kim</surname> <given-names>SB</given-names></name><name><surname>Kim</surname> <given-names>K</given-names></name><name><surname>Leem</surname> <given-names>SH</given-names></name><name><surname>Lin</surname> <given-names>SY</given-names></name><name><surname>Lopez-Berestein</surname> <given-names>G</given-names></name><name><surname>Sood</surname> <given-names>AK</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair</article-title><source>Carcinogenesis</source><volume>33</volume><fpage>1843</fpage><lpage>1853</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgs167</pub-id><pub-id pub-id-type="pmid">22581827</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passerini</surname> <given-names>V</given-names></name><name><surname>Ozeri-Galai</surname> <given-names>E</given-names></name><name><surname>de Pagter</surname> <given-names>MS</given-names></name><name><surname>Donnelly</surname> <given-names>N</given-names></name><name><surname>Schmalbrock</surname> <given-names>S</given-names></name><name><surname>Kloosterman</surname> <given-names>WP</given-names></name><name><surname>Kerem</surname> <given-names>B</given-names></name><name><surname>Storchová</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The presence of extra chromosomes leads to genomic instability</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10754</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10754</pub-id><pub-id pub-id-type="pmid">26876972</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patch</surname> <given-names>AM</given-names></name><name><surname>Christie</surname> <given-names>EL</given-names></name><name><surname>Etemadmoghadam</surname> <given-names>D</given-names></name><name><surname>Garsed</surname> <given-names>DW</given-names></name><name><surname>George</surname> <given-names>J</given-names></name><name><surname>Fereday</surname> <given-names>S</given-names></name><name><surname>Nones</surname> <given-names>K</given-names></name><name><surname>Cowin</surname> <given-names>P</given-names></name><name><surname>Alsop</surname> <given-names>K</given-names></name><name><surname>Bailey</surname> <given-names>PJ</given-names></name><name><surname>Kassahn</surname> <given-names>KS</given-names></name><name><surname>Newell</surname> <given-names>F</given-names></name><name><surname>Quinn</surname> <given-names>MC</given-names></name><name><surname>Kazakoff</surname> <given-names>S</given-names></name><name><surname>Quek</surname> <given-names>K</given-names></name><name><surname>Wilhelm-Benartzi</surname> <given-names>C</given-names></name><name><surname>Curry</surname> <given-names>E</given-names></name><name><surname>Leong</surname> <given-names>HS</given-names></name><name><surname>Hamilton</surname> <given-names>A</given-names></name><name><surname>Mileshkin</surname> <given-names>L</given-names></name><name><surname>Au-Yeung</surname> <given-names>G</given-names></name><name><surname>Kennedy</surname> <given-names>C</given-names></name><name><surname>Hung</surname> <given-names>J</given-names></name><name><surname>Chiew</surname> <given-names>YE</given-names></name><name><surname>Harnett</surname> <given-names>P</given-names></name><name><surname>Friedlander</surname> <given-names>M</given-names></name><name><surname>Quinn</surname> <given-names>M</given-names></name><name><surname>Pyman</surname> <given-names>J</given-names></name><name><surname>Cordner</surname> <given-names>S</given-names></name><name><surname>O'Brien</surname> <given-names>P</given-names></name><name><surname>Leditschke</surname> <given-names>J</given-names></name><name><surname>Young</surname> <given-names>G</given-names></name><name><surname>Strachan</surname> <given-names>K</given-names></name><name><surname>Waring</surname> <given-names>P</given-names></name><name><surname>Azar</surname> <given-names>W</given-names></name><name><surname>Mitchell</surname> <given-names>C</given-names></name><name><surname>Traficante</surname> <given-names>N</given-names></name><name><surname>Hendley</surname> <given-names>J</given-names></name><name><surname>Thorne</surname> <given-names>H</given-names></name><name><surname>Shackleton</surname> <given-names>M</given-names></name><name><surname>Miller</surname> <given-names>DK</given-names></name><name><surname>Arnau</surname> <given-names>GM</given-names></name><name><surname>Tothill</surname> <given-names>RW</given-names></name><name><surname>Holloway</surname> <given-names>TP</given-names></name><name><surname>Semple</surname> <given-names>T</given-names></name><name><surname>Harliwong</surname> <given-names>I</given-names></name><name><surname>Nourse</surname> <given-names>C</given-names></name><name><surname>Nourbakhsh</surname> <given-names>E</given-names></name><name><surname>Manning</surname> <given-names>S</given-names></name><name><surname>Idrisoglu</surname> <given-names>S</given-names></name><name><surname>Bruxner</surname> <given-names>TJ</given-names></name><name><surname>Christ</surname> <given-names>AN</given-names></name><name><surname>Poudel</surname> <given-names>B</given-names></name><name><surname>Holmes</surname> <given-names>O</given-names></name><name><surname>Anderson</surname> <given-names>M</given-names></name><name><surname>Leonard</surname> <given-names>C</given-names></name><name><surname>Lonie</surname> <given-names>A</given-names></name><name><surname>Hall</surname> <given-names>N</given-names></name><name><surname>Wood</surname> <given-names>S</given-names></name><name><surname>Taylor</surname> <given-names>DF</given-names></name><name><surname>Xu</surname> <given-names>Q</given-names></name><name><surname>Fink</surname> <given-names>JL</given-names></name><name><surname>Waddell</surname> <given-names>N</given-names></name><name><surname>Drapkin</surname> <given-names>R</given-names></name><name><surname>Stronach</surname> <given-names>E</given-names></name><name><surname>Gabra</surname> <given-names>H</given-names></name><name><surname>Brown</surname> <given-names>R</given-names></name><name><surname>Jewell</surname> <given-names>A</given-names></name><name><surname>Nagaraj</surname> <given-names>SH</given-names></name><name><surname>Markham</surname> <given-names>E</given-names></name><name><surname>Wilson</surname> <given-names>PJ</given-names></name><name><surname>Ellul</surname> <given-names>J</given-names></name><name><surname>McNally</surname> <given-names>O</given-names></name><name><surname>Doyle</surname> <given-names>MA</given-names></name><name><surname>Vedururu</surname> <given-names>R</given-names></name><name><surname>Stewart</surname> <given-names>C</given-names></name><name><surname>Lengyel</surname> <given-names>E</given-names></name><name><surname>Pearson</surname> <given-names>JV</given-names></name><name><surname>Waddell</surname> <given-names>N</given-names></name><name><surname>deFazio</surname> <given-names>A</given-names></name><name><surname>Grimmond</surname> <given-names>SM</given-names></name><name><surname>Bowtell</surname> <given-names>DD</given-names></name><collab>Australian Ovarian Cancer Study Group</collab></person-group><year iso-8601-date="2015">2015</year><article-title>Whole-genome characterization of chemoresistant ovarian cancer</article-title><source>Nature</source><volume>521</volume><fpage>489</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1038/nature14410</pub-id><pub-id pub-id-type="pmid">26017449</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrovic</surname> <given-names>V</given-names></name><name><surname>Costa</surname> <given-names>RH</given-names></name><name><surname>Lau</surname> <given-names>LF</given-names></name><name><surname>Raychaudhuri</surname> <given-names>P</given-names></name><name><surname>Tyner</surname> <given-names>AL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin</article-title><source>Cancer Biology &amp; Therapy</source><volume>9</volume><fpage>1008</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.4161/cbt.9.12.11710</pub-id><pub-id pub-id-type="pmid">20372080</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname> <given-names>AJ</given-names></name><name><surname>Johnson</surname> <given-names>RD</given-names></name><name><surname>Thompson</surname> <given-names>LH</given-names></name><name><surname>Jasin</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>XRCC3 promotes homology-directed repair of DNA damage in mammalian cells</article-title><source>Genes &amp; Development</source><volume>13</volume><fpage>2633</fpage><lpage>2638</lpage><pub-id pub-id-type="doi">10.1101/gad.13.20.2633</pub-id><pub-id pub-id-type="pmid">10541549</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wright</surname> <given-names>J</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roh</surname> <given-names>Y-G</given-names></name><name><surname>Mun</surname> <given-names>J-Y</given-names></name><name><surname>Kim</surname> <given-names>S-K</given-names></name><name><surname>Park</surname> <given-names>WY</given-names></name><name><surname>Jeong</surname> <given-names>M-S</given-names></name><name><surname>Kim</surname> <given-names>TN</given-names></name><name><surname>Kim</surname> <given-names>W-T</given-names></name><name><surname>Choi</surname> <given-names>YH</given-names></name><name><surname>Chu</surname> <given-names>I-S</given-names></name><name><surname>Leem</surname> <given-names>S-H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fanconi Anemia pathway activation by FOXM1 is critical to bladder Cancer recurrence and anticancer drug resistance</article-title><source>Cancers</source><volume>12</volume><elocation-id>1417</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12061417</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saldivar</surname> <given-names>JC</given-names></name><name><surname>Hamperl</surname> <given-names>S</given-names></name><name><surname>Bocek</surname> <given-names>MJ</given-names></name><name><surname>Chung</surname> <given-names>M</given-names></name><name><surname>Bass</surname> <given-names>TE</given-names></name><name><surname>Cisneros-Soberanis</surname> <given-names>F</given-names></name><name><surname>Samejima</surname> <given-names>K</given-names></name><name><surname>Xie</surname> <given-names>L</given-names></name><name><surname>Paulson</surname> <given-names>JR</given-names></name><name><surname>Earnshaw</surname> <given-names>WC</given-names></name><name><surname>Cortez</surname> <given-names>D</given-names></name><name><surname>Meyer</surname> <given-names>T</given-names></name><name><surname>Cimprich</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An intrinsic S/G<sub>2</sub> checkpoint enforced by ATR</article-title><source>Science</source><volume>361</volume><fpage>806</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1126/science.aap9346</pub-id><pub-id pub-id-type="pmid">30139873</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname> <given-names>CA</given-names></name><name><surname>Rasband</surname> <given-names>WS</given-names></name><name><surname>Eliceiri</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>NIH Image to ImageJ: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Serov</surname> <given-names>SF</given-names></name><name><surname>Scully</surname> <given-names>RE</given-names></name><name><surname>Sobin</surname> <given-names>LH</given-names></name></person-group><year iso-8601-date="1973">1973</year><source>Histological Typing of Ovarian Tumours [By] S F. Serov [And] R. E. Scully in Collaboration with L. H. Sobin and Pathologists in Ten Countries</source><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname> <given-names>J</given-names></name><name><surname>Jelinek</surname> <given-names>J</given-names></name><name><surname>Chang</surname> <given-names>H</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Qin</surname> <given-names>T</given-names></name><name><surname>Chung</surname> <given-names>W</given-names></name><name><surname>Oki</surname> <given-names>Y</given-names></name><name><surname>Issa</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Silencing of bidirectional promoters by DNA methylation in tumorigenesis</article-title><source>Cancer Research</source><volume>66</volume><fpage>5077</fpage><lpage>5084</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2629</pub-id><pub-id pub-id-type="pmid">16707430</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>J</given-names></name><name><surname>Song</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Luo</surname> <given-names>R</given-names></name><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>Ran</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Multi-omics analysis reveals epithelial-mesenchymal transition-related gene FOXM1 as a novel prognostic biomarker in clear cell renal carcinoma</article-title><source>Aging</source><volume>11</volume><fpage>10316</fpage><lpage>10337</lpage><pub-id pub-id-type="doi">10.18632/aging.102459</pub-id><pub-id pub-id-type="pmid">31743108</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonnenblick</surname> <given-names>A</given-names></name><name><surname>de Azambuja</surname> <given-names>E</given-names></name><name><surname>Azim</surname> <given-names>HA</given-names></name><name><surname>Piccart</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An update on PARP inhibitors--moving to the adjuvant setting</article-title><source>Nature Reviews Clinical Oncology</source><volume>12</volume><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2014.163</pub-id><pub-id pub-id-type="pmid">25286972</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soong</surname> <given-names>TR</given-names></name><name><surname>Howitt</surname> <given-names>BE</given-names></name><name><surname>Horowitz</surname> <given-names>N</given-names></name><name><surname>Nucci</surname> <given-names>MR</given-names></name><name><surname>Crum</surname> <given-names>CP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The fallopian tube, &quot;precursor escape&quot; and narrowing the knowledge gap to the origins of high-grade serous carcinoma</article-title><source>Gynecologic Oncology</source><volume>152</volume><fpage>426</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2018.11.033</pub-id><pub-id pub-id-type="pmid">30503267</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Xu</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Qiao</surname> <given-names>D</given-names></name><name><surname>Bu</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>HEDGEHOG/GLI modulates the PRR11-SKA2 bidirectional transcription unit in lung squamous cell carcinomas</article-title><source>Genes</source><volume>12</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.3390/genes12010120</pub-id><pub-id pub-id-type="pmid">33477943</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabatabaei Dakhili</surname> <given-names>SA</given-names></name><name><surname>Pérez</surname> <given-names>DJ</given-names></name><name><surname>Gopal</surname> <given-names>K</given-names></name><name><surname>Tabatabaei Dakhili</surname> <given-names>SY</given-names></name><name><surname>Ussher</surname> <given-names>JR</given-names></name><name><surname>Velázquez-Martínez</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A structure-activity relationship study of forkhead domain inhibitors (FDI): The importance of halogen binding interactions</article-title><source>Bioorganic Chemistry</source><volume>93</volume><elocation-id>103269</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.103269</pub-id><pub-id pub-id-type="pmid">31654840</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname> <given-names>D</given-names></name><name><surname>Jones</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome</article-title><source>Molecular Biology and Evolution</source><volume>21</volume><fpage>463</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1093/molbev/msh040</pub-id><pub-id pub-id-type="pmid">14660682</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>H</given-names></name><name><surname>Meng</surname> <given-names>X</given-names></name><name><surname>Huang</surname> <given-names>X</given-names></name><name><surname>Meng</surname> <given-names>L</given-names></name><name><surname>Ding</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Shan</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Two-fold elevation of expression of FoxM1 transcription factor in mouse embryonic fibroblasts enhances cell cycle checkpoint activity by stimulating p21 and Chk1 transcription</article-title><source>Cell Proliferation</source><volume>43</volume><fpage>494</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2184.2010.00699.x</pub-id><pub-id pub-id-type="pmid">20887555</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tassi</surname> <given-names>RA</given-names></name><name><surname>Todeschini</surname> <given-names>P</given-names></name><name><surname>Siegel</surname> <given-names>ER</given-names></name><name><surname>Calza</surname> <given-names>S</given-names></name><name><surname>Cappella</surname> <given-names>P</given-names></name><name><surname>Ardighieri</surname> <given-names>L</given-names></name><name><surname>Cadei</surname> <given-names>M</given-names></name><name><surname>Bugatti</surname> <given-names>M</given-names></name><name><surname>Romani</surname> <given-names>C</given-names></name><name><surname>Bandiera</surname> <given-names>E</given-names></name><name><surname>Zanotti</surname> <given-names>L</given-names></name><name><surname>Tassone</surname> <given-names>L</given-names></name><name><surname>Guarino</surname> <given-names>D</given-names></name><name><surname>Santonocito</surname> <given-names>C</given-names></name><name><surname>Capoluongo</surname> <given-names>ED</given-names></name><name><surname>Beltrame</surname> <given-names>L</given-names></name><name><surname>Erba</surname> <given-names>E</given-names></name><name><surname>Marchini</surname> <given-names>S</given-names></name><name><surname>D'Incalci</surname> <given-names>M</given-names></name><name><surname>Donzelli</surname> <given-names>C</given-names></name><name><surname>Santin</surname> <given-names>AD</given-names></name><name><surname>Pecorelli</surname> <given-names>S</given-names></name><name><surname>Sartori</surname> <given-names>E</given-names></name><name><surname>Bignotti</surname> <given-names>E</given-names></name><name><surname>Odicino</surname> <given-names>F</given-names></name><name><surname>Ravaggi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian Cancer patients</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>36</volume><elocation-id>63</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-017-0536-y</pub-id><pub-id pub-id-type="pmid">28482906</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakore</surname> <given-names>PI</given-names></name><name><surname>D'Ippolito</surname> <given-names>AM</given-names></name><name><surname>Song</surname> <given-names>L</given-names></name><name><surname>Safi</surname> <given-names>A</given-names></name><name><surname>Shivakumar</surname> <given-names>NK</given-names></name><name><surname>Kabadi</surname> <given-names>AM</given-names></name><name><surname>Reddy</surname> <given-names>TE</given-names></name><name><surname>Crawford</surname> <given-names>GE</given-names></name><name><surname>Gersbach</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements</article-title><source>Nature methods</source><volume>12</volume><fpage>1143</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3630</pub-id><pub-id pub-id-type="pmid">26501517</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2011">2011</year><article-title>Integrated genomic analyses of ovarian carcinoma</article-title><source>Nature</source><volume>474</volume><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/nature10166</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname> <given-names>J</given-names></name><name><surname>Christensen</surname> <given-names>B</given-names></name><name><surname>Marsit</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Pan-Cancer analysis reveals differential susceptibility of bidirectional gene promoters to DNA methylation, somatic mutations, and copy number alterations</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>2296</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19082296</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirosh</surname> <given-names>I</given-names></name><name><surname>Izar</surname> <given-names>B</given-names></name><name><surname>Prakadan</surname> <given-names>SM</given-names></name><name><surname>Wadsworth</surname> <given-names>MH</given-names></name><name><surname>Treacy</surname> <given-names>D</given-names></name><name><surname>Trombetta</surname> <given-names>JJ</given-names></name><name><surname>Rotem</surname> <given-names>A</given-names></name><name><surname>Rodman</surname> <given-names>C</given-names></name><name><surname>Lian</surname> <given-names>C</given-names></name><name><surname>Murphy</surname> <given-names>G</given-names></name><name><surname>Fallahi-Sichani</surname> <given-names>M</given-names></name><name><surname>Dutton-Regester</surname> <given-names>K</given-names></name><name><surname>Lin</surname> <given-names>JR</given-names></name><name><surname>Cohen</surname> <given-names>O</given-names></name><name><surname>Shah</surname> <given-names>P</given-names></name><name><surname>Lu</surname> <given-names>D</given-names></name><name><surname>Genshaft</surname> <given-names>AS</given-names></name><name><surname>Hughes</surname> <given-names>TK</given-names></name><name><surname>Ziegler</surname> <given-names>CG</given-names></name><name><surname>Kazer</surname> <given-names>SW</given-names></name><name><surname>Gaillard</surname> <given-names>A</given-names></name><name><surname>Kolb</surname> <given-names>KE</given-names></name><name><surname>Villani</surname> <given-names>AC</given-names></name><name><surname>Johannessen</surname> <given-names>CM</given-names></name><name><surname>Andreev</surname> <given-names>AY</given-names></name><name><surname>Van Allen</surname> <given-names>EM</given-names></name><name><surname>Bertagnolli</surname> <given-names>M</given-names></name><name><surname>Sorger</surname> <given-names>PK</given-names></name><name><surname>Sullivan</surname> <given-names>RJ</given-names></name><name><surname>Flaherty</surname> <given-names>KT</given-names></name><name><surname>Frederick</surname> <given-names>DT</given-names></name><name><surname>Jané-Valbuena</surname> <given-names>J</given-names></name><name><surname>Yoon</surname> <given-names>CH</given-names></name><name><surname>Rozenblatt-Rosen</surname> <given-names>O</given-names></name><name><surname>Shalek</surname> <given-names>AK</given-names></name><name><surname>Regev</surname> <given-names>A</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq</article-title><source>Science</source><volume>352</volume><fpage>189</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1126/science.aad0501</pub-id><pub-id pub-id-type="pmid">27124452</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinklein</surname> <given-names>ND</given-names></name><name><surname>Aldred</surname> <given-names>SF</given-names></name><name><surname>Hartman</surname> <given-names>SJ</given-names></name><name><surname>Schroeder</surname> <given-names>DI</given-names></name><name><surname>Otillar</surname> <given-names>RP</given-names></name><name><surname>Myers</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>An abundance of bidirectional promoters in the human genome</article-title><source>Genome Research</source><volume>14</volume><fpage>62</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1101/gr.1982804</pub-id><pub-id pub-id-type="pmid">14707170</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Characterization of bidirectional gene pairs in The Cancer Genome Atlas (TCGA) dataset</article-title><source>PeerJ</source><volume>7</volume><elocation-id>e7107</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.7107</pub-id><pub-id pub-id-type="pmid">31245179</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubhi</surname> <given-names>T</given-names></name><name><surname>Brown</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exploiting DNA replication stress for Cancer treatment</article-title><source>Cancer Research</source><volume>79</volume><fpage>1730</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3631</pub-id><pub-id pub-id-type="pmid">30967400</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivian</surname> <given-names>J</given-names></name><name><surname>Rao</surname> <given-names>AA</given-names></name><name><surname>Nothaft</surname> <given-names>FA</given-names></name><name><surname>Ketchum</surname> <given-names>C</given-names></name><name><surname>Armstrong</surname> <given-names>J</given-names></name><name><surname>Novak</surname> <given-names>A</given-names></name><name><surname>Pfeil</surname> <given-names>J</given-names></name><name><surname>Narkizian</surname> <given-names>J</given-names></name><name><surname>Deran</surname> <given-names>AD</given-names></name><name><surname>Musselman-Brown</surname> <given-names>A</given-names></name><name><surname>Schmidt</surname> <given-names>H</given-names></name><name><surname>Amstutz</surname> <given-names>P</given-names></name><name><surname>Craft</surname> <given-names>B</given-names></name><name><surname>Goldman</surname> <given-names>M</given-names></name><name><surname>Rosenbloom</surname> <given-names>K</given-names></name><name><surname>Cline</surname> <given-names>M</given-names></name><name><surname>O'Connor</surname> <given-names>B</given-names></name><name><surname>Hanna</surname> <given-names>M</given-names></name><name><surname>Birger</surname> <given-names>C</given-names></name><name><surname>Kent</surname> <given-names>WJ</given-names></name><name><surname>Patterson</surname> <given-names>DA</given-names></name><name><surname>Joseph</surname> <given-names>AD</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Zaranek</surname> <given-names>S</given-names></name><name><surname>Getz</surname> <given-names>G</given-names></name><name><surname>Haussler</surname> <given-names>D</given-names></name><name><surname>Paten</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Toil enables reproducible, open source, big biomedical data analyses</article-title><source>Nature Biotechnology</source><volume>35</volume><fpage>314</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1038/nbt.3772</pub-id><pub-id pub-id-type="pmid">28398314</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakano</surname> <given-names>C</given-names></name><name><surname>Byun</surname> <given-names>JS</given-names></name><name><surname>Di</surname> <given-names>LJ</given-names></name><name><surname>Gardner</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The dual lives of bidirectional promoters</article-title><source>Biochimica et biophysica acta</source><volume>1819</volume><fpage>688</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2012.02.006</pub-id><pub-id pub-id-type="pmid">22366276</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wen</surname> <given-names>L</given-names></name><name><surname>Zhao</surname> <given-names>SH</given-names></name><name><surname>Ai</surname> <given-names>ZH</given-names></name><name><surname>Guo</surname> <given-names>JZ</given-names></name><name><surname>Liu</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients</article-title><source>Lung Cancer</source><volume>79</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2012.10.019</pub-id><pub-id pub-id-type="pmid">23177020</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Weng</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Cai</surname> <given-names>W</given-names></name><name><surname>Xie</surname> <given-names>M</given-names></name><name><surname>Long</surname> <given-names>Y</given-names></name><name><surname>Ai</surname> <given-names>Q</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Du</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Niu</surname> <given-names>Y</given-names></name><name><surname>Song</surname> <given-names>F</given-names></name><name><surname>Ozaki</surname> <given-names>T</given-names></name><name><surname>Bu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The gene pair PRR11 and SKA2 shares a NF-Y-regulated bidirectional promoter and contributes to lung cancer development</article-title><source>Biochimica et biophysica acta</source><volume>1849</volume><fpage>1133</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2015.07.002</pub-id><pub-id pub-id-type="pmid">26162986</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Cui</surname> <given-names>M</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Cao</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>G</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Silencing of FoxM1 blocks growth, migration and invasion of papillary thyroid carcinoma cells</article-title><source>Oncology Letters</source><volume>19</volume><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.11108</pub-id><pub-id pub-id-type="pmid">31897117</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitfield</surname> <given-names>ML</given-names></name><name><surname>George</surname> <given-names>LK</given-names></name><name><surname>Grant</surname> <given-names>GD</given-names></name><name><surname>Perou</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Common markers of proliferation</article-title><source>Nature reviews. Cancer</source><volume>6</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nrc1802</pub-id><pub-id pub-id-type="pmid">16491069</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname> <given-names>T</given-names></name><name><surname>Said</surname> <given-names>M</given-names></name><name><surname>Naim</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons</article-title><source>Genes</source><volume>11</volume><elocation-id>642</elocation-id><pub-id pub-id-type="doi">10.3390/genes11060642</pub-id><pub-id pub-id-type="pmid">32532049</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winterhoff</surname> <given-names>BJ</given-names></name><name><surname>Maile</surname> <given-names>M</given-names></name><name><surname>Mitra</surname> <given-names>AK</given-names></name><name><surname>Sebe</surname> <given-names>A</given-names></name><name><surname>Bazzaro</surname> <given-names>M</given-names></name><name><surname>Geller</surname> <given-names>MA</given-names></name><name><surname>Abrahante</surname> <given-names>JE</given-names></name><name><surname>Klein</surname> <given-names>M</given-names></name><name><surname>Hellweg</surname> <given-names>R</given-names></name><name><surname>Mullany</surname> <given-names>SA</given-names></name><name><surname>Beckman</surname> <given-names>K</given-names></name><name><surname>Daniel</surname> <given-names>J</given-names></name><name><surname>Starr</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells</article-title><source>Gynecologic Oncology</source><volume>144</volume><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2017.01.015</pub-id><pub-id pub-id-type="pmid">28111004</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woloszynska-Read</surname> <given-names>A</given-names></name><name><surname>Mhawech-Fauceglia</surname> <given-names>P</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Odunsi</surname> <given-names>K</given-names></name><name><surname>Karpf</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer</article-title><source>Clinical Cancer Research</source><volume>14</volume><fpage>3283</fpage><lpage>3290</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5279</pub-id><pub-id pub-id-type="pmid">18519754</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wonsey</surname> <given-names>DR</given-names></name><name><surname>Follettie</surname> <given-names>MT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe</article-title><source>Cancer Research</source><volume>65</volume><fpage>5181</fpage><lpage>5189</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4059</pub-id><pub-id pub-id-type="pmid">15958562</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Tang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Guo</surname> <given-names>W</given-names></name><name><surname>Cao</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Guan</surname> <given-names>M</given-names></name><name><surname>Yang</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer</article-title><source>Theranostics</source><volume>10</volume><fpage>3939</fpage><lpage>3951</lpage><pub-id pub-id-type="doi">10.7150/thno.39341</pub-id><pub-id pub-id-type="pmid">32226530</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname> <given-names>Q</given-names></name><name><surname>Tan</surname> <given-names>G</given-names></name><name><surname>Jiang</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>K</given-names></name><name><surname>Tan</surname> <given-names>W</given-names></name><name><surname>Tan</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Suppression of FOXM1 transcriptional activities via a Single-Stranded DNA aptamer generated by SELEX</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>45377</elocation-id><pub-id pub-id-type="doi">10.1038/srep45377</pub-id><pub-id pub-id-type="pmid">28358012</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname> <given-names>L</given-names></name><name><surname>Chiang</surname> <given-names>L</given-names></name><name><surname>He</surname> <given-names>B</given-names></name><name><surname>Zhao</surname> <given-names>YY</given-names></name><name><surname>Winoto</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FoxM1, a forkhead transcription factor is a master cell cycle regulator for mouse mature T cells but not double positive thymocytes</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e9229</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0009229</pub-id><pub-id pub-id-type="pmid">20169079</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>MQ</given-names></name><name><surname>Koehly</surname> <given-names>LM</given-names></name><name><surname>Elnitski</surname> <given-names>LL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Comprehensive annotation of bidirectional promoters identifies co-regulation among breast and ovarian Cancer genes</article-title><source>PLOS Computational Biology</source><volume>3</volume><elocation-id>e72</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.0030072</pub-id><pub-id pub-id-type="pmid">17447839</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Cai</surname> <given-names>S</given-names></name><name><surname>Ling</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Tao</surname> <given-names>L</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of a Five-Gene Prognostic Model and Its Potential Drug Repurposing in Colorectal Cancer Based on TCGA, GTEx and GEO Databases</article-title><source>Frontiers in Genetics</source><volume>11</volume><elocation-id>622659</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2020.622659</pub-id><pub-id pub-id-type="pmid">33537062</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazinski</surname> <given-names>SA</given-names></name><name><surname>Comaills</surname> <given-names>V</given-names></name><name><surname>Buisson</surname> <given-names>R</given-names></name><name><surname>Genois</surname> <given-names>MM</given-names></name><name><surname>Nguyen</surname> <given-names>HD</given-names></name><name><surname>Ho</surname> <given-names>CK</given-names></name><name><surname>Todorova Kwan</surname> <given-names>T</given-names></name><name><surname>Morris</surname> <given-names>R</given-names></name><name><surname>Lauffer</surname> <given-names>S</given-names></name><name><surname>Nussenzweig</surname> <given-names>A</given-names></name><name><surname>Ramaswamy</surname> <given-names>S</given-names></name><name><surname>Benes</surname> <given-names>CH</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Maheswaran</surname> <given-names>S</given-names></name><name><surname>Birrer</surname> <given-names>MJ</given-names></name><name><surname>Zou</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells</article-title><source>Genes &amp; Development</source><volume>31</volume><fpage>318</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1101/gad.290957.116</pub-id><pub-id pub-id-type="pmid">28242626</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>H</given-names></name><name><surname>Kelly</surname> <given-names>TF</given-names></name><name><surname>Samadani</surname> <given-names>U</given-names></name><name><surname>Lim</surname> <given-names>L</given-names></name><name><surname>Rubio</surname> <given-names>S</given-names></name><name><surname>Overdier</surname> <given-names>DG</given-names></name><name><surname>Roebuck</surname> <given-names>KA</given-names></name><name><surname>Costa</surname> <given-names>RH</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues</article-title><source>Molecular and Cellular Biology</source><volume>17</volume><fpage>1626</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1128/MCB.17.3.1626</pub-id><pub-id pub-id-type="pmid">9032290</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Coulouris</surname> <given-names>G</given-names></name><name><surname>Zaretskaya</surname> <given-names>I</given-names></name><name><surname>Cutcutache</surname> <given-names>I</given-names></name><name><surname>Rozen</surname> <given-names>S</given-names></name><name><surname>Madden</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction</article-title><source>BMC Bioinformatics</source><volume>13</volume><elocation-id>134</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-13-134</pub-id><pub-id pub-id-type="pmid">22708584</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Cheng</surname> <given-names>L</given-names></name><name><surname>Minn</surname> <given-names>K</given-names></name><name><surname>Madan</surname> <given-names>R</given-names></name><name><surname>Godwin</surname> <given-names>AK</given-names></name><name><surname>Shridhar</surname> <given-names>V</given-names></name><name><surname>Chien</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells</article-title><source>Oncotarget</source><volume>5</volume><fpage>11365</fpage><lpage>11380</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2497</pub-id><pub-id pub-id-type="pmid">25426548</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Kong</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells</article-title><source>Oncology Letters</source><volume>11</volume><fpage>2685</fpage><lpage>2691</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4228</pub-id><pub-id pub-id-type="pmid">27073539</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Siu</surname> <given-names>MK</given-names></name><name><surname>Jiang</surname> <given-names>L</given-names></name><name><surname>Tam</surname> <given-names>KF</given-names></name><name><surname>Ngan</surname> <given-names>HY</given-names></name><name><surname>Le</surname> <given-names>XF</given-names></name><name><surname>Wong</surname> <given-names>OG</given-names></name><name><surname>Wong</surname> <given-names>ES</given-names></name><name><surname>Gomes</surname> <given-names>AR</given-names></name><name><surname>Bella</surname> <given-names>L</given-names></name><name><surname>Khongkow</surname> <given-names>P</given-names></name><name><surname>Lam</surname> <given-names>EW</given-names></name><name><surname>Cheung</surname> <given-names>AN</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e113478</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0113478</pub-id><pub-id pub-id-type="pmid">25411964</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname> <given-names>Y</given-names></name><name><surname>Laws</surname> <given-names>MJ</given-names></name><name><surname>Sanabria Guillen</surname> <given-names>V</given-names></name><name><surname>Kim</surname> <given-names>SH</given-names></name><name><surname>Dey</surname> <given-names>P</given-names></name><name><surname>Smith</surname> <given-names>BP</given-names></name><name><surname>Gong</surname> <given-names>P</given-names></name><name><surname>Bindman</surname> <given-names>N</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Carlson</surname> <given-names>K</given-names></name><name><surname>Yasuda</surname> <given-names>MA</given-names></name><name><surname>Singh</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>El-Ashry</surname> <given-names>D</given-names></name><name><surname>Madak-Erdogan</surname> <given-names>Z</given-names></name><name><surname>Katzenellenbogen</surname> <given-names>JA</given-names></name><name><surname>Katzenellenbogen</surname> <given-names>BS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Suppression of FOXM1 activities and breast Cancer growth in vitro and in vivo by a new class of compounds</article-title><source>Npj Breast Cancer</source><volume>5</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1038/s41523-019-0141-7</pub-id><pub-id pub-id-type="pmid">31815181</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zona</surname> <given-names>S</given-names></name><name><surname>Bella</surname> <given-names>L</given-names></name><name><surname>Burton</surname> <given-names>MJ</given-names></name><name><surname>Nestal de Moraes</surname> <given-names>G</given-names></name><name><surname>Lam</surname> <given-names>EW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance</article-title><source>Biochimica Et Biophysica Acta (BBA) - Gene Regulatory Mechanisms</source><volume>1839</volume><fpage>1316</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.09.016</pub-id><pub-id pub-id-type="pmid">25287128</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><boxed-text><table-wrap id="keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle">Reagent type (species) or resource</th><th align="center" valign="middle">Designation</th><th align="center" valign="middle">Source or reference</th><th align="center" valign="middle">Identifiers</th><th align="center" valign="middle">Additional information</th></tr></thead><tbody><tr><td align="center" valign="middle">Gene (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">FOXM1</td><td align="center" valign="middle">GenBank</td><td align="center" valign="middle">Gene ID: 2305</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Gene (<italic>Homo sapiens</italic>)</td><td align="center" valign="middle">RHNO1</td><td align="center" valign="middle">GenBank</td><td align="center" valign="middle">Gene ID: 83695</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">FOXM1 (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">5436</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">β-Actin (mouse monoclonal)</td><td align="center" valign="bottom">Santa Cruz</td><td align="center" valign="bottom">sc-47778</td><td align="center" valign="bottom">(1:200)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">α-Tubulin (rabbit polyclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">2144</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">Lamin B (goat polyclonal)</td><td align="center" valign="bottom">Santa Cruz</td><td align="center" valign="bottom">sc-6217</td><td align="center" valign="bottom">Discontinued</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">Histone H3 (goat polyclonal)</td><td align="center" valign="bottom">Santa Cruz</td><td align="center" valign="bottom">sc-8654</td><td align="center" valign="bottom">Discontinued</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">CHEK1 (mouse monoclonal)</td><td align="center" valign="bottom">Santa Cruz</td><td align="center" valign="bottom">sc-8408</td><td align="center" valign="bottom">(1:200)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">P-CHEK1 S345 (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">2348</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">P-CHEK1 S317 (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">12302</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">RPA32/RPA2 (rabbit monoclonal)</td><td align="center" valign="bottom">Abcam</td><td align="center" valign="bottom">ab76420</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">RPA32 (S33) (rabbit polyclonal)</td><td align="center" valign="bottom">Bethyl</td><td align="center" valign="bottom">A300-246A-M</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">H2AX (goat polyclonal)</td><td align="center" valign="bottom">Bethyl</td><td align="center" valign="bottom">A303-837A</td><td align="center" valign="bottom">(1:2000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">P-H2AX S139 (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">9718</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">Flag (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">14793</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">HA (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">3724</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">RHNO1 (rabbit polyclonal)</td><td align="center" valign="bottom">Novus</td><td align="center" valign="bottom">NBP1-93694</td><td align="center" valign="bottom">Discontinued</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">RHNO1 (rabbit polyclonal)</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">HPA038682</td><td align="center" valign="bottom">Discontinued</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">TOPBP1 (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">14342</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">RAD9 (rabbit polyclonal)</td><td align="center" valign="bottom">Santa Cruz</td><td align="center" valign="bottom">sc-8324</td><td align="center" valign="bottom">Discontinued</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">RAD1 (rabbit monoclonal)</td><td align="center" valign="bottom">Invitrogen</td><td align="center" valign="bottom">702149</td><td align="center" valign="bottom">(1–2 µg/mL)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">HUS1 (rabbit monoclonal)</td><td align="center" valign="bottom">Cell Signaling Technology</td><td align="center" valign="bottom">16416</td><td align="center" valign="bottom">(1:1000)</td></tr><tr><td align="center" valign="bottom">Antibody</td><td align="center" valign="bottom">Anti-HA magnetic beads (mouse monoclonal)</td><td align="center" valign="bottom">Pierce</td><td align="center" valign="bottom">88837</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">COV362</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">7071904</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">COV318</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">7071903</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">KURAMOCHI</td><td align="center" valign="bottom">JCRB</td><td align="center" valign="bottom">JCRB0098</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">OVSAHO</td><td align="center" valign="bottom">JCRB</td><td align="center" valign="bottom">JCRB1046</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">SNU-119</td><td align="center" valign="bottom">Korean Cell Line Bank</td><td align="center" valign="bottom">00119</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">OVCAR4</td><td align="center" valign="bottom">NCI</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">OVCAR8</td><td align="center" valign="bottom">NCI</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">OVCAR3</td><td align="center" valign="bottom">ATCC</td><td align="center" valign="bottom">HTB-161</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">CAOV3</td><td align="center" valign="bottom">Anirban Mitra</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">OVCAR5</td><td align="center" valign="bottom">Anirban Mitra</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">UWB1.289</td><td align="center" valign="bottom">Lee Zou</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">UWB1-SyR12</td><td align="center" valign="bottom">Lee Zou</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">UWB1-SyR13</td><td align="center" valign="bottom">Lee Zou</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">hOSE</td><td align="center" valign="bottom">ScienCell</td><td align="center" valign="bottom">7310</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">FT190</td><td align="center" valign="bottom">Ronny Drapkin</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">FT282-E1</td><td align="center" valign="bottom">Ronny Drapkin</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">FT282</td><td align="center" valign="bottom">Ronny Drapkin</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">IOSE-21</td><td align="center" valign="bottom">Francis Balkwill</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">IOSE-121</td><td align="center" valign="bottom">Nelly Auersperg</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">283T</td><td align="center" valign="bottom">ATCC</td><td align="center" valign="bottom">CRL-3216</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">U2OS-DR-GFP (282C)</td><td align="center" valign="bottom">Jeremy Stark</td><td align="center" valign="bottom"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Cell line (<italic>Homo sapiens</italic>)</td><td align="center" valign="middle">OVCAR8-DR-GFP</td><td align="center" valign="middle">Larry Karnitz and Scott Kaufmann</td><td align="center" valign="middle"/><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Chemical compound, drug</td><td align="center" valign="middle">Berzosertib</td><td align="center" valign="middle">SelleckChem</td><td align="center" valign="middle">VE-822</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Chemical compound, drug</td><td align="center" valign="bottom">Olaparib</td><td align="center" valign="bottom">SelleckChem</td><td align="center" valign="bottom">ABT-888</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Chemical compound, drug</td><td align="center" valign="bottom">Hydroxyurea</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">H8627</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Chemical compound, drug</td><td align="center" valign="bottom">Carboplatin</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">C2538</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Chemical compound, drug</td><td align="center" valign="bottom">Etoposide</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">E1383</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="middle">Chemical compound, drug</td><td align="center" valign="bottom">Doxycycline</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">D9891</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Direct-zol RNA Purification Kit</td><td align="center" valign="bottom">Zymo Research</td><td align="center" valign="bottom">R2072</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Comet Assay Kit</td><td align="center" valign="bottom">Trevigen</td><td align="center" valign="bottom">4250-050-K</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">iScript cDNA Synthesis Kit</td><td align="center" valign="bottom">Bio-Rad</td><td align="center" valign="bottom">1708890</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">DNA-free kit</td><td align="center" valign="bottom">Ambion</td><td align="center" valign="bottom">AM1906</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">NE-PER Nuclear and Cytoplasmic Extraction Kit</td><td align="center" valign="bottom">Pierce</td><td align="center" valign="bottom">78833</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">BCA protein assay</td><td align="center" valign="bottom">Pierce</td><td align="center" valign="bottom">23225</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Enhanced chemiluminescence</td><td align="center" valign="bottom">Pierce</td><td align="center" valign="bottom">32106</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Puregene Tissue Kit</td><td align="center" valign="bottom">QIAGEN</td><td align="center" valign="bottom">158667</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">EZ DNA Methylation Kit</td><td align="center" valign="bottom">Zymo Research</td><td align="center" valign="bottom">D5001</td><td align="center" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">QIAquick Gel Extraction Kit</td><td align="center" valign="bottom">QIAGEN</td><td align="center" valign="bottom">28704</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">TOPO TA Cloning Kit</td><td align="center" valign="bottom">Invirogen</td><td align="center" valign="bottom">K457501</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">FirstChoice RLM-RACE Kit</td><td align="center" valign="bottom">Ambion</td><td align="center" valign="bottom">AM1700</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Dual-Luciferase Reporter Assay System</td><td align="center" valign="bottom">Promega</td><td align="center" valign="bottom">E1910</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Phospha-Light SEAP Reporter Gene Assay System</td><td align="center" valign="bottom">Thermo Scientific</td><td align="center" valign="bottom">T1015</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">TRIzol reagent</td><td align="center" valign="bottom">Thermo Scientific</td><td align="center" valign="bottom">15596026</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Lipofectamine 2000 reagent</td><td align="center" valign="bottom">Life Technologies</td><td align="center" valign="bottom">11668019</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">QuickExtract</td><td align="center" valign="bottom">Lucigen</td><td align="center" valign="bottom">QE09050</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">M-PER</td><td align="center" valign="bottom">Pierce</td><td align="center" valign="bottom">78501</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Halt Protease and Phosphatase Cocktail</td><td align="center" valign="bottom">Pierce</td><td align="center" valign="bottom">78440</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Turbo Nuclease</td><td align="center" valign="bottom">Sigma</td><td align="center" valign="bottom">T4330-50KU</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">AlamarBlue</td><td align="center" valign="bottom">Bio-Rad</td><td align="center" valign="bottom">BUF012A</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Commercial assay or kit</td><td align="center" valign="bottom">Vectashield with DAPI</td><td align="center" valign="bottom">Vector Laboratories</td><td align="center" valign="bottom">H-1200-10</td><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCBASceI</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">26477</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCW57-GFP-P2A-MCS</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">71783</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCW57-GFP-P2A-MCS-(Neo)</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">89181</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCW57-MCS1-P2A-MCS2-(Hygro)</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">80922</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCW57-MCS1-P2A-MCS2-(Blast)</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">80921</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCW57-RFP-P2A-MCS</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">78933</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCW57-RFP-P2A-MCS-(Neo)</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">89182</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pTRIPZ Non-silencing</td><td align="center" valign="bottom">Dharmacon</td><td align="center" valign="bottom">NC0257175</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pGL4 Luc Rluc Empty</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">64034</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCMV6-SEAP</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">24595</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pTurbo-GFP-RFP-empty</td><td align="center" valign="bottom">Custom</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pTurbo-GFP-PGK</td><td align="center" valign="bottom">Custom</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pTurbo-RFP-PGK</td><td align="center" valign="bottom">Custom</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pTurboGFP-RFP-FOXM1-RHNO1</td><td align="center" valign="bottom">Custom</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pLentiCRISPRv2</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">52961</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">PX458-WT-Cas9-empty</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">48138</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">lenti-SAMv2-Puro</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">92062</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">lenti-MPHv2-Neo</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">92065</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pLV hU6-sgRNA hUbC-dCas9-KRAB-T2A-Puro (KRAB)</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">71236</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">psPAX2</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">12260</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pMD2.G</td><td align="center" valign="bottom">Addgene</td><td align="center" valign="bottom">12259</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pOTB7-RHNO1</td><td align="center" valign="bottom">Harvard PlasmID Repository</td><td align="center" valign="bottom">HsCD00326310</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pENTR-MGC RHNO1 siR</td><td align="center" valign="bottom">Stephen Elledge</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pENTR-MGC RHNO1 SWV</td><td align="center" valign="bottom">Stephen Elledge</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">pCMV6 AN-HA empty</td><td align="center" valign="bottom">Origene</td><td align="center" valign="bottom">PS100013</td><td align="center" valign="bottom">Plasmid</td></tr><tr><td align="center" valign="bottom">Genetic reagent (<italic>Homo sapiens</italic>)</td><td align="center" valign="bottom">AdNGUS24i</td><td align="center" valign="bottom">Frank Graham and Phillip Ng</td><td align="center" valign="bottom"/><td align="center" valign="bottom">Adenovirus</td></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Prism 8 statistical software</td><td align="center" valign="bottom">GraphPad</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Lasergene SeqMan Pro</td><td align="center" valign="bottom">DNASTAR</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Comet Analysis Software</td><td align="center" valign="bottom">Trevigen</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">R package</td><td align="center" valign="bottom">R Project</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Cell Ranger Single Cell Software</td><td align="center" valign="bottom">10X Genomics</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">GSEA software version 3</td><td align="center" valign="bottom">Broad Institute</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Cufflinks (v2.1.1)</td><td align="center" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.1621">https://doi.org/10.1038/nbt.1621</ext-link></td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Trim Galore software package</td><td align="center" valign="bottom">The Babraham Institute</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">TopHat (v2.0.8)</td><td align="center" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/gb-2013-14-4-r36">https://doi.org/10.1186/gb-2013-14-4-r36</ext-link></td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Cuffdiff (v2.1.1)</td><td align="center" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt.2450">https://doi.org/10.1038/nbt.2450</ext-link></td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">Perl</td><td align="center" valign="bottom">The Perl Foundation</td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="center" valign="bottom">Software, algorithm</td><td align="center" valign="bottom">scImpute</td><td align="center" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41467-018-03405-7">https://doi.org/10.1038/s41467-018-03405-7</ext-link></td><td align="center" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></boxed-text></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55070.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Reviewing Editor</role><aff><institution>University of Alberta</institution><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names> </name><role>Reviewer</role><aff><institution>University of Alberta</institution><country>Canada</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Shepherd</surname><given-names>Trevor G</given-names></name><role>Reviewer</role><aff><institution>Western University</institution><country>Canada</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The current manuscript by Barger et al. describes a bidirectional promoter (BDP) regulating FOXM1 and RHNO1. This paper was able to outline some of the putative functional ramifications of co-regulating FOXM1 and RHNO1 in ovarian cancer and illuminated a hitherto unappreciated role for RHNO1 in the regulation of DNA repair and resistance to therapy. These findings support future studies designed to interrogate and even target RHNO1 and its bidirectional promoter in cancers, with a particular emphasis on therapy resistant ovarian cancers.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Co-regulation and functional cooperativity of FOXM1 and RHNO1 bidirectional genes in ovarian cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Lynne-Marie Postovit as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Maureen Murphy as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Trevor G Shepherd (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The current manuscript by Barger et al. describes a bidirectional promoter (BDP) regulating FOXM1 and RHNO1. Based on a very large number of well-described, appropriate and properly executed experiments, the authors concluded that FOXM1 and RHNO1 are coregulated in ovarian cancers and functionally cooperate in ovarian cancer cells. While this discovery describes a rather standard BDP, this paper was able to outline some of the putative functional ramifications of co-regulating FOXM1 and RHNO1. Specifically, this paper presented a previously unknown role for RHNO1 in ovarian cancers wherein the locus (containing the BDP) is located. Indeed, some of these functions may have previously been attributed to FOXM1 alone. This possibility was not fully explored in this manuscript, and instead a concept of co-operativity was introduced.</p><p>Three scientists, including myself, have reviewed your paper. We were all impressed with the work. The study is rigorous and the data are well organized and presented in a logical fashion. However, enhancements would be needed prior to publication in <italic>eLife</italic>. Specifically, studies are needed to better understand the cooperative role of RHNO and the BDP (versus FOXM1) in DNA repair and the susceptibility of ovarian cancer cells to PARP inhibitors.</p><p>Accordingly, please address all of the reviewer's concerns (outlined below). A certain number of experiments would also be required. These include an enhancement of the RNAseq analysis as well as experiments designed to better elucidate the role of RHNO in ovarian cancer DNA repair and/or to better characterize the concept of co-operativity. The referees discussed the need for in vivo models; and while it was felt that these would enhance the study, we agreed that these experiments would be out of the scope of the work and thus not needed for this paper.</p><p>Essential revisions:</p><p>1. The notion that FOXM1 and RHNO1 increase in cell lines in accordance with copy number (Figure 2E) is not overly convincing given the RT-PCR assay used and putative differences in PCR efficiencies. Please include absolute copy numbers for FOXM1 and RHNO1 (with ddPCR or a standard curve) and clearly demarcate copy numbers for each cell line analyzed. Also, Figure 2F- the authors state that protein expression increased with genomic copy number. This may be the case for SNU-119 but seems to be less obvious for the other cell lines. Please provide additional comments.</p><p>2. Several studies have demonstrated a role for FOXM1 in the regulation of ovarian cancer phenotypes including DNA repair in response to PARP inhibition, EMT and glucose metabolism. This is in contrast to the results obtained in this study, particularly since gene alterations detected with RNAseq seemed minimal. This could be due to the use of different cell lines and/or may have been somehow associated with the RNA sequencing analyses. This must be rectified. The following enhancements are suggested:</p><p>– The description of the RNAseq analysis should be improved. How many biological replicates were analyzed?</p><p>– Please include a heatmap and list of altered genes for each cell line.</p><p>– Please indicate the percent overlap in alterations between cell lines.</p><p>– Please include principle components analyses.</p><p>– Since it seems that RHNO1 is mediating a number of effects associated with the BDP, it would be important to determine the extent to which RHNO1, FOXM1 and/or BDP ablation elicits similar responses.</p><p>– The validations have no statistics, and there are no measurements of protein. It is difficult, with this data, to conclude that cell cycle genes are altered, as suggested.</p><p>3. The authors performed single cell (sc) RNA-seq in FTE and HGS cell lines but the results are confined to two observations in a table as unpublished data. These data overall are highly relevant to the current study and should be elaborated on in the paper, including figures of the clusters, descriptions and gene lists.</p><p>4. The cell cycle analyses in 5C, 7D and 8E do not show major changes. It is unclear if the cells were synchronized and statistics are absent. Given the aforementioned weaknesses in the RNAseq data, I would suggest removing this data. Otherwise, the experiments must be improved, with solid assays to measure proliferative indices, as well as an improved workflow for cell cycle analysis.</p><p>5. It seems that a putative role for RHNO1 in the regulation of DNA repair in ovarian cancer is a major discovery in this paper. Hence, the experiments showing this should be enhanced.</p><p>– RHNO1 localization studies should be expanded to include IF, perhaps in combination with γ-H2AX foci imaging.</p><p>– DNA repair should be directly measured in the cells used in Figures 7, 8 and 9. This would include all of the assays shown in S14 (Showing a role for RHNO1 in DNA repair) as well as a measurement of γ-H2AX foci. At least one model should also determine whether the effects of BDP KO can be rescued by RHNO1 (but not the SWV mutant). These experiments are needed to adequately link the BDP to the regulation of DNA repair (and susceptibility to PARP inhibitors) and to firmly establish the roles of FOXM1 and RHNO1 in DNA repair independently of proliferation which could be a confounder in the ALAMAR BLUE assay (which is an estimate of live cell numbers).</p><p>– Analysis of FOXM1 and RHNO1 in tumors from patients that were resistant to PARPi or developed resistance to PARPi would support the in vitro conclusions. Do the authors have access to such samples?</p><p>– In addition to PARPi, cellular data for response to platinum chemotherapy (sensitivity/resistance) would be informative particularly in the context of the disease. Have the authors performed similar experiments using platinum in the ovarian cancer cells?</p><p>6. In a number of experiments (Figure 5 and Figure 6) it is suggested that RHNO1 and FOXM1 work cooperatively. It is difficult to see how the data show this; as the effects of dual knockdown is only marginally greater than that of RHNO1 knockdown. This may not even be the case as it does not appear that multiple comparisons were made (for example with an ANOVA). Please conduct an ANOVA on Figure 5B, 5C (if it is kept), 6E, 6F, 7D (if it is kept), 8E (if it is kept), and S15D and adjust conclusions accordingly. Also, in Figure 6F – dual loss and HR efficiency in the bone cancer cell line was more robust than the ovarian cancer cell line, which showed only a modest although statistically significant difference. Did the authors examine additional HGS ovarian cancer line to support the cooperativity? Perhaps the authors can better define or focus this functional cooperativity, or consider describing it more accurately.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.55070.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The notion that FOXM1 and RHNO1 increase in cell lines in accordance with copy number (Figure 2E) is not overly convincing given the RT-PCR assay used and putative differences in PCR efficiencies. Please include absolute copy numbers for FOXM1 and RHNO1 (with ddPCR or a standard curve) and clearly demarcate copy numbers for each cell line analyzed. Also, Figure 2F- the authors state that protein expression increased with genomic copy number. This may be the case for SNU-119 but seems to be less obvious for the other cell lines. Please provide additional comments.</p></disp-quote><p>We show that <italic>FOXM1</italic> and <italic>RHNO1</italic> mRNA expression correlates with copy number in HGSC in RNA-seq and microarray data in Figure 3A (HGSC tumors, N=157; p&lt;0.0001) and 3B (HGSC cell lines, N=23; p&lt;0.0001). The data in Figure 3C-D only serve as a small validation using laboratory samples from cell lines. Figure 3C presents absolute RNA copy number data determined from standard curves of all target genes and is normalized to 18s rRNA, which reflects cDNA input. PCR efficiencies approach 100% for target genes. We revised Figure 3C-D to present the copy number for each cell line, as determined by the CCLE and NCI60 consortia. A direct relationship between genomic copy number and <italic>FOXM1</italic> and <italic>RHNO1</italic> expression is apparent, but additional mechanisms regulate their expression, as we have described for FOXM1 previously (Barger et al., Oncotarget, 2015; Barger et al., Cancers, 2019).</p><p>We added the following sentence to the text (p. 6): “Although the associations were significant, they were not uniform, indicating that mechanisms besides copy number status regulate FOXM1 and RHNO1 expression in HGSC. This is consistent with our prior studies of FOXM1 regulation (22,32).”</p><disp-quote content-type="editor-comment"><p>2. Several studies have demonstrated a role for FOXM1 in the regulation of ovarian cancer phenotypes including DNA repair in response to PARP inhibition, EMT and glucose metabolism. This is in contrast to the results obtained in this study, particularly since gene alterations detected with RNAseq seemed minimal. This could be due to the use of different cell lines and/or may have been somehow associated with the RNA sequencing analyses. This must be rectified. The following enhancements are suggested:</p><p>– The description of the RNAseq analysis should be improved. How many biological replicates were analyzed?</p><p>– Please include a heatmap and list of altered genes for each cell line.</p><p>– Please indicate the percent overlap in alterations between cell lines.</p><p>– Please include principle components analyses.</p><p>– Since it seems that RHNO1 is mediating a number of effects associated with the BDP, it would be important to determine the extent to which RHNO1, FOXM1 and/or BDP ablation elicits similar responses.</p><p>– The validations have no statistics, and there are no measurements of protein. It is difficult, with this data, to conclude that cell cycle genes are altered, as suggested.</p></disp-quote><p>We agree with this comment, and point out that presentation of bulk RNA-seq data was limited to one supplementary figure (Figure S13). After consideration of the additional studies required to characterize the impact of FOXM1 and/or RHNO1 knockdown and F/R-BDP repression on HGSC cell gene expression, we decided to remove bulk RNA-seq studies from the manuscript. Such studies are tangential to the point of the manuscript, are extensive, and are better suited for later presentation as a separate paper.</p><disp-quote content-type="editor-comment"><p>3. The authors performed single cell (sc) RNA-seq in FTE and HGS cell lines but the results are confined to two observations in a table as unpublished data. These data overall are highly relevant to the current study and should be elaborated on in the paper, including figures of the clusters, descriptions and gene lists.</p></disp-quote><p>We revised the manuscript to add new scRNA-seq data relevant to FOXM1 and RHNO1. Figures 4C-D show the normalized expression counts of <italic>FOXM1</italic> and <italic>RHNO1</italic> in FT282 and OVCAR8 cells, respectively, while Figure 4E shows the overall level of <italic>FOXM1</italic> and <italic>RHNO1</italic> expression in the two cell types. Figure 5 shows the distribution of correlation coefficients for all bidirectional gene (BDG) pairs in the two cell types and plots the correlations observed between <italic>FOXM1</italic> and <italic>RHNO1</italic>. Figure 5, Table Supplement 1, presents the raw correlation data for all genomic BDG pairs. Figure 5, Figure Supplement 1, shows principal component analysis (PCA) of FT282 and OVCAR8 transcriptomes. Full description of all scRNA-seq data, unrelated to BDGs and FOXM1/RHNO1, is beyond the scope of the manuscript. We deposited the scRNA-seq into GEO (GSE 150864).</p><disp-quote content-type="editor-comment"><p>4. The cell cycle analyses in 5C, 7D and 8E do not show major changes. It is unclear if the cells were synchronized and statistics are absent. Given the aforementioned weaknesses in the RNAseq data, I would suggest removing this data. Otherwise, the experiments must be improved, with solid assays to measure proliferative indices, as well as an improved workflow for cell cycle analysis.</p></disp-quote><p>We agree that the cell cycle changes observed in FOXM1 and RHNO1 depleted cells, in the absence of drug treatment, showed minor changes. Therefore, as suggested, we removed these data. After olaparib treatment, depletion of FOXM1 and/or RHNO1 did significantly alter OVCAR8 cell cycle (Figure 17D, Figure 18E). These analyses used asynchronous cell cultures. In the future, we plan to use cell synchronizations to better define cell cycle effects downstream of FOXM1 and/or RHNO1 depletion in HGSC cells.</p><disp-quote content-type="editor-comment"><p>5. It seems that a putative role for RHNO1 in the regulation of DNA repair in ovarian cancer is a major discovery in this paper. Hence, the experiments showing this should be enhanced.</p><p>– RHNO1 localization studies should be expanded to include IF, perhaps in combination with γ-H2AX foci imaging.</p></disp-quote><p>IF of endogenous RHNO1 is not feasible due to the lack of a suitable primary antibody. We attempted IF of HA-RHNO1 but did not observe nuclear foci so we discontinued that line of studies. We conducted western blot analyses of γ-H2AX levels in chromatin from FOXM1 and/or RHNO1 knockdown OVCAR8 cells, with or without olaparib treatment (Figure 17C). γ-H2AX foci analyses gave inconsistent results so we are not comfortable reporting them at this time.</p><disp-quote content-type="editor-comment"><p>– DNA repair should be directly measured in the cells used in Figures 7, 8 and 9. This would include all of the assays shown in S14 (Showing a role for RHNO1 in DNA repair) as well as a measurement of γ-H2AX foci. At least one model should also determine whether the effects of BDP KO can be rescued by RHNO1 (but not the SWV mutant). These experiments are needed to adequately link the BDP to the regulation of DNA repair (and susceptibility to PARP inhibitors) and to firmly establish the roles of FOXM1 and RHNO1 in DNA repair independently of proliferation which could be a confounder in the ALAMAR BLUE assay (which is an estimate of live cell numbers).</p></disp-quote><p>The data shown in the prior Figure 7 and Figure S14 (now Figure 17 and Figure 13) are from OVCAR8 cells with dox-inducible FOXM1 and/or RHNO1 shRNAs. We presented functional HR data (DR-GFP assay) for these cells in Figure 16, which we feel addresses the main point. We also note that the data shown in the prior Figure 8 (now Figure 18) are from OVCAR8 cells expressing NT sgRNA or F/R-BDP-KRAB sgRNA. Thus, we attempted to make OVCAR8 F/R-BDP-KRAB, DR-GFP cells. Unfortunately, we were unsuccessful, due to the complexity of the cell engineering coupled with severe limitations on time and lab personnel. We would like to complete such experiments in the future, but feel that our manuscript is extensive enough at present to warrant publication.</p><disp-quote content-type="editor-comment"><p>– Analysis of FOXM1 and RHNO1 in tumors from patients that were resistant to PARPi or developed resistance to PARPi would support the in vitro conclusions. Do the authors have access to such samples?</p></disp-quote><p>We queried GEO and contacted a number of clinical collaborators. Unfortunately, we have not yet identified suitable data to address this important question. We will continue to query GEO and follow the literature in this area to address this question in the future.</p><disp-quote content-type="editor-comment"><p>– In addition to PARPi, cellular data for response to platinum chemotherapy (sensitivity/resistance) would be informative particularly in the context of the disease. Have the authors performed similar experiments using platinum in the ovarian cancer cells?</p></disp-quote><p>We added data showing the impact of FOXM1 and RHNO1 knockdown on OVCAR8 response to carboplatin (Figure 20). Depletion of either or both genes reduced clonogenic growth following carboplatin treatment.</p><disp-quote content-type="editor-comment"><p>6. In a number of experiments (Figure 5 and Figure 6) it is suggested that RHNO1 and FOXM1 work cooperatively. It is difficult to see how the data show this; as the effects of dual knockdown is only marginally greater than that of RHNO1 knockdown. This may not even be the case as it does not appear that multiple comparisons were made (for example with an ANOVA). Please conduct an ANOVA on Figure 5B, 5C (if it is kept), 6E, 6F, 7D (if it is kept), 8E (if it is kept), and S15D and adjust conclusions accordingly. Also, in Figure 6F- dual loss and HR efficiency in the bone cancer cell line was more robust than the ovarian cancer cell line, which showed only a modest although statistically significant difference. Did the authors examine additional HGS ovarian cancer line to support the cooperativity? Perhaps the authors can better define or focus this functional cooperativity, or consider describing it more accurately.</p></disp-quote><p>We agree that for several cell phenotypes the effect of RHNO1 knockdown is similar to the effects of dual knockdown. We now present results of ANOVA testing and adjusted the interpretation of our results accordingly. We added examination of the effect of dual FOXM1 and RHNO1 knockdown in the CAOV3 HGSC cell line (Figure 12, Figure Supplement 1), as suggested.</p><p>We revised the title of the manuscript to accurately describe the relationship between FOXM1 and RHNO1 function:</p><p>Original title: Co-regulation and functional cooperativity of FOXM1 and RHNO1 bidirectional genes in ovarian cancer.</p><p>Revised title: Co-regulation and function of FOXM1/RHNO1 bidirectional genes in cancer.</p></body></sub-article></article>